BLOOD PRESSURE A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R EFERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright ©2003 by ICON Group International, Inc. Copyright ©2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Blood Pressure: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83588-8 1. Blood Pressure-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on blood pressure. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON BLOOD PRESSURE...................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Blood Pressure............................................................................... 8 E-Journals: PubMed Central ....................................................................................................... 97 The National Library of Medicine: PubMed .............................................................................. 102 CHAPTER 2. NUTRITION AND BLOOD PRESSURE .......................................................................... 209 Overview.................................................................................................................................... 209 Finding Nutrition Studies on Blood Pressure ........................................................................... 209 Federal Resources on Nutrition ................................................................................................. 215 Additional Web Resources ......................................................................................................... 216 CHAPTER 3. ALTERNATIVE MEDICINE AND BLOOD PRESSURE ................................................... 223 Overview.................................................................................................................................... 223 The Combined Health Information Database............................................................................. 223 National Center for Complementary and Alternative Medicine................................................ 224 Additional Web Resources ......................................................................................................... 234 General References ..................................................................................................................... 266 CHAPTER 4. DISSERTATIONS ON BLOOD PRESSURE ..................................................................... 267 Overview.................................................................................................................................... 267 Dissertations on Blood Pressure ................................................................................................ 267 Keeping Current ........................................................................................................................ 275 CHAPTER 5. CLINICAL TRIALS AND BLOOD PRESSURE ................................................................ 277 Overview.................................................................................................................................... 277 Recent Trials on Blood Pressure ................................................................................................ 277 Keeping Current on Clinical Trials ........................................................................................... 290 CHAPTER 6. PATENTS ON BLOOD PRESSURE ................................................................................ 293 Overview.................................................................................................................................... 293 Patents on Blood Pressure.......................................................................................................... 293 Patent Applications on Blood Pressure...................................................................................... 420 Keeping Current ........................................................................................................................ 486 CHAPTER 7. BOOKS ON BLOOD PRESSURE .................................................................................... 487 Overview.................................................................................................................................... 487 Book Summaries: Federal Agencies............................................................................................ 487 Book Summaries: Online Booksellers......................................................................................... 488 The National Library of Medicine Book Index ........................................................................... 505 Chapters on Blood Pressure ....................................................................................................... 507 Directories.................................................................................................................................. 507 CHAPTER 8. MULTIMEDIA ON BLOOD PRESSURE ......................................................................... 509 Overview.................................................................................................................................... 509 Video Recordings ....................................................................................................................... 509 Bibliography: Multimedia on Blood Pressure ............................................................................ 518 CHAPTER 9. PERIODICALS AND NEWS ON BLOOD PRESSURE ...................................................... 521 Overview.................................................................................................................................... 521 News Services and Press Releases.............................................................................................. 521 Newsletters on Blood Pressure................................................................................................... 524 Newsletter Articles .................................................................................................................... 525 Academic Periodicals covering Blood Pressure.......................................................................... 526 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 527 Overview.................................................................................................................................... 527 U.S. Pharmacopeia..................................................................................................................... 527
viii Contents
Commercial Databases ............................................................................................................... 533 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 537 Overview.................................................................................................................................... 537 NIH Guidelines.......................................................................................................................... 537 NIH Databases........................................................................................................................... 539 Other Commercial Databases..................................................................................................... 543 APPENDIX B. PATIENT RESOURCES ............................................................................................... 545 Overview.................................................................................................................................... 545 Patient Guideline Sources.......................................................................................................... 545 Associations and Blood Pressure................................................................................................ 560 Finding Associations.................................................................................................................. 566 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 569 Overview.................................................................................................................................... 569 Preparation................................................................................................................................. 569 Finding a Local Medical Library................................................................................................ 569 Medical Libraries in the U.S. and Canada ................................................................................. 569 ONLINE GLOSSARIES................................................................................................................ 575 Online Dictionary Directories ................................................................................................... 578 BLOOD PRESSURE DICTIONARY .......................................................................................... 579 INDEX .............................................................................................................................................. 681
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with blood pressure is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about blood pressure, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to blood pressure, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on blood pressure. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to blood pressure, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on blood pressure. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON BLOOD PRESSURE Overview In this chapter, we will show you how to locate peer-reviewed references and studies on blood pressure.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and blood pressure, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “blood pressure” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Blood Pressure and the U.K. Prospective Diabetes Study Source: Diabetes Spectrum. 14(4): 235-240. October, 2001. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: Control of blood pressure is important to people with diabetes. This article provides background information on the design and results of the United Kingdom Prospective Diabetes Study blood pressure study and the potential difficulties of translating this landmark study into practice. The authors address the practical and quality assurance issues surrounding blood pressure and offers information about potential pitfalls that can lead to errors of measurement. The authors also explore methods of patient participation in the measurement of blood pressure and in decision
4
Blood Pressure
making about control of high blood pressure and explain why a participatory approach is needed. The authors comment on the failure of medical practice to achieve the substantial potential among patients with coronary heart disease (CHD) to reduce the risk of recurrent disease and death. For example, when the second study, conducted in 1999 and 2000, was compared to the first study, conducted in 1995 and 1996, the prevalence of smoking was unchanged, obesity had increased, and the proportion with hypertension was unchanged, although aspirin continued to be widely used and cholesterol was substantially reduced. This shows that there is substantial room for patients, nurses, and educators to be influential in reducing blood pressure and cardiovascular risks. Patient educational, empowerment, and self-management roles will be needed, with health care professionals encouraging patients to be active participants in their care. Sharing information, skills, and tools between patients and providers will be key. 2 figures. 19 references. •
Blood Pressure in Young Adulthood and the Risk of Type 2 Diabetes in Middle Age Source: Diabetes Care. 26(4): 1110-1115. April 2003. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: Hypertension (high blood pressure) is known to accompany type 2 diabetes in middle age, but it is unknown how early in life blood pressure (BP) begins to rise among individuals who later develop diabetes. This study evaluated elevated BP as a long-term predictor of type 2 diabetes. The prospective cohort study included 1,152 white male medical students; incident (new) diabetes was identified by self-report through mailed questionnaires verified by medical record review. During a median follow up of 38 years, 77 cases of incident diabetes occurred. The mean age of diabetes diagnosis was 58 years. As early as age 30 years, mean systolic BP and diastolic BP were significantly higher in men who developed diabetes during follow up than in those who remained nondiabetic. After adjustment for body mass index (BMI) and other risk factors for diabetes, systolic BP and diastolic BP at age 30 years remained significantly higher in individuals who developed diabetes than in their nondiabetic counterparts. The authors conclude that BP elevations precede the development of type 2 diabetes in middle age by 20 to 25 years. Higher BP in the prediabetic state might contribute to the presence of vascular disease at the time of diagnosis of type 2 diabetes. 1 figure. 2 tables. 38 references.
•
Increase in Nocturnal Blood Pressure and Progression To Microalbuminuria in Type 1 Diabetes Source: New England Journal of Medicine. 347(11): 797-805. September 12, 2002. Contact: Available from New England Journal of Medicine. 860 Winter Street, Waltham, MA 02451-1413. (781) 893-3800. Website: www.nejm.org. Summary: Patients with type 1 diabetes mellitus and microalbuminuria (microscopic protein in the urine) often have elevated blood pressure while they are asleep, but it is not known whether the elevation develops concomitantly with microalbuminuria or precedes it. This article reports on a study of 75 adolescents and young adults with type 1 diabetes with normal urinary albumin excretion and blood pressure for more than five years. Ambulatory blood pressure monitoring was used to assess blood pressure at the initial evaluation and about two years later, at which time all subjects had normal urinary albumin excretion. Subsequently, subjects were monitored for the development of microalbuminuria. Microalbuminuria developed in 14 subjects, whereas the other 61
Studies
5
continued to have normal urinary albumin excretion. The mean systolic pressure during sleep increased significantly in the subjects who ultimately had microalbuminuria, but not in the subjects with normal albumin excretion. The authors conclude that in persons with type 1 diabetes, an increase in systolic blood pressure during sleep precedes the development of microalbuminuria. In those whose blood pressure during sleep decreases normally, the progression from normal albumin excretion to microalbuminuria appears to be less likely. 4 figures. 2 tables. 37 references. •
15-Year Longitudinal Study of Blood Pressure and Dementia Source: Lancet. 347: 1141-1145. April 27, 1996. Summary: This journal article describes a 15-year study of the association between blood pressure and the development of dementia in older people. Residents of Goteborg, Sweden, who were 70 years in 1970-1972 participated in this study. A random subsample of 382 residents who did not have dementia on psychiatric evaluation at age 70 years were followed for 15 years with repeated neuropsychiatric examination and physical examination, electrocardiogram, chest radiograph, and blood tests. The results suggest that participants who developed dementia at age 79-85 years had significantly higher systolic blood pressure at age 70 years and significantly higher diastolic blood pressure at ages 70 and 75 years than did those who did not develop dementia. A significant association was found between higher diastolic blood pressure at age 70 years and subsequent development of Alzheimer's disease, and between higher diastolic blood pressure at age 75 years and subsequent development of vascular dementia. Participants with white matter lesions on computed tomography at age 85 years had higher blood pressure at age 70 than those without such lesions. In participants who developed dementia, blood pressure declined just before dementia onset and was then similar to or lower than that in participants without dementia. The authors conclude that increased blood pressure at age 70 years may increase the risk of developing dementia 10 to 15 years later. 4 figures, 1 table, 30 references.
•
Midlife Blood Pressure and Dementia: The Honolulu-Asia Aging Study Source: Neurobiology of Aging. 21: 49-55. 2000. Summary: This journal article examines the association between mid-life blood pressure and late-life dementia. Data are from the sample of 3,703 Japanese-American men who were followed in the Honolulu Heart Program and reexamined for dementia. Researchers determined the risk for dementia associated with categories of systolic (SBP) and diastolic (DBP) blood pressure, stratified by treatment with anti-hypertensive medication. Among those never treated for hypertension, the odds ratio for dementia was 3.8 for men with DBP of 90-94, and 4.3 for DBP of 95 and over. Compared to those with SBP of 110-139, the risk for dementia in men with SBP 160 and higher was 4.8. Blood pressure was not associated with risk for dementia in treated men. The findings suggest that elevated blood pressure in mid-life can increase risk of late-life dementia in men never treated with anti-hypertensive medication. 3 tables, 42 references. (AA-M).
•
Cross-Sectional Association Between Blood Pressure and Alzheimer's Disease in a Biracial Community Population of Older Persons Source: Journal of Gerontology. 55A(3): M130-M136. 2000. Summary: This journal article examines the cross-sectional association of blood pressure and Alzheimer's disease (AD) in a biracial community population of older people. Inhome interviews were completed with 6,162 residents age 65 years or older. A stratified
6
Blood Pressure
random sample of 729 participants was clinically evaluated and 243 were diagnosed with AD. In logistic regression models adjusted for age, sex, education, and race, there was no association between blood pressure measured as a continuous variable and AD. In categorical analyses, however, prevalence of AD was significantly higher among persons with low systolic pressure compared with the referent group of 130-139 mmHg, and with low diastolic pressure compared to the referent of 70-79 mmHg. High systolic and diastolic categories were not statistically different from the referent group, although there was some evidence that the associations differed by race. The odds ratios changed little with further adjustment for apolipoprotein E genotype, antihypertensive medications, body mass, stroke, diabetes, or heart disease. 1 figure, 3 tables, 39 references. •
Current and Remote Blood Pressure and Cognitive Decline Source: JAMA. Journal of the American Medical Association. 281(5): 438-445. February 3, 1999. Summary: This journal article examines the possibility that blood pressure (BP) in middle age predicts later cognitive decline. A total of 3,657 residents of East Boston, Massachusetts, aged 65 years and older, had baseline BP measurements as part of the Established Populations for the Epidemiologic Study of the Elderly in 1982 and 1983. The Short Portable Mental Status Questionnaire and the East Boston Memory Test were administered at baseline and at 3 and 6 years. Nine years before the baseline assessment, 2,068 study participants also had their BP measured as part of the Hypertension Detection and Follow-up Program. Results of analyses adjusted for age, sex, and education showed no strong linear association between BP and cognition, but raised the possibility of more complex associations. These associations were fairly small in magnitude, and varied according to whether level of cognitive function or change in cognitive function was assessed, and according to which test was used to measure cognition. The evidence suggested a U-shaped association between BP and level of performance on the mental status questionnaire, but no effect of BP on memory function or change in cognitive function on either test. 4 figures, 4 tables, 34 references.
•
Low Blood Pressure and Incidence of Dementia in a Very Old Sample: Dependent on Initial Cognition Source: JAGS. 47(6): 723-726. June 1999. Summary: This population-based study of 304 nondemented people in Sweden, aged 75 to 96 years at baseline, examined whether initially low blood pressure is related to the incidence of dementia. DSM-III-R criteria were used for dementia with Hachinski's scale being used for a differential diagnosis between Alzheimer's disease (AD) and vascular dementia. Criteria for AD were similar to those of the NINCDS-ADRDA criteria. The diagnosis of dementia was given after consensus among three independent physicians. Arterial blood pressure, antihypertensive drug use, and medical histories were determined. The Cox proportional hazards regression model was used to calculate the relative risk of developing dementia in relation to baseline blood pressure levels. After an average of 3 years, 81 dementia cases were identified. Those with systolic pressure equal to or greater than 140 mm Hg had a significantly higher risk of dementia and AD. A baseline Mini-Mental State Examination (MMSE) of less than 24 significantly predicted the occurrence of dementia, and systolic pressure equal to or greater than 140 mm Hg was significantly related to MMSE scores of less than 24 at baseline. These results suggest that low blood pressure may be an early correlate of a dementing
Studies
7
process, although researchers believe a causative effect cannot be definitely ruled out. 2 tables, 21 references. (AA-M). •
Relationship Between Ethnicity and Glycemic Control, Lipid Profiles, and Blood Pressure During the First 9 Years of Type 2 Diabetes: U.K. Prospective Diabetes Study (UKPDS 55) Source: Diabetes Care. 24(7): 1167-1174. July 2001. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This review article describes a study that assessed the relationship among self reported ethnicity, metabolic control, and blood pressure during treatment of type 2 diabetes. The study population consisted of 2,999 people newly diagnosed with type 2 diabetes recruited to the United Kingdom Prospective Diabetes Study (UKPDS) who were randomized to conventional or intensive glucose control policies if their fasting plasma glucose levels remained greater than 6 mmol per liter after a dietary run in. Among the patients, 2,484 were white Caucasian (WC), 265 patients were AfroCaribbean (AC), and 250 patients were Asian of Indian origin (IA). Variables were assessed at 3, 6, and 9 years. During the 9 year study period, body weight increased more in WC patients than in AC and IA patients. After adjusting for age, gender, baseline value, treatment allocation, and change in weight, there were no consistent ethnic differences in mean change in fasting plasma glucose or glycosylated hemoglobin. After adjustment for antihypertensive therapy, increase in systolic blood pressure at 9 years was greatest in AC patients. Mean diastolic blood pressure, total cholesterol, and low density lipoprotein cholesterol decreased progressively during the 9 years in each group. In AC patients, the mean increase in high density lipoprotein cholesterol at 3 years, which was maintained at year 9, and the mean decrease in plasma triglyceride level at 9 years were greater than in WC and IA patients. The article concludes that the study shows important ethnic differences in body weight, lipid profiles, and blood pressure, but not glycemic control, during 9 years after diagnosis of type 2 diabetes. AC patients maintained the most favorable lipid profiles, but hypertension developed in more AC patients than WC or IA patients. Ethnicity specific glycemic control of type 2 diabetes seems unnecessary, but other risk factors need to be addressed independently. 1 appendix. 4 figures. 2 tables. 31 references. (AA-M).
•
Association Between Midlife Blood Pressure Levels and Late-Life Cognitive Function: The Honolulu-Asia Aging Study Source: JAMA. Journal of the American Medical Association. 274(23): 1846-1851. December 20, 1995. Summary: This study assessed the long-term relationship of midlife blood pressure levels to late-life cognitive function. The study involved 4,678 surviving members of the prospective Honolulu Heart Program from which 3,735 Japanese-American men, aged 78 years, living in a Hawaiian community or in institutions were selected. Researchers used the 100-point Cognitive Abilities Screening Instrument to measure cognitive function. Midlife systolic blood pressure (SBP) and diastolic blood pressure (DBP) values were measured in 1965, 1968, and 1971. Results, when controlled for age and education, suggest that the risk for intermediate and poor cognitive function increased progressively with increasing level of midlife SBP category. For every 10 mm Hg increase in SBP there appeared to be an increase in risk for intermediate cognitive function of 7 percent and for poor cognitive function of 9 percent. According to the
8
Blood Pressure
authors, adjustment for prevalent stroke, coronary heart disease, and subclinical atherosclerosis reduced the strength of the relationship between midlife SBP and poor cognitive function to 5 percent. The level of cognitive function did not appear to be associated with midlife DBP. The results suggest that midlife SBP may help predict reduced cognitive function in later life. Early control of SBP levels may reduce the risk for cognitive impairment in old age. 4 tables, 43 references. (AA-M).
Federally Funded Research on Blood Pressure The U.S. Government supports a variety of research studies relating to blood pressure. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to blood pressure. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore blood pressure. The following is typical of the type of information found when searching the CRISP database for blood pressure: •
Project Title: 20-HETE AND ITS INTERACTION WITH NO IN PREGNANT RATS Principal Investigator & Institution: Wang, Mong-Heng; Pharmacology; New York Medical College Valhalla, NY 10595 Timing: Fiscal Year 2002; Project Start 19-JUL-2002; Project End 30-NOV-2002 Summary: (provided by applicant): This is a proposal to investigate the mechanisms regulating renal vascular and tubular (medullary thick ascending limb; mTAL) synthesis of 20-hydroxyeicosatetraenoic acid (20-HETE) during pregnancy. 20-HETE is a major cytochrome P450 (CYP) 4A-derived eicosanoid in the rat kidney whose potent effects on vascular tone and tubular ion transport implicate it in the regulation of renal function and in the control of blood pressure. Normal pregnancy in humans and rats is associated with increases in the glomerular filtration rate and renal blood flow along with a significant decrease in arterial pressure and total peripheral resistance. The exact mechanisms mediating these physiological changes are not fully understood. Preliminary studies demonstrated distinct patterns of CYP4A isoform expression and 20-HETE synthesis in renal microvessels and mTAL during pregnancy and a transient reduction in systolic blood pressure and urinary sodium excretion following administration of an inhibitor of 20-HETE synthesis in pregnant rats. We hypothesize that renal 20-HETE synthesis is affected during gestation and that 20-HETE is involved in the regulation of renal function and blood pressure during pregnancy. Experiments will be performed in Aim 1 to characterize vascular and mTAL 20-HETE synthesis and CYP4A expression in pregnant rats at different gestational days, and in Aim 2 to
2 Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
9
determine the consequence of inhibition and over-expression of CYP4A proteins in pregnant rats on renal 20-HETE synthesis, vascular reactivity, mTAL potassium channel activity, urinary electrolyte levels, and blood pressure. It has been shown that nitric oxide (NO) inhibits CYP4A activity and expression; inhibition of its production results in signs similar to preeclampsia. Experiments in Aims 3 and 4 will examine the possibility that NO presents a mechanism that regulates CYP4A expression and 20HETE synthesis during pregnancy. The present proposal sets the basis for understanding mechanisms that regulate 20-HETE synthesis in the kidney during pregnancy. Ultimately, this knowledge can uncover new therapeutic targets and provide novel loci for the control and treatment of pregnancy-induced hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AFRICAN HYPERTENSION
AMERICAN
STUDY
OF
KIDNEY
DISEASE
&
Principal Investigator & Institution: Randall, Otelio S. Professor of Medicine; Medicine; Howard University 2400 6Th St Nw Washington, DC 20059 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 30-JUN-2003 Summary: Hypertension is considered one of the major causes of end stage renal disease (ESRD) in the general population, and the number one cause in African Americans. Despite the availability of potent antihypertensive drugs, the number of hypertensive African Americans progressing to ESRD continues to rise. This disproportionately high prevalence of ESRD in African Americans cannot be explained by the higher prevalence of hypertension. Whether this is due to more susceptibility of the kidney of African Americans to hypertensive injury or due to concurrent existence of unidentified renal factors is not known. There is preliminary evidence suggesting that antihypertensive drugs may retard the progression of hypertensive renal disease, but no clinical trial has been conducted to test this hypothesis in African Americans. This proposed multi-center project is designed to study the following: if the pathological lesion in "hypertensive renal disease" is purely a result of persistent hypertension; if one anti-hypertensive drug is better than another in terms of preservation of renal function; and the level of blood pressure suitable for the survival of the kidney. Hypertensive African Americans, 18-70 years of age with no other known disease that can affect the kidney, will be screened for blood pressure qualification, and will undergo glomerular filtration rate (GFR) tests. Those who qualify, based on blood pressure levels and the GFR results will then be randomized in a double-masked fashion to one of the three major antihypertensive classes (converting enzyme inhibitor, calcium channel blocker, or beta blocker) and to one of two pressure levels: mean blood pressure greater than 92 millimeter of mercury (mmHg), or 102 to 107 mmHg. Other antihypertensive drugs will be added to keep the blood pressure at the desired level. The blood pressure of the randomized subjects will then be monitored on a monthly basis and compliance to medication(s) will be checked at the same time. Their renal function will also be tracked with periodic GFR tests throughout the study period, which will last approximately four years. All data will be collected and sent to the Data Coordinating Center (DCC) for analyses and interpretation. The goal of the African American Study of Kidney Disease and Hypertension (AASK) full- scale trial is to better understand the physiopathology of hypertensive renal disease in an effort to develop guidelines to prevent the increasing prevalence of ESRD in African Americans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
10 Blood Pressure
•
Project Title: AFRICAN HYPERTENSION
AMERICAN
STUDY
OF
KIDNEY
DISEASE
IN
Principal Investigator & Institution: Rostand, Stephen G. Medicine; University of Alabama at Birmingham Uab Station Birmingham, AL 35294 Timing: Fiscal Year 2001; Project Start 19-AUG-1994; Project End 30-JUN-2003 Summary: The first goal of this application is to initiate a Clinical Center for the Full Scale phase of the "African-American Study of Kidney Disease and Hypertension". This study is a cooperative, multicenter, prospective, double-masked, randomized study that will follow a three by two factorial design. This study will be limited to about 900 African-Americans recruited from 14 Clinical Centers. Eligibility for participation will be determined by strict inclusion and exclusion criteria. Only those with seated diastolic blood pressure equal to or more than 95 mmHg and with glomerular filtration rate (GFR) 25 - 70 mmHg/1.73m2, without malignant hypertension or systemic disease and who are willing to cooperate will be considered. This study will consist of three phases: (l) Recruitment (24 months); (2) Intervention and follow-up (45 months); (3) Data analysis, close-out, results reporting (12 months). The second goal of this study is to test whether one of three different initial randomized drugs: angiotensin converting enzyme inhibitor (ACEi), calcium channel blocker (CCB) or beta blocker. better reduces the rate of decline of UFR in African-Americans with renal insufficiency attributed to hypertension. A third goal is to examine if one of two levels of blood pressure control (equal to or less than 92 mmHg vs. 102-107 mmHg, mean arterial pressure) is better at preserving renal function. Assignment to treatment and blood pressure groups will be randomized and the treatment regimen will be double-masked. Subsequent to assignment. no other ACEis, CCBs or beta- blockers will be used. If a blood pressure goal is not reached in a participant on maximal doses of the assigned drugs, additional antihypertensives will be used in the following order: (l) diuretics (furosemide); (2) alpha-blocker (doxazosin); (3) central alpha2 agonist (clonidine); (4) minoxidil or hydralazine. This study has major health related implications for disease prevention in that it will try to examine if renal failure due to hypertension that occurs in an extremely high risk African-American population can be slowed or prevented, thereby reducing the need for dialysis and renal transplantation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANG II AND AVP ISORECEPTORS IN BLOOD PRESSURE Principal Investigator & Institution: Ruiz-Opazo, Nelson; Asociate Professor; Medicine; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2001; Project Start 15-DEC-1998; Project End 30-NOV-2002 Summary: Vasopressin (AVP) and angiotensin II (AngII) hormonal systems modulate a variety of physiologic functions affecting multiple organ systems. Of singular importance, is their role in blood pressure regulation. Our long term objective is to dissect the specific contribution of novel AngII and AVP receptors in blood pressure regulation in normal and pathophysiological states. Several isoreceptors for both AngII and AVP have been recently characterized. Of these, the dual AngII/AVP receptor, isolated by us, elucidates novel information providing the bases for new hypotheses and questions. In this research proposal, we will test the following hypotheses: 1) Based on the detected abundance and assignment by immunocytochemical localization of the AngII/AVP receptor polypeptide to renal epithelial cells of the outer medullary thick ascending limb tubules and inner medullary collecting ducts, we hypothesize that the AngII/AVP receptor is a prominent renal physiologic target for AngII and AVP, and
Studies 11
therefore plays an important role in salt- water balance and blood pressure regulation; 2) Based on the elucidation of functional significant mutations in the Dahl Salt-Sensitive rat AngII/AVP receptor, we hypothesize that the AngII/AVP receptor is a genetic determinant for salt-sensitive hypertension in the Dahl Salt- Sensitive hypertensive rat. Accordingly, the following specific aims are prioritized: I) Dissection of potential pathophysiologic involvement of the AngII/AVP receptor in hypertension 1A) Assessment of the specific contribution(s) of N119S and C163R substitutions to the increased sensitivity to Ang II and AVP and enhanced Gs-coupling observed in the Dahl S AngII/AVP receptor; 1B) Genetic cosegregation analysis of the AngII/AVP receptor with blood pressure and renal pathology in an F2 (Dahl S male x Dahl R female) cohort comprised of male and female rats in order to determine whether the mutant AngII/AVP receptor cosegregates with high blood pressure and/or with hypertensive renal disease. II) Dissection of physiologic role of the AngII/AVP receptor: 2A) Tissue specific, spatial and temporal expression patterns in development of the AngII/AVP receptor gene, establishing a foundation for assessing its function in an integrated biologic experimental system as in the gene targeting experiments proposed below. 2B) Targeted disruption of the AngII/AVP receptor gene in mice in order to define its physiologic role in an integrated biologic experimental system. These studies will elucidate the physiologic role of the AngII/AVP receptor and will define the status of the AngII/AVP receptor as a candidate hypertension susceptibility gene, thus paving the way for the direct assessment of the mechanistic role of this receptor in salt-sensitive hypertension and its role in the development of hypertension in selective human populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANGIOTENSIN RECEPTORS IN CENTRAL OSMONSENSITIVITY Principal Investigator & Institution: Morris, Mariana; Professor and Chair; Pharmacology and Toxicology; Wright State University Colonel Glenn Hwy Dayton, OH 45435 Timing: Fiscal Year 2002; Project Start 12-JUL-2002; Project End 30-JUN-2006 Summary: (provided by applicant): Angiotensin (Ang) AT1 receptors are critical in the control of blood pressure and fluid/electrolyte balance. AT1 receptors exist in two forms, AT1a and AT1b, which are homologous in gene and protein structure, making it impossible to distinguish pharmacologically. Genetic engineering techniques have produced models which allow for the investigation of gene/function interactions. Removal of AT1 a receptors appears to activate central Ang receptors, particularly in osmosensitive brain regions. The net result is an enhancement of the blood pressure and central neuroendocrine responses to stimuli which alter fluid/electrolyte balance. We propose to test the hypothesis that Ang receptors in specific brain regions are critical in the regulation of osmotic balance. Using the AT1 aKO model, we will determine the nature of the central nervous system changes with a focus on Ang/vasopressin (VP) interactions. The problem will be addressed at the level of the whole animal and. the individual neuron. For in vivo studies, we will use a method for chronic cardiovascular monitoring and blood sampling in the conscious mouse. The goal is to determine the role of Ang receptors in osmosensitivity, studying the regulation of blood pressure, heart rate, peptide secretion and neural activation. Markers for CNS activation include c-Fos, Ang receptors, Ang receptor mRNA and VP mRNA. Cellular studies aim at elucidating the mechanisms by which Ang modulates osmosensitivity in VP neurons. In vitro studies will use perfused brain slices for determination of electrophysiological properties underlying osmosensitivity. The specific aims are: 1. Are osmotic-induced
12 Blood Pressure
peptide and cardiovascular responses altered in AT1 aKO? This will address the issue of whether acute or chronic osmotic stimulation alters the central and peripheral VP system, the central Mg receptor system, and cardiovascular and fluid balance. Experiments will further test the effect of Ang receptor blockade and enzymatic inhibition to document the extent and specificity of Mg input. 2. What are the cellular mechanisms underlying osmosensitivity in AT1aKO? The basic question relates to the nature of the cellular changes and whether these are mediated by intrinsic mechanisms. 3. What is the relationship between the central Ang system and the alterations in osmosensitivity? This will address the issue of whether there are changes in responses to Ang II or other Mg peptides and whether these are important in osmotic responsiveness. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ANTIHYPERTENSIVE THERAPY IN AUTOSOMAL DOMINANT PKD Principal Investigator & Institution: Schrier, Robert W. Professor; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, CO 800450508 Timing: Fiscal Year 2001; Project Start 01-APR-2001; Project End 31-MAR-2006 Summary: (the applicant's description verbatim): The long-term objective of this research is to reduce the morbidity and mortality of autosomal dominant polycystic kidney disease (ADPKD). This project is an on-going 5-year clinical trial to test the hypothesis that intensive blood pressure control with angiotensin converting enzyme inhibitors (ACEI) as first-line drugs will slow the progression of ADPKD in children. Progression in children will be measured by increase in renal volume as determined by ultrasound imaging, reflecting increased number and size of renal cysts. Secondary aims are to evaluate the effect of intensive blood pressure control on left ventricular mass index, on microalbuminuria and proteinuria, and on the activation level of several growth-related and inflammatory cytokines. Three groups of children and young adults, age 4 to 21 years, will be randomized to different treatments: 1. Hypertensive subjects with blood pressures above the 95th percentile for age-, gender- and height-matched children will be randomized to intensive or standard blood pressure control, with intensive control defined as lowering blood pressure to the 45th to 50th percentile and standard control as lowering blood pressure to the 85th to 90th percentile. 2. Borderline hypertensive subjects with blood pressures between the 75th and 95th percentile will be randomized to treatment to lower the blood pressure to the 45th to 50th percentile versus no treatment. 3. Normotensive subjects (blood pressure between the 25th and 75th percentile) will be randomized to treatment with ACEI as long as blood pressure stays above the 25th percentile versus no treatment. The first-line drug for all groups is enalapril, second-line drugs for groups 1 and 2 are amlodipine and hydrochiorothiazide. The primary outcome variable is the increase in renal volume per year, compared between the different treatment levels or between treatment and no treatment. If intensive blood pressure control can be shown to reduce progressive renal enlargement, it would change screening and treatment recommendations for children from ADPKD families, and would have a major impact on the morbidity associated with large kidneys and with end-stage renal disease in ADPKD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIHYPERTENSIVE THERAPY IN CHILDREN WITH ADPKD Principal Investigator & Institution: Fick-Brosnahan, Godela M.; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, CO 800450508
Studies 13
Timing: Fiscal Year 2001; Project Start 01-APR-1985; Project End 30-JUN-2006 Summary: The long-term objective of this research is to reduce the morbidity and mortality of autosomal dominant polycystic kidney disease (ADPKD). This Project is a 5-year clinical trial to test the hypothesis blood pressure control with angiotensin converting enzyme inhibitors (ACEI) as first- line drugs will slow the progression of ADPKD in children. Progression in children will be measured by the increase in renal volume, which reflects an increased number and size of renal cysts, as determined by magnetic resonance imaging. Secondary aims are to evaluate the effect of intensive blood pressure control on left ventricular mass index, on microalbuminuria and proteinuria, and on the activation level of several growth-related and inflammatory cytokines. Three groups of children and young adults, age 4 to 21 years, will be randomized to different treatments: 1. Hypertensive subjects with blood pressure above the 9th percentile for age-, and gender- and height-matched children will be randomized to intensive or standard blood pressure control, with intensive control defined as lowering blood pressure to the 45th or 50th percentile and standard control as powering control defined as lowering blood pressure to the 85th to 90th percentile. 2. Borderline hypertensive subjects with blood pressures between the 75th and 95th percentile will be randomized to treatment to power the blood pressure to the 45th to 50th percentile or not treatment. 3. Normotensive subjects (blood pressure between the 25th and 75th percentile) will be randomized to treatment with ACEI or to no treatment. The first-line drug for all groups is enalapril, second-line drugs for groups 1 and 2 are amlodipine and hydrochlorothiazide. The primary outcome variable is the increase in renal volume per year, compared between the different blood pressure levels or between ACEI treatment and no treatment. If intensive blood pressure control or treatment with ACEI can be shown to reduce progressive renal enlargement, it would change screening and treatment recommendations for children from ADPKD families, and would have a major impact on the morbidity associated with large kidneys and with end-stage renal disease in ADPKD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ARTERIAL BAROREFLEX CONTROL OF BLOOD PRESSURE-EXERCISE Principal Investigator & Institution: Raven, Peter B. Professor and Chairman; Integrative Physiology; University of North Texas Hlth Sci Ctr Fort Worth, TX 761072699 Timing: Fiscal Year 2001; Project Start 01-JUL-1994; Project End 30-JUN-2003 Summary: (Applicant's abstract): Previously, we have demonstrated that the carotid baroreflex control of blood pressure during dynamic exercise is classically reset to the prevailing blood pressure of the dynamic exercise. Aortic baroreflex control of heart rate was also reset to the prevailing blood pressure without a change in maximal gain. Additionally, our findings suggest that at rest the arterial baroreflex function is modulated by aerobic fitness, cardiopulmonary baroreceptor load and increases in the intramuscular pressure. However, the mechanisms by which 1) the arterial baroreflexes are reset during exercise, 2) the interaction between increases in muscle pressure and the arterial baroreflex function, and 3) the effect of aerobic fitness on arterial and cardiopulmonary baroreflex function remain to the defined. We hypothesize that the feed forward mechanism of central command resets the baroreflexes in parallel with the induction of motor activity and continuous modulation of this resetting is provided by activation of intramuscular mechanoreceptors within the active tissue. We further hypothesize that increases in aerobic fitness results in an increased blood volume and a resetting of the aortic and cardiopulmonary baroreflex. In order to test these hypotheses
14 Blood Pressure
we will use a historically unique experimental paradigm in which muscle tendon vibration will be used to selectively increase or decrease central command. During steady state exercise (a constant exercise pressor reflex input) with and without muscle tendon vibration, carotid arterial baroreflex function will be determined using procedures developed in our laboratory. Using a similar experimental paradigm and increasing intramuscular pressure by using lower body positive pressure, the interactions between central command and intramuscular pressure will be examined. Additionally, using techniques developed in our laboratory and measures of MSNA, NE spill-over and leg vascular conductance we will selectively model the aortic and cardiopulmonary baroreflexes of high and low fit endurance exercise trained subjects. A unique aspect of this investigation is that the data obtained is immediately relevant to the healthy human and will provide significant fundamental information for the investigation of blood pressure regulation during physical activity of patients with heart failure, hypertension and intermittent claudication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AT2 RECEPTORS IN BLOOD PRESSURE AND RENAL FUNCTION Principal Investigator & Institution: Carey, Robert M. Professor and Dean; General Clinical Research Ctr; University of Virginia Charlottesville Box 400195 Charlottesville, VA 22904 Timing: Fiscal Year 2001; Project Start 27-AUG-2001; Project End 31-JUL-2005 Summary: (provided by applicant): The overall objective is to test the hypothesis that the angiotensin type-2 (AT2) receptor plays an important role in the control of blood pressure and kidney function through the generation of bradykinin (BK), nitric oxide (NO) and guanosine cyclic 3', 5' monophosphate (cGMP). The specific aims are (1) to test the hypothesis that AT2 receptor stimulation mediates renal and systemic vasodilation and hypotension by increasing the production of BK, NO and cGMP and (2) to test the hypothesis that AT2 receptor stimulation, through increased renal production of BK, NO and cGMP, induces natriuresis. The investigators have demonstrated that the AT2 receptor is expressed in the kidney, heart and peripheral vasculature and stimulates renal BK, NO and cGMP. The principal investigator's recent studies in mice lacking the AT2 receptor (AT2-Null) demonstrate a sustained pressor and antinatriuretic hypersensitivity to angiotensin II (ANG II), accompanied by a marked reduction in BK, NO, cGMP. These results suggest that the AT2 receptor may function as an opponent of the actions of ANG II at the AT1 receptor. The principal investigator has recently demonstrated that valsartan-infused rats without functioning AT1 receptors have hypotensive respoflses to Ang II that are fully blocked by the AT2 receptor antagonist, PD 123319.The proposed experiments represent a systematic approach to the role of the AT2 receptor in vasodilation and natriuresis and the renal mechanisms of these actions in the valsartan-infused (AT1 receptor-blocked) rat model. This model will allow evaluations of the role of the AT2 receptor and its signalling mechanisms in the absence of interference by functional AT1 receptors. The proposed studies will clarify the role of the AT2 receptor in the control of blood pressure and kidney function. An understanding of the function of the AT2 receptor is necessary for an assessment of its potential role in the pathophysiology of hypertension and as a target for antihypertensive therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 15
•
Project Title: AUTOREGULATION OF CEREBRAL BLOOD FLOW IN ACUTE ISCHEMIA Principal Investigator & Institution: Powers, William J. Professor of Neurology & Radiology; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-MAY-2008 Summary: Hypertension is one of the most significant risk factors for ischemic stroke. Long term treatment of hypertension after stroke has been shown to reduce the incidence of recurrent stroke by 28% and major cardiovascular complications by 26%. However, in the setting of acute ischemic stroke it has been difficult to determine the appropriate treatment of elevated blood pressure due to the overwhelming concern that lowering blood pressure in this setting might worsen cerebral ischemia. These concerns are based primarily on studies of CBF in animal models. Very few studies of the effect of pharmacological reduction of elevated blood pressure on CBF following acute ischemic stroke in humans have been done and they do not provide adequate data to settle this issue. The goal of this research project is to determine the effect of controlled, graded pharmacologic reduction of blood pressure on rCBF following acute ischemic stroke using positron emission tomography (PET) and to carefully monitor the clinical effects and safety of treatment. This specific null hypothesis will be tested: Pharmacological reduction of mean arterial blood pressure (MAP) by 15 +/- 5 mm Hg in patients with a recent cerebral infarction and elevated blood pressure does not produce a statistically significant reduction in regional cerebral blood flow. This Specific Aim will be carried out: Between day 3-14 after onset, sixty patients with a hemispheric cerebral infarction and mean arterial blood pressure of 120-150 mm Hg will undergo a detailed neurological examination and measurements of rCBF, regional cerebral metabolic rate (rCMRO2), and regional oxygen extraction fraction (rOEF) using PET. Blood pressure will then be lowered pharmacologically in two steps of 7.5 +/- 5 mm Hg each using intravenous labetalol. The neurological examination and CBF measurements will be repeated after each step. This study is not designed to provide data on whether blood pressure in the acute setting improves outcome. This can only be done by randomized treatment trials with clinical outcome measures. These data can, however, be used to help design such a trial and, in the meantime, provide helpful guidelines when reduction in arterial pressure is deemed to be necessary for other reasons. This study will provide esssential information necessary to translate data from animal studies into treatment for human cerebrovascular disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BEHAVIORAL TREATMENT OF HYPERTENSION Principal Investigator & Institution: Blumenthal, James A. Professor; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 01-DEC-2000; Project End 30-NOV-2001 Summary: Purpose: The study which we have now completed was a single, randomized clinical trial of exercise and weight management with three long term objectives. The first was to evaluate the efficacy of two behavioral interventions--aerobic exercise and weight management--in reducing blood pressure (BP) in people with mild HTN; the second was to examine the mechanisms by which BP was reduced; and the third was to investigate the effects of behavioral treatment on cognitive performance and related aspects of quality of life. Methods: We recruited 144 individuals with mild HTN. Individuals who were eligible but unable to participate in the intervention were initially assigned to a non-random control group (N=11). However, this practice was stopped
16 Blood Pressure
and we are only including the 133 fully randomized subjects in our data analysis. Volunteers were randomly assigned to 6 months of exercise alone, exercise with weight management, or a control group. Subjects underwent evaluations at baseline and at 6 months, in addition to an eligibility screening--physical exam and blood and urine samples. Measurements of BP were obtained in the clinic, during ambulatory BP monitoring, and during physical exercise and mental stress testing. BPs were also obtained at 1 year follow-up. To examine potential mechanisms responsible for BP changes, subjects underwent glucose tolerance testing, lipid analysis, studies of heart rate variability, and hemodynamic and neuroendocrine assessments. Because hypertension has been shown to be associated with measurable changes in cognitive function, which may be reversible when BP is normalized, subjects also completed neuropsychological assessments along with psychometric testing. Finally, the clinical significance of the BP changes were determined by repeat cardiac echocardiography, as well as by repeated BP testing at baseline, 6 months, and 1 year follow-up. Results: Results indicate that while exercise alone is effective in reducing both systolic and diastolic blood pressure, the addition of a behavioral weight loss program augments significantly the efficacy of exercise alone. The magnitude of the resting clinic blood pressure reductions were 4-5 mm in the Exercise alone condition, but increased to 5-8 mm in the combined exercise and weight loss condition. Larger BP reductions also were observed for the combined condition relative to exercise alone with ambulatory blood pressure monitoring during routine activities of daily living, particularly for DBP, and during mental stress testing in the laboratory setting. In terms of potential mechanisms that may be responsible for the BP changes, changes in glucose metabolism and increased vagal tone were associated with BP reductions. Exercise alone was not associated with significant weight loss or changes in body composition. In addition exercise alone did not improve insulin sensitivity (as assessed indirectly by fasting plasma insulin), insulin secretory response, or plasma glucose. While the FPG in the present sample of hypertensive patients was normal, they did demonstrate substantial insulin resistance, as indicated by the presence of fasting and post prandial hyperinsulinemia. Consistent with this other research, the present findings did not show a substantial effect of exercise alone on glucose or insulin parameters unless the exercise was combined with diet. It would appear that a weight loss, over and above exercise alone, is necessary to induce favorable metabolic changes. Increased heart rate variability was also associated with exercise training, particularly among patients who also lost weight. Aerobic endurance training was associated with an increase in mean RR interval (bradycardia) at rest and that this bradycardia was accompanied by an increase in the standard deviation of R-R interval. This improvement was even greater among patients who lost weight in the Combination group. In contrast to findings from other studies, no treatment effects were observed for lipids or catecholamines in this project. Significance: Hypertension (HTN) is a major health problem in the U.S. placing some 58 million Americans at increased risk for stroke, myocardial infarction, kidney failure, and peripheral vascular disease. The information obtained from this study will have important practical significance by determining the efficacy of exercise and weight reduction in lowering BP in men and women with mild hypertension, and by assessing the clinical importance of these changes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 17
•
Project Title: BLOOD PRESSURE CANDIDATE GENE SCREENING--A NEW PARADIGM Principal Investigator & Institution: Cicila, George T. Physiology/Molecular Medicine; Medical College of Ohio at Toledo Research & Grants Admin. Toledo, OH 436145804 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2003 Summary: (Adapted from the Investigator's Abstract) The essential mechanisms (and the genes underlying them) leading to hypertension need identification for better understanding and treatment of this complex disorder. The most direct way of accomplishing this is to identify genes regulating blood pressure in animal models of genetic hypertension. The applicants have linked loci on rat chromosomes 3 and 7 to blood pressure quantitative trait loci (BP QTL) in a segregating population bred from inbred Dahl salt-sensitive (S) and salt-resistant (R) rats fed a high salt diet. Introgression of R-rat derived chromosomal regions containing these two QTLs into S rats resulted in congenic strains with significantly lower blood pressure and cardiac mass compared to S rats, confirming the presence of BP QTL in the introgressed regions of chromosomes 3 and 7. Similar methodology has been used by others to develop congenic strains carrying BP QTLs located on six other chromosomes, resulting in a panel of eight congenic strains derived from the Dahl rat model of blood pressure salt-sensitivity. The applicant hypothesizes that gene(s) underlying a given BP QTL may be differentially expressed in target organs/tissues. If so, such a gene should also be differentially regulated in congenic strains carrying different BP QTL. Gene(s) responsible for a QTL's effect should show a congenic strain-specific differential-pattern of expression in a target organ(s) and should map to the chromosomal interval carried by that particular congenic strain. Therefore, genes having such characteristics will be superior candidates as genes responsible for, at least in part, a specific BP QTL. The applicant proposes to identify candidate genes for BP QTL as follows: Differentially expressed genes will be identified in the kidneys of S and R rats, on both low NaCl (genetic-differences) and high NaCl diets (salt-responsive). Renal RNA expression of such differentiallyexpressed genes will be examined in a panel of congenic strains carrying Dahl rat BP QTL, where each strain carries a low blood pressure allele for a different BP QTL on a background of S-rat alleles. Genes having a congenic strain-specific pattern of differential gene expression will be mapped to determine their genomic location. Genes with a 1) congenic strain-specific pattern of differential gene expression and 2) mapping to the introgressed chromosomal region containing a specific BP QTL, will be considered strong candidates for the gene(s) responsible for blood pressure differences associated with this QTL. This new approach should accelerate the identification of strong candidate genes for particular BP QTL and, potentially, of new blood pressure regulatory mechanisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BLOOD PRESSURE IN POSTMENOPAUSAL WOMEN: A GCRC STUDY Principal Investigator & Institution: Seely, Ellen W. Professor; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2003; Project Start 15-JUL-2003; Project End 31-MAY-2008 Summary: (provided by applicant): This is a Mid-Career Investigator (K 24) proposal for Ellen Seely, MD. The goal of this proposal is threefold. First, it would increase the depth of Dr. Seely's research by enabling the investigator to receive further advanced training in human genetics. Second, it would give the investigator the supported time to
18 Blood Pressure
formally train young investigators in patient-oriented research in the field of hormonal control of blood pressure. Third, it would allow the investigator to use her experience as Associate Program Director of the General Clinical Research Center (GCRC) to teach the next generation of patient-oriented researchers about the use of a GCRC for the study of human pathophysiology using varied GCRC-based investigative techniques. Dr. Seely's research topic "Blood Pressure in Postmenopausal Women: a GCRC Study" serves as fertile ground for a K24. Hypertension affects over 20 million women in the United States and the majority of these women are postmenopausal. Although there is clearly a genetic component to hypertension in both men and women, its incidence increases dramatically in women following menopause superceding that in men and suggests that the hormonal milieu of the premenopausal state may be protective against the manifestation of hypertension. The overall goal of Dr. Seely's research plan is to utilize the GCRC for detailed studies of the pathophysiology of hypertension in postmenopausal women. Dr. Seely plans to determine how polymorphisms of genes of the renin-angiotensin-aldosterone system (RAAS), a major regulator of blood pressure, are influenced by estradiol. An understanding of the interaction of estradiol with specific polymorphisms of the RAAS that lead to blood pressure lowering may enable the development of selective estrogen receptor modulators that have antihypertensive effects. Thus, funding of this proposal will allow Dr. Seely to expand her own research career and simultaneously provide time to expand her mentorship role. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BLOOD PRESSURE REACTIVITY IN BLACKS--FUNCTION OF EXERCISE/FAMILIAL HYPERTENSION Principal Investigator & Institution: Bond, Vernon; Howard University 2400 6Th St Nw Washington, DC 20059 Timing: Fiscal Year 2001 Summary: African Americans have the highest incidence of essential hypertension (HT) than any racial group in the United States. The cause of this high prevalence of HIV in this population is not known. There is an undeniable genetic component to HT; however, this account for only a portion of the variance in blood pressure (BP) leading many researchers to emphasize the additional importance of environmental factors such as stress and physical inactivity. Studies have indicated that physically inactive individuals and offspring of hypertensive parents have an exaggerated BP response to stress. Demonstrations of abnormal increases in BP responsiveness to stress among normotensive individuals is of clinical importance in that such pressor reactivity is associated with the cause of or a marker for future development of HT. This abnormal increase in BP reactivity to stress in both sedentary individuals and offspring of hypertensive parents is attributed to an elevated sympathetic neural activity (SNA) which alters the cardiac output and or systemic vascular resistance. Aerobic physical activity intervention has been shown to decrease the SNA and thus may alter the pressor reactivity to stress. Whether a familial history of HT interact with physical activity to affect BP responses to stress in African Americans is not known. We hypothesize that aerobic physical activity intervention will attenuate the BP response to stress in sedentary normotensive young adult African Americans with a familial history of HIT. We further hypothesize that aerobic physical activity will attenuate the BP response to groups of sedentary normotensive young adult African Americans with a familial history of HT (n= 12 females and 12 males) and without a familial history of HT (n= 12 females and 12 males) will undergo a 12 week aerobic physical activity intervention program. Similar size sedentary groups with familial HT (12 females and 12
Studies 19
males) and without familial HT (12 females and 12 males) will not undergo the physical activity intervention and will serve as the control. Systolic Bp, diastolic BP, and mean arterial BP responses at baseline and during conditions of provocative mental and physical stress will be determined and analyzed for between-group differences. Maximal oxygen uptake, cardiac output, stroke volume, systemic vascular resistance, heart rate, cardiac autonomic outflow, and skeletal muscle blood flow will be measured to determine the possible mechanism(s) of observed effects. The pattern of responses observed will increase our understanding of the interaction of genetics, physical activity interventions, and stress in the control of BP, and the cardiovascular factors involved in BP control. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BLOOD PRESSURE REDUCTION AND INSULIN SENSITIVITY IN HYPERTENSION Principal Investigator & Institution: Raskin, Phillip; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105 Timing: Fiscal Year 2001 Summary: Excess insulin production might be a factor leading to high blood pressure since it has been shown that insulin produces salt retention in the kidneys and increases the blood levels of adrenalin. It has also been suggested that decreased insulin sensitivity could be a consequence not a cause of hypertension. In order to evaluate if decreased insulin sensitivity is a consequence or a cause of high blood pressure investigators will study the effects of different hypotensive medications on insulin sensitivity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CARDIAC RECEPTOR ACTIVITY IN THE PREGNANT RAT Principal Investigator & Institution: Hines, Mary Christina. Thompson Professor of Research; None; University of Missouri Kansas City Kansas City, MO 64110 Timing: Fiscal Year 2001; Project Start 01-JUN-1996; Project End 30-APR-2006 Summary: Increased blood volume and decreased blood pressure are early and sustained alterations of pregnancy that are directly correlated with positive outcomes. The chronic maintenance of these cardiovascular adjustments implies a significant change in autonomic regulatory pathways, and it is known that reflex effects mediated by these pathways are attenuated during rat and human pregnancy, and further blunted during diseases, such as preeclampsia. One of our long-term objectives is to characterize alterations in these neural reflex pathways during pregnancy and to elucidate mechanisms involved. Understanding changes in these cardiovascular regulatory systems will improve clinical management of blood volume and pressure during pregnancy. Using the pregnant rat model, which undergoes hemodynamic changes similar to those in humans, we have demonstrated that afferent discharge in the autonomic receptors, which regulate blood volume and blood pressure, is attenuated during pregnancy. One explanation for a reduction in cardiac receptor sensitivity is the suggestion that pregnancy actually represents an "underfilled" state, and this concept will be explored in the present proposal. In addition, we are investigating the role of alterations in wall stretch and local paracrine factors in the reduction of afferent receptor firing during pregnancy. Based on our findings in the current funding cycle, three aims are proposed for this competing renewal: Aim #1: we will determine if exogenous blood volume expansion restores cardiac receptor activity in the late-pregnant rat to levels
20 Blood Pressure
observed in the nonpregnant animal, and if volume expansion has a differential effect in the early-pregnant animal; Aim #2: right atrial pressure/dimension relationships will be measured in late-pregnant and nonpregnant animals to gain a better understanding of the degree of stretch "sensed" by cardiac receptors; Aim #3: we will determine whether nitric oxide and/or endothelin, substances known to decrease baroreceptor firing in nonpregnant animals, mediate the reduction in cardiac and baroreceptor activity we have observed during pregnancy. The proposed research plan stems logically from the investigator's currently funded work on alterations in autonomic regulation of cardiovascular function during pregnancy. Data collected during the current grant period have provided intriguing new information about gestational modulation of autonomic receptor activity in the gravid rat. In this competitive renewal we will focus our efforts on mechanisms involved in these changes of pregnancy. The insights gained from these investigations will extend the understanding cardiovascular control in a heretofore-unstudied component of autonomic regulatory pathways in pregnancy, and will further elucidate physiologic as well and pathologic mechanisms of blood volume and blood pressure control during pregnancy that will broaden our knowledge base for clinical management of the pregnant woman. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CARDIOVASCULAR AUTONOMIC CONTROL IN STRESS AND ANXIETY Principal Investigator & Institution: Sloan, Richard P. Professor; Psychiatry; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-JAN-2003 Summary: (Adapted from the Applicant's Abstract): This is an application for an Independent Scientist Award (K02) to study cardiovascular autonomic control in stress and anxiety. It is based on a research program whose focus is to explore the relationships among psychological/behavioral characteristics such as anxiety, hostility, depression, and physical conditioning, the central and autonomic nervous system, and the cardiovascular and respiratory systems. The application proposes a series of experiments deriving from a model which identifies blood pressure variability (BPV) as a potential mechanism by which psychological/psychiatric factors and health behaviors confer increased risk of coronary artery disease (CAD) and catastrophic cardiac events. While evidence suggests that psychological factors such as anxiety, depression, and hostility are associated with increased risk of CAD, the mechanisms by which these factors exert their pathogenic effects are only poorly understood. Our model holds that autonomic control of the heart serves a buffering or inhibitory function over oscillations in blood pressure, which recent research in vascular biology and dynamics suggests may have pathogenic effects on the endothelium, in the case of atherogenesis, and on plaque stability, in the case of catastrophic cardiac events. We recently have shown that under conditions of psychological stress, the magnitude of these blood pressure oscillations is inversely related to the degree of autonomic control of the heart, as measured by heart period variability (HPV). Thus, in subjects with high levels of cardiac autonomic control, blood pressure oscillations are minimal whereas in subjects with low levels of control, they are increased considerably. Since psychological/behavioral characteristics such as anxiety, depression, and hostility have been shown to be associated with lower levels of HPV, these characteristics may be associated with disinhibition of blood pressure oscillations, either at rest, or more likely, in response to psychological stress. Together, these findings suggest that the mechanism by which psychological characteristics such as hostility have their pathogenic effect is through
Studies 21
reduced inhibition of BPV responses to challenge, which in turn promotes atherogenesis and plaque rupture. In this application, 5 experimental tests of this model are proposed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CARDIOVASCULAR EFFECTS OF THE ADRENOMEDULLIN GENE Principal Investigator & Institution: Caron, Kathleen M. Pathology and Lab Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 01-JUN-2001 Summary: The objective of this proposal is to identify the physiological functions of a newly identified vasoactive peptide, Adrenomedullin (Adm). Preliminary studies have suggested a variety of functions for Adm. Most acclaimed is Adm's potential role in blood pressure regulation since it has been found at markedly elevated plasma levels in patients with multiple forms of hypertension. Other studies have implicated Adm in such physiological processes as natriuresis, regulation of aldosterone, ACTH and renin secretion, thirst, embryonic implantation, and cellular proliferation. To examine the function of Adm within an intact physiological milieu, a series of mice will be generated that contain between 0-4 copies of the Adm gene by using the methods of homologous recombination in embryonic stem cells and the mechanisms of gene disruption and gene duplication. The specific aims of this proposal are to: 1) determine the essential biological functions of the Adm gene within an intact physiological milieu by characterizing a knockout mouse model and 2) determine the effects of varying Adm gene expression on blood pressure and related cardiovascular parameters by characterizing a "gene titration" of Adm. Elucidation of the physiological functions of Adm will enhance our general understanding of this new peptide. Moreover, determining the role of Adm in blood pressure regulation will lead to a better understanding of blood pressure homeostasis and may lead to new genetic and pharmacological strategies for the prevention or therapy of hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CARDIOVASCULAR REGULATION--AUTONOMIC/METABOLIC MECHANISMS Principal Investigator & Institution: Biaggioni, Italo; Professor of Medicine and Pharmacology; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Local metabolic factors play an important role in modulating vascular smooth muscle tone, and interact with the autonomic nervous system to contribute to cardiovascular regulation. Nitric oxide (NO) is arguably one of the most important of these metabolic factors. Experimental evidence suggests that endothelial-derived NO exerts tonic vasodilatory effects even under resting conditions. Neuronal-derived NO acts centrally to inhibit sympathetic tone, and on presynaptic aderenergic neurons to inhibit norepinephrine release. There is substantial evidence that several disease states are characterized by ?NO deficiency?, including hypercholesterolemia, smoking and, potentially, hypertension. It is though that this NO deficiency contributes to the adverse cardiovascular events that characterizes these patient populations. Experimental systemic blockade of NO synthesis leads to an increase in blood pressure, indicating its importance on cardiovascular regulation. In normal subjects, however, the pressor effect of systemic NO inhibition is modest because of the restraining effect of the baroreflex. It is difficult, therefore, to gauge the
22 Blood Pressure
importance of NO on blood pressure regulation because of the 'close loop' characteristics of autonomic regulation. Similarly, the relative contribution of neuronal NO and endothelial NO to blood pressure control remains unclear. It would be advantageous, therefore, to develop a human model where the increase in blood pressure produced by systemic NOS inhibition reflects selective endothelial NO inhibition, unrestrained by baroreflex buffering. Patients with pure autonomic failure represent such a human model. Similarly, we can induce transient autonomic failure by blocking neurotransmission at the level of autonomic ganglia with trimethaphan. We propose to use these models to test the hypothesis that endothelial nitric oxide is an important modulator of blood pressure under normal conditions, and that its impairment contributes to hypertension. We will inhibit NO synthesis with L-arginine analogs to determine its effect on normal subjects, normotensive offspring of hypertensive parents, patients with essential hypertension, and patients with pure autonomic failure. About half of patients with pure autonomic failure paradoxically develop hypertension driven by increased vascular resistance. We also propose a proofof-concept study to determine if modulation of NO mechanisms with L-citrulline and Larginine provide a novel therapeutic option in this human model of hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR L-ARGININE UPTAKE IN HYPERTENSION Principal Investigator & Institution: Mattson, David L. Professor; Medical College of Wisconsin Po Box26509 Milwaukee, WI 532264801 Timing: Fiscal Year 2003; Project Start 01-MAR-2003; Project End 28-FEB-2008 Summary: Nitric oxide (NO) in the kidney plays a critical role in the regulation of fluid and electrolyte balance and blood pressure. It has been widely accepted that both the production of NO and NO-dependent effects, are independent of extracellular Larginine and cellular L-arginine uptake; yet a series of recent studies from our laboratory and other laboratories has provided reason to question this view. These studies have demonstrated that supplementation of L-arginine, the substrate for NO synthase (NOS), directly into the renal medulla prevents sodium sensitive hypertension in the Dahl salt-sensitive (SS/Mcw) rat. Further experiments indicate that the cellular availability of L-arginine can regulate the production of NO and reactive oxygen species (ROS) in the kidney. We hypothesize that a deficiency in the L-arginine-nitric oxide pathway in the tubular and vascular segments of the kidney of the Dahl SS/Mcw rat contributes to the development of sodium-sensitive hypertension by reducing the availability of NO and/or increasing the levels of ROS. We will test this hypothesis in three Specific Aims. Aim 1 will utilize cellular and molecular techniques to quantify the differences in L-arginine uptake in whole tissue and isolated renal tubules and blood vessels of the SS/Mcw rat in comparison to control rats. Further studies in this aim will characterize the influence of altered L-arginine uptake mechanisms on NO release in renal tubules and blood vessels of the SS/Mcw rat. Aim 2 will employ novel in vivo microdialysis techniques to determine if the deficiency in L-arginine transport contributes to the decreased availability of NO and elevation in free radicals observed in the kidney of the SS/Mcw rat. Moreover, it will be determined if increased cellular Larginine uptake will normalize the levels of NO and ROS in the SS/Mcw rat. Experiments in Aim 3 will then determine the effects on renal function and arterial blood pressure when NO and ROS levels in the kidney are manipulated by altering cellular L-arginine uptake. Studies in this aim will describe the in vivo effects of manipulation of cellular L-arginine uptake on the acute pressure-natriuresis-diuresis relationship, intrarenal blood flow distribution, and the long-term regulation of fluid
Studies 23
and electrolyte balance and arterial blood pressure in SS/Mcw and control rats. Together, this integrated approach will determine the important role of cellular arginine uptake by cationic amino acid transporters (CAT) in the production of NO and ROS in the kidney, the regulation of renal sodium excretion, and the long-term control of arterial blood pressure in the Dahl SS/Mcw rat. Results of these studies should provide novel insights into the role of cationic amino acid transport in the control of renal function and arterial blood pressure. Moreover, these results may reveal that altering the dietary amino acid content and/or manipulating L-arginine uptake mechanisms may reduce the incidence of hypertension in the general population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CEREBROVASCULAR HEMODYNAMICS IN PRETERM BRAIN INJURY Principal Investigator & Institution: Watkins, Timothy W.; Children's Hospital (Boston) Boston, MA 021155737 Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2002 Summary: Preterm brain injury remains an important complication of premature birth. Both hemodynamic abnormalities and alterations of cerebral blood flow have been associated with injury, but reliable methods for prospective identification of imminent injury are not available. To identify prospective physiologic risk factors, three aspects of the relationship among of oscillations of heart rate, oscillations of blood pressure, and oscillations of cerebral blood flow will be quantified: the arterial baroreflex, cerebral autoregulation, and the relation of the arterial baroreflex to cerebral autoregulation. These measurements will be obtained from a population of preterm neonates of birthweight less than 1000 grams. Measurements will be obtained at 8 hours, 24 hours, and one week of life. Oscillations of cerebral blood flow will be detected and quantified by near Infrared spectroscopy. Specific Aim number 1: Arterial baroreflex. Transfer functions analysis will quantify the response of heart rate to changes in arterial blood pressure. Hypothesis: Neonates who are subsequently found by head ultrasound to have severe brain injury will fail to exhibit normal baroreflex activity. This will be indicated by a lesser response of heart rate to changes in arterial blood pressure, and a response time that is lengthened. Specific Aim number 2: Cerebral autoregulation. Transfer function analysis will quantify cerebral autoregulation, defined as the normal buffering of changes in arterial blood pressure, so that passive relationships between arterial blood pressure and cerebral blood flow are enhanced. Hypothesis: Neonates who are subsequently found by head ultrasound to have severe brain injury will fail to exhibit normal cerebral autoregulation. This will be indicated by a greater response of cerebral blood flow to changes in arterial blood pressure, and a response time that is shortened. Specific Aim number 3. Arterial baroreflex vs. Cerebral autoregulation. Spectral coherence of the arterial baroreflex relation will be compared to the spectral coherence of cerebral autoregulation. Correlation between these two coherences will serve as a measure of association between them. Hypothesis: Enhanced baroreflex activity is a physiologic marker for better cerebral autoregulation. This will be indicated by a negative correlation between the coherence of the baroreflex and the coherence of cerebral autoregulation. This proposal will combine novel measurement of oscillations in cerebral blood flow with advanced signal processing techniques to quantify the relationship among oscillations of heart rate, oscillations of blood pressure, and oscillations of cerebral blood flow. By representing heart rate, blood pressure, and cerebrovascular blood flow as dynamic quantities, if may be possible to model their
24 Blood Pressure
relation to each other in a more useful way. This approach may provide the necessary and thus far unavailable foundation for an effective neuroprotective clinical strategy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHRONIC NEURAL CONTROL OF BLOOD PRESSURE Principal Investigator & Institution: Sved, Alan F. Professor of Neuroscience & Psychiatry; Neuroscience; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2001; Project Start 01-JAN-1997; Project End 31-JAN-2004 Summary: The central nervous system (CNS) plays a key role in regulation of arterial blood pressure and an abnormality of the central neural control may result in hypertension or predispose an individual to develop hypertension in response to other factors. Studies conducted the current grant period have highlighted the role of the CNS in baroreceptor- independent long-term control of blood pressure. These studies have focused on the role of neurons in the rostral ventrolateral medulla (RVLM) in maintaining the tonic drive of sympathetic vasomotor tones are unknown. During the current grant period we have found that blockade receptors for excitatory amino acid neurotransmitters (EAA) in the RVLM will reduce blood pressure to the same extend as total autonomic blockade provide that neurons in the caudal ventrolateral medulla are inhibited. Based primarily on this observation, we have developed the hypothesis that tonically active EAA-mediated inputs to the RVLM excite RVLM-sympathoexcitatory neurons and simultaneously excite inhibitory inputs to these neurons via a circuit through the caudal ventrolateral medulla. Furthermore, we hypothesize that this balance between excitatory and inhibitory inputs to RVLM- sympathoexcitatory neurons controlled tonically by EAA-mediated inputs to the RVLM governs the longterm control of sympathetic vasomoter tone, and alteration of this balance may result in hypertension. Furthermore, based on preliminary data we proposed that the tonicallyactive EAA-mediated input to the RVLM comes from a specific region of the pontine reticular formation. To test these hypothesis, we propose a series of experiments to be conducted in anesthetized as well as conscious rats. Most experiments involved recording blood pressure and sympathetic nerve activity while altering the function of discrete regions of the brain stem by microinjection of neuroactive drugs. Five specific aims will be addressed: [1] to further examine the role of EAA-mediated inputs to the RVLM in the tonic regulation of sympathetic vasomotor tone; [2] to determine whether tonically-active EAA-mediated inputs to the RVLM originate from the pontine reticular formation; [3] to determine if the effects of tonically-active EAA-mediated inputs to the RVLM are altered in the chronic absence of baroreceptor feedback to the brain; [4] to determine whether the balance between excitatory and inhibitory inputs to RVLM sympathoexcitory neuron driven by tonically- active EAA-mediated inputs to the RVLM is altered in models of experimental hypertension; and [5] to begin to determine the role of the C1 population of neurons in the RVLM in mediating the responses driven by tonically-active inputs to the RVLM. These studies will contribute to our understanding of the neural control of blood pressure, and therefore may provide new insight to the pathogenesis and treatment of hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SYNDROME
CIRCULATORY
DYSFUNCTION
IN
CHRONIC
FATIGUE
Principal Investigator & Institution: Stewart, Julian M. Professor; Pediatrics; New York Medical College Valhalla, NY 10595
Studies 25
Timing: Fiscal Year 2001; Project Start 24-AUG-2001; Project End 31-JUL-2005 Summary: Chronic fatigue syndrome (CFS) is associated with orthostatic intolerance which often takes the form of postural orthostatic tachycardia syndrome (POTS) in adolescents. Preliminary data suggest the novel concept that defective vasoconstriction produces POTS in CFS with cardiac autonomic changes as a secondary response. CFS patients will be compared to healthy controls and to controls with simple faints to test 3 hypotheses: 1) Blood is redistributed peripherally and redistribution is enhanced during orthostasis producing increased microvascular filtration and dependent edema. Central hypovolemia causes decreased cardiac output, reflex tachycardia and reduced cerebral blood flow. This is enhanced during orthostasis producing increased microvascular filtration, dependent edema, and peripheral pooling. These changes alter the interstitium, and cause reflex tachycardia, reduced cerebral blood flow and often hypotension. Blood volume and cardiac output using the indocyanine green dye dilution technique will be measured supine, during conventional 700 head-up tilt, and during low angle head-up tilt. Cerebral blood flow velocity (CBFv) will be estimated by transcranial Doppler ultrasonography. Thoracic, splanchnic, and pelvic vascular volumes will be measured by impedance plethysmography, and limb blood flow, arterial flow, venous volume-pressure relation, and venous pressure will be measured by venous occlusion strain gauge plethysmography. These will show increased blood flow to lower extremities when upright. Central hypovolemia will occur and will reduce CBF and produce symptoms of CFS. Cardiac autonomic status including baroreflex will be assessed by heart rate and blood pressure variability and transfer function. Baroreflex and heart rate variability will be decreased and blood pressure variability will be increased related to circulatory deficit 2) The defect in vasoconstriction is heterogeneous comprising abnormal arterial baroreflex mediated sympathetic vasoconstriction in one subgroup of CFS patients and abnormal local vasoconstriction in a second subgroup with defective veno-arteriolar reflex (arterial baroreflex insensitive dysfunction). Low angle tilt will be used to activate baroreflex mediated and local reflexes. Local reflexes including myogenic, metabolic and veno-arteriolar will be sorted out through use of supine testing designed to specifically stimulate a specific reflex (limb hang, large pressure step and reactive hyperemia) and measuring peripheral resistance. 3) Cardiac autonomic findings are secondary to circulatory changes. Thus, tachycardia relates to vagal withdrawal because of circulatory insufficiency. CFS patients will be treated with midodrine or placebo in a cross-over study. Using supine and low angle tilt experiments, circulatory measurements and psychological instruments will be combined to demonstrate that circulatory abnormalities, autonomic abnormalities and symptoms correct in a subgroup of CFS patients with low resting peripheral resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL SIGNIFICANCE OF BLOOD PRESSURE IN THE VERY OLD Principal Investigator & Institution: Satish, Shiva; Internal Medicine; University of Texas Medical Br Galveston 301 University Blvd Galveston, TX 77555 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2006 Summary: (provided by applicant): The clinical significance of elevated blood pressure in the very old, those aged 80 and older is unclear. It s been difficult to demonstrate increased morbidity and mortality associated with elevated blood pressure in the very old. Several population-based studies have shown either no relationship or even a positive association between blood pressure and survival in the very old. We and others
26 Blood Pressure
have shown that among the 80+ population the relationship between systolic blood pressure and mortality is more L-shaped, with highest mortality associated with systolic blood pressure of 120mm Hg or lower and lowest mortality at systolic blood pressures of 180 or higher. It has been argued that this observed L-shaped relationship is due to underlying comorbidity leading to both lower blood pressure and increased mortality. If this argument is correct, then it should be possible to identify a sub-population of healthy elderly without any comorbidity for whom the relationship of blood pressure to mortality is similar to what is found in younger populations. In this project our objective is to amine the effect of comorbidity on the relationship between blood pressure and morbidity and mortality in very old. To address these questions, we will examine the cohort of individuals at four EPESE sites (East Boston, New Haven, Iowa and Piedmont, NC) who were alive at the six year follow-up. Those 9134 subjects aged 71 years or more at 6-year follow-up point were followed for an additional 4 years. Detailed information also available regarding blood pressure, chronic medical conditions, health status, functional status, BMI, medication use and other variables. We will examine the relationship between blood pressure and adverse outcomes in the very old using Cox Proportional Hazard Analyses and Survival Analyses. Sample will be stratified based on comorbidity, functional status, blood pressure lowering medication use and blood pressure changes over time. A series of stratified analyses will be performed to examine the relationship between blood pressure and adverse outcomes, for different subsets of the older population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETERMINATIONS OF MECHANISMS OF POTS USING ACUTE LABORATORY Principal Investigator & Institution: Low, Phillip A. Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2001 Summary: A variety of approaches have been used to alleviate symptoms in POTS (Postural Tachycardia Syndrome). Drugs reported to be of benefit include midodrine, propranolol, clonidine, and phenobarbital. Other measures used include volume expansion and physical countermaneuvers. These treatments may influence pathophysiologic mechanisms of POTS, such as alpha-receptor dysfunction, betareceptor supersensitivity, venous pooling or brainstem center dysfunction. Little is know about effects of these interventions on hemodynamic indices in POTS, or whether changes in indices correlated with improvements in symptoms. The aim is to study hemodynamic indices and symptom scores in POTS patients acutely treated with a variety of interventions. We studied 22 subjects meeting the criteria of POTS [20 females, 1 male, ages 28.7 + 6.8 yrs, range 14-39]. Subjects were studied with a routine 5 minute tilt protocol, monitoring ECG, noninvasive beat-to-beat blood pressure and impedance plethysmography, before and after the administration of an intervention (i.v. saline, midodrine, propranolol, clonidine, or phenobarbital). The hemodynamic indices used were: heart period (ECG), systolic, mean, and diastolic blood pressure (Finapres), cardiac output, stroke volume, end-diastolic volume, and peak flow (impedance plethysmography), and total peripheral resistance (calculated). Subjects used a visual analog scale to record any change in their symptoms between the tilts. Symptoms scores improved significantly after midodrine and saline. Midodrine and propranolol reduced the resting heart rate (p < 0.005) and the immediate and 5 minute heart rate responses to tild (p < 0.002). Clonidine accentuated the immediate drop in blood pressure tilt-up (p < 0.05). Effects on other hemodynamic indices were complex. We conclude that midodrine
Studies 27
and i.v. saline are effective in decreasing symptoms on tilt in patients with POTS when given acutely. Effects of treatments on heart rate and blood pressure responses generally reflected the known pharmacologic mechanisms of the agents. More complex effects on other hemodynamic indices will be discussed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIETARY PATTERNS, SODIUM INTAKE, AND BLOOD PRESSURE Principal Investigator & Institution: Vollmer, William M. Senior Investigator; Kaiser Foundation Research Institute 1800 Harrison St, 16Th Fl Oakland, CA 94612 Timing: Fiscal Year 2001; Project Start 01-FEB-1997; Project End 31-JUL-2002 Summary: DASH2 is a multi-center, randomized clinical trial designed to compare the effects of three levels of sodium take and two dietary patterns on blood pressure. This coordinating center application is one of a coordinated set of applications from the five participating institutions. The two dietary patterns are a ~control diet~ that is typical of what Americans generally eat and a ~combination diet~ that is high in fruits, vegetables, fiber and low-fat dairy products and has a reduced total fat, saturated fat, and cholesterol content. The sodium levels range from high (reflecting current US consumption), to medium (reflecting current recommendations), to low (reflecting potentially optimal levels) and vary slightly according to calorie level. Participants are assigned to one of the two dietary patterns using a parallel group design, and are fed at each sodium level using a crossover design. Study participants (n=400) are adults, aged 22 and older, with high normal diastolic blood pressure. Stage 1 (mild) hypertension. Baseline range from 159/95. Half of the participants are African American and half are female. Participants attend a series of three eligibility screening visits followed by a towweek run-in feeding period and three one-month intervention feeding periods one at each of the three sodium levels. The study provides participants with all of their food during the run-in and intervention feeding periods, although participants resume their normal diets for up to five days between each of the three intervention feeding periods. During the controlled feeding periods participants are required to attend the clinic for at least one meal per day, five days per week, and take home food to eat for their other meals. Clinics deliver the interventions in four successive cohorts, with approximately 25 randomized participants per cohort, over a tow-year period. In support of the trial, the coordinating center: prepares and distributes all study documents, including the protocol, manual of procedures, and study forms; designs and implements a data management system; monitors and reports on trial progress; develops and implements trialwide quality control procedures; contacts with a central laboratory and a food analysis laboratory to provide analysis of blood, urine, and food speciments; develops a mechanism for randomizing study participants; caries out data analysis for the trial; conduct site visits; organizes central training and certification of staff; establishes a system of trialwide communications; and provides logistical support to the trial. The proposed DASH2 trial extends research on sodium intake and dietary patterns to address several issues of great relevance to clinical practice and public health. Sodium reduction, coupled with the dietary pattern, has great promise to lower blood pressure to an extent hitherto not demonstrated for any nonpharamacologic treatment and may be an alternative to drug therapy for persons with stage 1 hypertension or high normal blood pressure. For persons with moderate-to-severe hypertension, it may reduce medication requirements and simplify treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
28 Blood Pressure
•
Project Title: DOSE-RESPONSE TO EXERCISE IN WOMEN AGED 45-75 YEARS Principal Investigator & Institution: Blair, Steven N. Professor; Cooper Institute Dallas, TX 75230 Timing: Fiscal Year 2001; Project Start 15-JAN-2001; Project End 31-DEC-2005 Summary: The primary goal of the Dose-Response to Exercise in Women Aged 45-75 Years (DREW) is to investigate the effects of different amounts of exercise on both cardiorespiratory fitness and risk factors for cardiovascular disease. Participants will be sedentary, overweight or obese, postmenopausal women who have high normal blood pressure or Stage I hypertension, and thus are at moderately high risk for cardiovascular disease. A total of 450 women (35 percent will be from minority groups) will be randomly assigned to a control group (N=100) or to 1 of 3 exercise groups (N=150 for the lowest exercise dose and 100 each in the two highest exercise groups). Women assigned to the exercise groups will exercise for 6 months at energy expenditures of 4, 8, or 12 kcal/kg per week. These exercises doses represent the consensus public health recommendation for physical activity from recently published guidelines from the U.S. Public Health Service, American Heart Association, and the American College of Sports Medicine (8 kcal/kg per week) and at doses 50 percent below (4 kcal/kg per week) 50 percent above (12 kcal/kg per week) the consensus dose. All women will exercise at 50 percent of VO2 max. The exercise sessions will take place in the laboratory, with individual supervision of each session and strict control of frequency, duration, and intensity. This will provide thorough documentation of the exact amount of exercise completed. Primary outcome measures are VO2 max and resting systolic blood pressure. Other cardiovascular disease risk factors, psychosocial variables, health-related quality of life, body composition, and fat distribution are secondary outcomes. Other secondary analyses will include a focus on the extent to which observed dose-response effects are modified by baseline levels of fitness, ethnicity, risk factors, or age. Assessments will take place at baseline and 6 months. The research will provide information about (1) patterns of change in outcomes produced by each of several exercise doses, (2) whether performing exercise at less than the current consensus dose has any benefit, (3) whether performing more exercise than the consensus dose has greater (or proportionally greater) health benefits, and (4) the characteristics of sedentary women who are most likely to benefit from various exercise doses. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECT OF A COMPUTER BASED REMINDER SYSTEM ON CARDIOVASC Principal Investigator & Institution: Phillips, Robert A. Director, Department of Medicine; Medicine; Mount Sinai School of Medicine of Nyu of New York University New York, NY 10029 Timing: Fiscal Year 2001; Project Start 05-FEB-2000; Project End 31-JAN-2003 Summary: Preventive strategies for cardiovascular disease are well-known, but physician implementation of these strategies has been less than optimal. Several studies have shown that computerized reminders and/or feedback increase utilization of preventive strategies. Patient-specific reminders suggest actions that a physician should consider at the time of visit. Patient-specific feedback is a report generated after the visit, which summarizes the collected data. Peer comparison feedback provides physicians with a periodic report analyzing their patient-care results in comparison with physicians in their own practice. We will conduct our project at the Mount Sinai Medical Center's
Studies 29
generated medical practice, where we currently have 3 teams (Groups A, B and C) or 40 primary care physicians (attendings and supervised housestaff; n=120 physicians) who serve our inner city population. We propose a two-year study, which involves all three groups. Group A physicians will receive two interventions: 1) Each physician will receive a personal digital assistant (PDA), which is a hand-held computer programmed with a reminder system that prompts entry of data essential to the management of blood pressure and lipids into standardized forms. 2) Each Group A physician will receive quarterly peer-comparison and patient-specific feedback. Group B physicians will collect data in the standard "paper chart" format and receive one intervention, i.e. quarterly peer-comparison feedback. Group C physicians will collect data in the standard fashion, however, these physicians receive no intervention (i.e. no personal digital assistant and no quarterly feedback and reminders). The aims of our study are: 1) To determine the combined of a physician- designed computer-based cardiovascular risk factor collection and reminder system and quarterly peer-comparison feedback to physicians on the degree of blood pressure and LDL-cholesterol control in an inner city population, and 2) To determine the effect of only quarterly peer- comparison feedback to physicians and groups on the degree of blood pressure and lipid control in an inner city population. Our hypothesis is that at the end of a two year intervention, use of personal digital assistants and a reminder/feedback system by Group A will improve blood pressure and lipid control by 10% compared to Group B. Group B, which receives only quarterly peer-comparison feedback, will have 10% improvement in blood pressure and lipid control compared to Group C, which documents visits in the usual fashion and receives no reminders nor feedback. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EMOTIONAL DISCLOSURE WRITING EFFECTS ON BLOOD PRESSURE Principal Investigator & Institution: Gerin, William; Medicine; Mount Sinai School of Medicine of Nyu of New York University New York, NY 10029 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-AUG-2003 Summary: (adapted from investigator's abstract): Expressive writing (EW) is an intervention technique that has been shown to produce improvements in psychological and physical health in several controlled studies to date. The intervention calls for participants to write an essay, for 20 minutes at a time, on 3 successive days, expressing their thoughts and feelings about a traumatic experience. The positive health benefits of this intervention have been demonstrated in both healthy subjects, in terms of increases in subjective well-being and immune function and decreased health center visits, and clinic patients (i.e., asthmatics and rheumatoid arthritis patients), in terms of decreased physical symptoms. The mechanisms by which EW may exercise its beneficial effects are consistent with those that may underlie elevated blood pressure and hypertension. However, no study has yet examined the effects of EW on blood pressure. The proposed research will test the effects of an EW intervention on subsequent 24-hour ambulatory blood pressure (ABP) levels using a randomized controlled trial in which uncontrolled mild hypertensives are randomly assigned to the EW condition or a control condition. Post-intervention ambulatory BP monitoring will be performed at 1 and 4 months. On ABP assessment days, catecholamine levels will also be examined as an index of sympathetic activity through analysis of 24-hour urine samples. Chronic sympathetic activation is one proposed mechanism by which EW may operate, and measurement of pre- and post-intervention catecholamines will provide a test of that hypothesis. The EW participants will be further assigned randomly to a second EW
30 Blood Pressure
intervention or to a control condition, permitting comparison of the effects of zero, one, and two administrations of the intervention on ambulatory BP. The content of written material will also be analyzed for insight terms that may predict the effectiveness of the intervention on subsequent ambulatory BP. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTROL
ENDOGENOUS
OPIOIDS,
PAIN
AND
BLOOD
PRESSURE
Principal Investigator & Institution: Mccubbin, James A. Professor and Chair; Psychology; Clemson University 300 Brackett Hall Clemson, SC 296345702 Timing: Fiscal Year 2001; Project Start 01-AUG-1989; Project End 31-JUL-2003 Summary: This proposal is for continuation of our ongoing research on opioid abnormalities and blood pressure reactivity in persons at risk for hypertension. We are gradually becoming aware that regulation of both blood pressure and pain sensitivity is altered in pre-hypertensive populations. For example, persons at risk for hypertension have decreased opioid inhibition of blood pressure responses to stress. Paradoxically, they also show antinociceptive effects consistent with exaggerated opioid function. The scientific meaningfulness, both basic and clinical, of the links between pain sensitivity alterations and blood pressure dysregulation remains to be clarified. Recent studies by ourselves and others have emphasized the importance of opioids in regulation of 1) neuroendocrine and blood pressure responses to stress in hypertension development, 2) behavioral responses to pain, and 3) the relationship between pain sensitivity and blood pressure. The purpose of this continuation proposal is to further examine the role of endogenous opioids in blood pressure dysregulation by studies of circulatory and behavioral responses to aversive stimuli in persons at enhanced risk for hypertension. This will be accomplished by comparison of the effects of opioid blockade with naltrexone on pain sensitivity and blood pressure reactivity in young men and women with mildly elevated casual blood pressure. We hypothesize that abnormalities of both blood pressure control and pain sensitivity in the early stages of hypertension development are linked to altered opioid peptide function. Persons at risk for hypertension will show exaggerated opioid inhibition of pain sensitivity in the face of diminished opioid inhibition of blood pressure reactivity. Improved understanding of the opioidergic basis of altered pain sensitivity and blood pressure control will clarify the poorly characterized etiology of essential hypertension and possibly offer new preventive, diagnostic and therapeutic strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENOS AND THE BLOOD LEAD-BLOOD PRESSURE RELATIONSHIP Principal Investigator & Institution: Lustberg, Mark; Epidemiology and Prev Medicine; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2001; Project Start 01-SEP-2001 Summary: Essential hypertension is a major cause of cardiovascular disease. Its etiologies are thought to involve both genetic and environmental factors. Elevated blood lead levels have been indicated as contributing factor in essential hypertension. It is unclear how lead exerts this effect. The purpose of this investigation is to consider endothelial nitric oxide synthase (eNOS) inhibition as a mechanism for this effect, using a population based approach and a recently reported Glu298Asp substitution polymorphism in eNOS. Specific Aims: 1) Describe the relation of the eNOS Glu298Asp polymorphism and blood pressure in this cohort. 2) Describe how the relation of lead
Studies 31
and blood pressure varies by the eNOS Glu298Asp polymorphism in this cohort. Methods: This will be a cross-sectional study of lead exposed workers and unexposed controls. Blood pressure and lead levels in these workers have been recorded, and blood samples have been taken. The blood samples will be genotyped for the Glu298Asp polymorphism. Linear regression models will be developed to examine the relation of lead and blood pressure in these workers. We will also consider stratified analyses, looking at odds ratios of hypertension. If eNOS is involved in lead induced increases in blood pressure, the lead-blood pressure relationship (the regression slopes or the odds ratios for hypertension) should different for individuals with and without Asp-variant eNOS. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ESTROGEN AND BRAIN CONTROL OF BLOOD PRESSURE Principal Investigator & Institution: Clark, John T. Assistant Professor; Meharry Medical College 1005-D B Todd Blvd Nashville, TN 37208 Timing: Fiscal Year 2001 Summary: The incidence of cardiovascular disease in women increases dramatically following menopause. This is, most likely, triggered by estrogen deprivation. The proposed collaborative project is designed to expand Dr. Clark's scientific armament so as to enable a successful transition to mainstream funding for his studies of neuroendocrine regulation of cardiovascular and sexual function during aging. Very few studies of neural control of the cardiovascular system have employed middle-aged rats that are most at risk for the hypertension and stroke, and none have carefully considered the potential collaborative contribution between the sympathetic nervous system and the cardiovascular system in the generation of stroke. This is especially important, because even a short term excess of vasoconstriction could greatly increase the mortality or morbidity associated with stroke. The proposed studies will test the hypothesis that the loss of normal and hypertensive female rats, thus allowing sympathetic nervous system response to increase. Further, the role of estrogen also increases the contractile responses of cerebral arteries to noradrenergic (sympathetic) stimulation. We hypothesize that these responses are potentiated in the stroke-prone rat. Our specific aims are to test the hypotheses that, in middle-aged female rats: [1] estrogen deprivation will result in decreased norepinephrine release in pre-optic- anterior hypothalamic area. This will be associated with increased blood pressure in normotensive and hypertensive female rats; [2] the interaction between estrogen and the nervous system occurs in specific areas relevant to blood pressure control, namely the organum vaculosum of the lamina terminalis, the subfornical organ, and the median pre-optic nucleus. Neuronal projections from these areas utilize angiotensin II and are responsive to estradiol; and [3] hypothalamic neurons, and in AT-1 gene expression in noradrenergic projections to the preoptic-anterior hypothalamic area. The antihypertensive effects of AT-1 receptor blockade will be attenuated in estrogen deprived middle-aged female rats. Taken together, these studies will provide important new information regarding the role of protective estrogens in neural regulation of blood pressure, and damage due to stroke, in stroke-prone hypertensive rats. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ETHNIC DIFFERENCES REGULATION AND BLOOD PRESSURE
IN
STRESS
INDUCED
SODIUM
Principal Investigator & Institution: Harshfield, Gregory A. Professor; Medical College of Georgia 1120 15Th St Augusta, GA 30912
32 Blood Pressure
Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2007 Summary: (provided by applicant) Essential hypertension has reached epidemic proportions in the African American (AA) community. Differences in the ability to regulate sodium adequately in a high salt environment and differences in stress have been hypothesized to contribute to the differences in essential hypertension between AAs and European Americans (Eas). The objective of Project 2 is to study the interactive relationship between salt and stress in the development of the ethnic differences in essential hypertension. The general hypothesis of this proposal is as follows: AAs compared to EAs are genetically predisposed to show slower natriuresis during and following stress due to differences in the regulation of vasoactive and volume regulatory agents. This results in extended periods of elevated blood pressure. The increased blood pressure load leads to the early development of preclinical disease states. Therefore, the first three aims of the study are to contrast AAs and EAs before, during, and two hours following a 60 minute behavioral challenge on changes in sodium handling (Aim 1), hemodynamic functioning (Aim 2), and vasoactive and volume regulatory agents of the sympathetic nervous system, the renin-angiotensinaldosterone system, and the endothelial system (Aim 3). The fourth aim of the study is to relate the response patterns to preclinical disease states of the heart (left ventricular mass), kidneys (micro albumin), and vasculature (pulse wave velocity, endothelial dependent vasodilation). The fifth aim of the study is to determine if the response pattern observed during laboratory testing is associated with blood pressure functioning during ambulatory testing. The final aims of the study are to determine the genetic polymorphism(s) associated with the hemodynamic change in blood pressure following stress. The proposed study will contribute significantly to the understanding of how salt and stress interact in the development of hypertension in AAs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FIELD CENTER - GENETICS OF HYPERTENSION Principal Investigator & Institution: Cooper, Richard S. Professor and Chair; Prev Medicine and Epidemiology; Loyola University Medical Center Lewis Towers, 13Th Fl Chicago, IL 60611 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals, carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim
Studies 33
1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENDER,NICOTINE AND STRESS-INDUCED ANALGESIA Principal Investigator & Institution: Girdler, Susan S. Associate Professor; Psychiatry; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 01-AUG-2001; Project End 30-APR-2005 Summary: Epidemiologic as well as laboratory-based studies all document that women are more sensitive to pain than men. Involvement of the female sex hormones is indicated by animal studies that show estrogen increases sensitivity to pain, while progesterone and its metabolites (allopregnanolone and THDOC) decrease sensitivity to pain. Animal studies also indicate that the modulation of pain sensitivity by the female sex hormones involves the endogenous opioids, particularly beta-endorphins. However, whether sex hormones and other neuroendocrine factors can account for gender differences in the human pain experience has not been directly investigated. Another potential factor which may modulate pain sensitivity differently in men and women, and which may itself involve female sex hormones, involves smoking-related analgesia. Thus, the purpose of Study 1 to examine gender differences in sensitivity to a variety of experimental pain procedures as a function of female menstrual cycle phase. Also, since animal studies show that stress-induced analgesia (SIA) is modulated by the estrous cycle, Study 1 will also examine whether the female menstrual cycle influences gender differences in SIA. Using a within-subjects, randomized design, 96 healthy, non-smokers will be tested for sensitivity to tourniquet-induced ischemic pain, cold pressor pain, and thermal pain during three separate test sessions. For women, one session will occur during the early follicular phase (days 2-5; low hormones), one session during the late follicular phase (days 9- 12; high estrogen) and one session during their luteal phase (510 days after ovulation; high estrogen and progestins). Men will also be tested three times. In order to examine SIA, sensitivity to experimental pain will be compared after 20 minutes of mental stress (speech and math) versus after a 20-minute rest control period, counterbalancing order of stress and rest. Relationships between pain sensitivity (i.e., threshold and tolerance levels) and cardiovascular (blood pressure and vascular resistance) and neuroendocrine factors (estradiol, progesterone, allopregnanolone, THDOC, beta-endorphins, cortisol, ACTH and catecholamines) will be examined. It is predicted that gender differences in pain sensitivity will be greatest in the late follicular, followed by the luteal phase, while gender differences will be least in the early follicular phase. Study 2 will examine gender differences in smoking-related analgesia by testing 60 healthy subjects (30 men, 30 women), with half of each group comprised of habitual smokers. Identical test procedures and dependent measures described for Study 1 will
34 Blood Pressure
be employed. Each subject will be tested only once, however, during the high estrogen phase of the female cycle since it is hypothesized that one mechanism by which smoking reduces pain sensitivity in women is via reductions in estrogen. It is anticipated that men will show greater evidence for smoking-related analgesia since smoking will activate two pain inhibitory mechanisms in men (i.e., blood pressure-related hypoalgesia and beta-endorphin mechanisms) while, for women, smoking will activate primarily beta-endorphin mechanisms (directly and indirectly via estrogen). The results of these studies, combined, are expected to provide insight into endogenous (sex hormones, beta-endorphins, blood pressure) and exogenous (smoking) pain modulatory mechanisms that may contribute to gender differences in the experience of pain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENES AND HIGH BP: MEXICAN AMERICAN FIELD CENTER Principal Investigator & Institution: Hanis, Craig L. Professor; Human Genetics Center; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, TX 77225 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals, carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 35
•
Project Title: GENETIC DETERMINANTS OF HIGH BLOOD PRESSURE Principal Investigator & Institution: Weder, Alan B. Professor; Internal Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals, carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC DETERMINANTS OF HIGH BLOOD PRESSURE (GENOA) Principal Investigator & Institution: Brown, C A. Medicine; University of Mississippi Medical Center 2500 N State St Jackson, MS 39216 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations
36 Blood Pressure
requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals, carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS OF SALT SENSITIVITY IN AFRICAN AMERICANS Principal Investigator & Institution: Wright, Jackson T. Professor of Medicine; Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2002; Project Start 15-MAY-2000; Project End 30-JUN-2005 Summary: The prevalence, morbidity, and mortality of arterial hypertension are disproportionately high in the African-American population. Essential hypertension is a polygenic and heterogeneous disorder. In particular, African-Americans display an amplified blood pressure response to salt. The cellular and molecular mechanisms of salt-sensitive hypertension in humans remain poorly defined and our knowledge of potential genetic mechanisms remains incomplete. We recently observed an augmented blood pressure response to a salt challenge in healthy non-obese African- Americans females as compared to Whites. African-Americans also had significantly higher intracellular Na and depressed activity of the Na pump (86 Rb uptake)as compared to Whites suggesting these may be important phenotypic markers of salt-sensitive hypertension. In fact, an increase in intracellular Na was positively correlated with the increases in systolic blood pressure following one week of low salt vs one week of high salt diet in African-Americans but not in Whites. The inverse relationship was noted for the Na pump in African-Americans. The proposed study will carry out genetic studies of sibships with at least two hypertensive embers ascertained from the AfricanAmerican population. Emphasizing model- free approaches to genetic linkage analysis based upon hypertensive sibling pairs, candidate genes that have been associated with salt-sensitive hypertension in either human or animal studies will be evaluated with respect to these intermediate phenotypes, and blood pressure responses to a salt challenge. The aims of this proposal are: l) To characterize the intermediate phenotypes of salt sensitivity, intracellular Na, sodium pump activity, and protein expression in a cohort of 500 hypertensive siblings in 160 sibships and to genotype these individuals;
Studies 37
wherever possible, parents of these subjects will also be genotyped in order to better establish identity by descent relationships. 2) To assess linkage of the various candidate loci with intermediate phenotypes relating to the magnitude of blood pressure change with a salt challenge using univariate and multivariate approaches. The overall aim of this project is to improve our understanding of the genetic basis and phenotypic characterization of salt-sensitive hypertension in African Americans. To this end, careful analytic attention will be paid to the development of improved phenotype definition, as well as to the consideration of gene-gene and gene-environment interaction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS OF VASCULAR REMODELING IN HYPERTENSION Principal Investigator & Institution: Berk, Bradford C. Professor & Chairman; Medicine; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2001; Project Start 01-JUN-1999; Project End 31-MAY-2003 Summary: An important long-term goal in the approach to treating atherosclerosis and hypertension is to understand the mechanisms that regulate the structure of blood vessels; a process we will term "vascular remodeling." Hypertension is a major risk factor for development of atherosclerosis (strong correlation between fatty streak formation and BP) and for clinical events (strong correlation between unstable angina, myocardial infarction, stroke and BP). Our major hypothesis is that hypertension is a major risk factor for atherosclerosis because the ability of the vessel to compensate for plaque burden (a process that requires outward vascular remodeling) is inhibited in hypertensive patients. We also suggest that impaired remodeling in hypertensives is due to 1) direct effects of elevated blood pressure, and 2) pressure-independent genes associated with essential hypertension that modulate the ability of the vessel to remodel. To gain insight into the mechanisms by which hypertension influences vascular remodeling we will selectively breed normotensive and hypertensive inbred rat strains that differ in their ability to remodel and perform a genetic analysis. Our preliminary data document significant differences in lumen diameter induced by blood flow among inbred rat strains. Our hypothesis is that among rats with genetic hypertension (e.g. SHR, SHR-SP, and Genetically Hypertensive rat of New Zealand (GH) there will be additional genetic determinants that modulate remodeling in response to physiologic stimuli such as flow. The use of genetic linkage analysis in the proposed project represents a novel approach to understanding the mechanisms that regulate vascular structure. Its advantage is that it is based on recombination probability, and requires no prior knowledge of the mechanisms to find the gene(s) that contribute to the process. We have developed and published a reproducible and quantitative model for flowdependent vascular remodeling. Using this model to study inbred rat strains we have made the exciting preliminary observation that the remodeling abilities of Brown Norway (BN, high) and GH (low) strains differ by more than 2 standard deviations. Based on these data our major goal is to perform a BN x GH cross and total genomic scan to identify major genes that alter the ability of vessels to remodel in hypertension. Aim 1: Characterize the time course of flow- induced remodeling in the carotid arteries of Brown Norway rats (BN, high remodelers) and Genetically hypertensive rats (GH, low remodelers). Aim 2: Intercross GH and BN to obtain 200 F2 progeny that express a range of remodeling and blood pressure phenotypes. Aim 3: Genotype P0 and F2 rats and use interval mapping to determine the chromosomal location of the quantitative trait loci (QTL) that are responsible for flow-induced remodeling and blood pressure. Aim 4. Create a congenic strain of GH rats containing genes associated with high remodeling ability.
38 Blood Pressure
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENOME-WIDE SEARCH FOR CVD GENE-ENVIRONMENT INTERACTIONS Principal Investigator & Institution: Shuldiner, Alan R. Professor of Medicine; Medicine; University of Maryland Balt Prof School Baltimore, MD 21201 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2006 Summary: (provided by applicant): The overall objective of this proposal is to localize chromosomal loci (and ultimately genes) that interact with specific environmental exposures to modify risk factors for CVD using state-of-the-art molecular and statistical genetic approaches in the Old Order Amish, a unique closed founder population who are relatively genetically homogeneous, and have very large family sizes and well documented genealogies. Since February 1995, Dr. Shuldiner and his coworkers have recruited and studied over 2500 Amish individuals, 1,000 of whom are participants of Amish Family Calcification Study (AFCS), a study designed to examine independent and joint genetic influences on osteoporosis and coronary artery disease. Extensive phenotypic characterization of AFCS participants include blood pressure, body composition, bone mineral density, lipids, and coronary artery calcification by electron beam CT. DNA already has been collected on all AFCS subjects and a 5-cM genome scan (approximately 800 short tandem repeat (STR) markers) will be completed by Summer 2002. The Specific Aims of this proposal are: (1) To perform four focused short-term interventions and to measure CVD responses in subjects of AFCS including high fat meal and changes in endothelial function as assessed by flow-mediated vasodilation (FMD) studies; cold presser stress and changes in FMD and blood pressure; a high salt and low salt diets and changes in blood pressure; and aspirin therapy and measures of platelet function; (2) To characterize the genetic epidemiology of the CVD related response to each short-term intervention; (3) To identify specific chromosomal loci that influence CVD related responses to the four interventions by performing genome-wide linkage analysis (4) To identify and localize chromosomal regions and genes influencing CVD related responses by exploiting the extended linkage disequilibrium in this relatively young founder population to perform LD mapping with densely distributed single nucleotide polymorphisms (SNPs) within linked regions; and (5) To determine if chromosomal regions linked to, or associated with, variation in CVD trait responses are also linked to, or associated with, variation in coronary artery or aortic calcification. Discovery of context-dependent CVD genes will provide (i) critical insights into molecular mechanisms and new molecular targets for therapeutics; (ii) clinically useful information that will allow physicians to individualize pharmacological and nonpharmacological therapy, and (iii) blood tests for the early detection of susceptibility individuals so that targeted preventative interventions can be instituted. These advances will impact substantially on the quality of life of millions of older Americans with CVD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: G-PROTEIN-COUPLED RECEPTOR KINASE GENE VARIANTS AND HYPERTENSION Principal Investigator & Institution: Jose, Pedro A. Professor of Pediatrics; University of Virginia Charlottesville Box 400195 Charlottesville, VA 22904 Timing: Fiscal Year 2002; Project Start 01-SEP-1997; Project End 31-AUG-2007 Summary: The renal dopaminergic system participates in the pathogenesis of genetic hypertension. In human essential hypertension, single nucleotide polymorphisms
Studies 39
(SNPs) of a G protein-coupled receptor kinase, GRK4, increase GRK activity and cause the serine phosphorylation and uncoupling of the D1 receptor from its effector proteins in proximal tubule cells, effects of which are mimicked in Chinese hamster ovary (CHO) cells. Moreover, expressing GRK4-gamma- A142V but not the wild type gene in mice produces hypertension and impairs the diuretic and natriuretic but not the hypotensive effects of D1-like agonist stimulation. Our primary hypothesis is that GRK4-gamma variants are responsible for the D1 receptor coupling defect in the kidney and cause the inability of the kidney to properly excrete sodium in genetic hypertension. Essential hypertension is a heterogeneous disease in which both genetics and environment contribute to elevate blood pressure. Many diseases, including essential hypertension, have their genesis during development. Sodium intake, early in life in humans and animals, without impairing growth, affects adult blood pressure. Our secondary hypothesis is that alterations in sodium intake affect the development of hypertension in transgenic mice carrying the GRK4-gamma gene variants. Indeed, the overall hypothesis of this program project is that expression of disease in the young depends upon developmental steps made early in life in response to external and internal environmental challenges. Specific aim 1 will determine in transgenic mice the interactions of GRK4-gamma-A142V, with age and sodium intake on blood pressure elevation and whether the effect of GRK4-gamma-A142V is receptor, renal, and nephron segment specific. Specific aim 2 will determine whether transgenic mice carrying more than one GRK4-gamma gene variant develop a hypertension that is more severe than those carrying only one GRK4-gamma gene variant. The significant interaction GRK4 SNPs in hypertension was greater in the presence of more than one GRK4 SNP. In CHO cells, the expression of more than GRK4-gamma gene variant impairs D1 receptor function to a greater extent than that noted in CHO cells expressing only one GRK4gamma gene variant. Specific aim 3 will determine whether GRK4-gamma gene variants affect blood pressure in D1 and D5 knockout mice. This aim will test the hypothesis that GRK4-gamma regulates D1 but not D5 receptors. These studies should elucidate the mechanisms by which GRK4-gamma gene variants promote the development of genetic hypertension and determine whether GRK4-gamma is a salt-sensitivity gene. The identification of individuals with a salt-sensitivity gene could form thescientific basis of sodium restriction in a selected target population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPERGEN-BOSTON UNIVERSITY/FRAMINGHAM FIELD CENTER Principal Investigator & Institution: Ellison, R Curtis. Chief; Medicine; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals,
40 Blood Pressure
carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPERGEN-NC Principal Investigator & Institution: Heiss, Gerardo; Professor; Epidemiology; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals, carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the
Studies 41
investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPERGEN-NETWORK ADMINISTRATION & UTAH FIELD CENTER Principal Investigator & Institution: Hunt, Steven C. Professor; Internal Medicine; University of Utah 200 S University St Salt Lake City, UT 84112 Timing: Fiscal Year 2001; Project Start 05-SEP-1995; Project End 30-JUN-2005 Summary: The NHLBI Family Blood Pressure Program is made up of four cooperating networks whose overall objective is to localize and characterize genes contributing to variation in blood pressure levels and hypertension status. The four networks were originally separately funded and competitive, but two critical realizations have led to full cooperation and collaboration. First, the oligogenic nature of blood pressure control dictates that large samples are necessary to achieve adequate statistical power for genomic linkage and association analyses. Second, linkage intervals are broad and contain large numbers of genes, so that success in identifying genes and mutations requires the effort of multiple laboratories freely sharing information. This coordination extends far beyond phenotyping and genotyping and is best exemplified by the Program's creation of a pooled data set and agreements about coordinated publications. During the initial funding period, the Program surpassed its original recruitment goals, carried out multiple genome-wide linkage and association analyses and created an interim pooled data set consisting of phenotype and genotype data from more than 10,000 individuals. In this renewal application, the Program proposes five specific aims to be carried out by all four networks. These aims can be grouped according to two complementary themes: First, these applicants will create and analyze a database of blood pressure- related phenotype and genotype data from all FBPP participants (Aim 1). Within linked regions, they will identify allelic variation within positional candidate genes and evaluate the relationship of these polymorphisms with blood pressure levels and hypertension status (Aims 2 and 3). Second, they will use quantitative measures of target organ damage to identify genes that influence susceptibility to develop hypertensive heart and kidney diseases (Aims 4 and 5). In addition to the Program specific aims, each network proposes specific aims to be carried out by that network alone, based on unique aspects of their population and interests and expertise of the investigators. The Family Blood Pressure Program represents the most determined multidisciplinary approach to the genetics of hypertension ever assembled. The resulting synthesis of ideas and amassed data permits rigorous hypothesis testing not otherwise possible and will hasten understanding of the previously elusive genetic variation responsible for disease risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HYPERTENSION ANGIOTENSIN SYSTEMS
AND
THE
ROLE
OF
TISSUE
RENIN
Principal Investigator & Institution: Sigmund, Curt D. Professor; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2001
42 Blood Pressure
Summary: An intrinsic tissue-renin angiotensin system (RAS) is defined as a tissuespecific system with the potential for the local generation and action for Ang-II. We and others hypothesize that this local generation of Ang-II may provide a level of local control independent of the circulating (or endocrine) system. It has been shown that the kidney and brain both express each RAS gene mRNA and contains each RAS product. Therefore, the kidney and brain may have the capability of generating ANG-II from AGT released locally from renal proximal convoluted tubules (PCT) or astrocytes, respectively. Before the inception of this project, the concept that intrinsic tissue renin systems existed was highly controversial because it was not experimentally feasible to physiologically separate the effects of tissue RAS from the endocrine RAS. We have since provided the first convincing evidence in support of the blood pressure regulatory function of a tissue RAS in the kidney. This was accomplished with the use of a transgenic model in which angiotensinogen (AGT) was specifically targeted to renal PCT cells and studies demonstrating that transgenic mice expressing RAS components specifically within the kidney exhibited chronic hypertension without changes in circulating Ang-II. Importantly, we recently demonstrated that the cre-loxP recombinase system could be used as an effective tool to generate a tissue-specific knockout of RAS genes to experimentally dissect tissue RAS. We will examine the overall hypothesis that intrinsic tissue renin-angiotensin systems play an integral role in the regulation of blood pressure and may participate in the development or maintenance of hypertension. We will focus on the specific aims: 1) we will test the hypothesis that the intra-renal RAS plays a critical role in the regulation of blood pressure and renal function, and when specifically ablated via the cre-loxP recombinase system will reduce blood pressure in a model of Ang II-dependent hypertension, lower basal blood pressure in normotensive mice, and alter renal function and 2) we will explore the hypothesis that an intrinsic RAS in the brain, derived from locally synthesized AGT (and therefore Ang-II), plays an important role in the regulation of basal blood pressure, and when specifically ablated will lower blood pressure in a model of Ang-II-dependent hypertension by altering central effector mechanisms. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPERTENSION, RISK FOR HYPERTENSION AND HYPOALGESIA Principal Investigator & Institution: France, Christopher R. Psychology; Ohio University Athens Athens, OH 45701 Timing: Fiscal Year 2001; Project Start 01-MAY-2000; Project End 30-APR-2004 Summary: The long-term objective of the proposed research is to evaluate hypoalgesia as a biobehavioral marker of risk for hypertension. The research will test the hypothesis that hypoalgesia and hypertension share a common pathophysiology (i.e., central opioid hyposensitivity) that is characterized by enhanced activation of endogenous opiates and supraspinal pain modulation systems. To the extent that this hypothesis is true, individual differences in nociceptive responses at rest, during opiate blockade, and during supraspinal activation may be used to predict longitudinal changes in blood pressure. The findings from this project may also help to explain the attenuation of clinical pain (e.g., angina) that can complicate early arid accurate detection of heart disease in individuals with hypertension. Three studies are proposed that will use the nociceptive flexion reflex (NFR), defined as the intensity of sural nerve stimulation required to elicit leg withdrawal, as an objective measure of nociception. Study l will determine NFR thresholds in controls and unmedicated patients with newly-diagnosed hypertension, and will assess endogenous opiates and descending pain modulation as mediators of hypertensive hypoalgesia. Study 2 will determine NFR thresholds in
Studies 43
young adults at high and low risk for hypertension (defined by parental history of hypertension and resting blood pressure), and will also assess endogenous opiates and descending pain modulation as mediators of hypoalgesia in those at high risk for hypertension. Study 3 will evaluate NFR thresholds at rest and changes in NFR threshold in response to Supraspinal modulation as predictors of longitudinal changes in blood pressure in young adults at high and low risk for hypertension. The proposed studies are important for several reasons. Studies l and 2 will assess promising mechanisms of hypoalgesia which may lead to important insights concerning the role of endogenous opiates in the pathophysiology of hypertension. Study 3 will evaluate nociceptive responses as a means of identifying those at greatest risk for hypertension among heterogeneous groups of high risk men and women. This information could be used to identify the best candidates for behavioral and other risk reduction efforts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPERTENSION: PREDICTION OF BIOFEEDBACK SUCCESS Principal Investigator & Institution: Yucha, Carolyn B. Associate Dean for Research; Adult and Elderly Nursing; University of Florida Gainesville, FL 32611 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2003 Summary: In the next century, our health care system will attempt to manage chronic illness in the largest aging population ever known. Non-adherence to pharmacological therapy and to non- pharmacological therapy will prove very costly. Hypertension, present in more than 50 million Americans, increases the risk of cardiovascular disease and its assoicated morbidity and mortality. Thus it is critical that adherence to treatment of hypertension be increased. While medications are effective in certain patients, their adverse effects make compliance with treatment difficult to ensure. In addition, more and more persons are turning to alternative medicine to deal with their health problems. Biofeedback offers an alternative to medical treatment, having been shown to reduce both systolic and diastolic blood pressures and/or allow the reduction of antihypertensive medications in some patients, while having no adverse effects. Yet biofeedback therapy is time-intensive and technician-intensive. Therefore, it is critical to be able to predict which patients with essential hypertension are most likely to lower his/her blood pressure using these techniques. This research proposes to test three different means of predicting whether a hypertensive subject will or will not be successful in lowering his/her blood pressure using biofeedback. Specifically, the first set of predictive criteria to be tested is that proposed by Weaver and McGrady (1995). This model is derived from five variables: heart rate, finger temperature, forehead muscle tension, plasma renin response to furosemide, and mean arterial pressure response to furosemide. The second prediction model is based on the magnitude of circadian variations in blood pressure as measured by 24-hour ambulatory blood pressure monitoring. The third prediction model is based on locus of control of behavior. A total of 60 hypertensive subjects will be studied over a three-year period. The results of this study will enable those caring for hypertensive persons to recommend treatment (i.e., biofeedback) in an individualized way, thereby promoting adherence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HYPERTHERMIA EFFECTS ON HUMAN BAROFLEX FUNCTION Principal Investigator & Institution: Crandall, Craig G. Associate Professor; Internal Medicine; University of Texas Sw Med Ctr/Dallas Dallas, TX 753909105
44 Blood Pressure
Timing: Fiscal Year 2001; Project Start 01-JAN-1999; Project End 31-DEC-2002 Summary: (Adapted from applicant's abstract): The effects of hyperthermia on human baroreflex control of blood pressure are unknown. Hyperthermia increases sympathetic activity in humans evidenced by increases in cardiac output, heart rate, splanchnic and renal vascular resistances, and muscle sympathetic nerve activity. Since baroreceptor control of these variables is described by a sigmoidal relationship between changes in these efferent variables relative to changes in blood pressure, the PI suggests that the functional reserve to further increase these variables during a hypotensive challenge will be reduced in hyperthermia if the respective baroreflex curves are not adjusted. Thus, the following, hypothesis will be tested: hyperthermia alters baroreceptor control of blood pressure in humans. Studies have shown that hyperthermia attenuates alphaadrenoceptor responsiveness in both intact animals and isolated vessels. Similar studies have not been conducted in humans. If alpha-adrenoceptor responsiveness in humans is likewise attenuated in this environment, baroreceptor adjustments to a reduction in blood pressure in hyperthermia will be less effective in maintaining pressure since end organ vascular responses are attenuated. Therefore, studies will be conducted to test the hypothesis that hyperthermia decreases alpha- adrenoceptor responsiveness in humans. A primary function of baroreflexes is to maintain blood pressure to adequately perfuse the cerebral circulation. The cerebral circulation has a wide autoregulatory range in which large changes in perfusion pressure do not appreciably change cerebral blood flow. Sympathetic stimulation shifts both the lower and upper limits of this autoregulatory curve to higher pressures. Such a shift reduces the reserve to maintain cerebral blood flow during reductions in perfusion pressure, and may predispose the individual to syncope during a hypotensive challenge. As previously mentioned, hyperthermia increases sympathetic activity, and therefore may decrease the reserve to maintain cerebral blood flow during reductions in perfusion pressure in this environment. Thus, the following hypothesis will be tested: hyperthermia shifts the cerebrovascular autoregulatory curve to higher pressures resulting in impaired autoregulation of cerebral blood flow to decreases in perfusion pressure. To address these issues, integrated and individual baroreflex function will be assessed in normothermia and hyperthermia, as will alpha-adrenoceptor responsiveness in both skin and muscle. Finally steady state and dynamic cerebrovascular autoregulation will be assessed in normothermia and hyperthermia using transcranial Doppler. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LOW-RENIN HYPERTENSION IN AFRICAN AMERICANS Principal Investigator & Institution: Pratt, J. Howard. Professor of Medicine; Medicine; Indiana Univ-Purdue Univ at Indianapolis 620 Union Drive, Room 618 Indianapolis, IN 462025167 Timing: Fiscal Year 2001; Project Start 05-JUN-2001; Project End 31-MAY-2004 Summary: (Verbatim from the application): Low-renin hypertension is common in African Americans, with many failing to achieve a normal blood pressure despite the availability of a wide variety of antihypertensive agents. The low-renin state is consistent with increased retention of sodium. We have evidence that blacks have higher overall activity of the epithelial sodium channel (ENaC), a principal site for reabsorption of sodium within the kidney and where certain molecular mutations result in retention of sodium and severe low-renin hypertension (Liddle's syndrome). ENaC is upregulated by aldosterone. In the present proposal, we will study the usefulness of two drugs that inhibit ENaC activity, spironolactone, an antagonist of aldosterone, and amiloride, a direct inhibitor of ENaC, in blacks with low-renin hypertension who have
Studies 45
shown resistance to treatment. We will follow a simple protocol wherein we will study patients taking an optimal regimen of antihypertensive medication including a full dose of diuretic but in whom a normal blood pressure has not been achieved. The patients will be randomized to either spironolactone 25 mg per day, amiloride 10 mg per day, the combination of spironolactone 25 mg and amiloride 10 mg per day, or placebo for 9 weeks. In Specific Aim #1, we will test the hypothesis that drug-resistant, low-renin hypertensive blacks normalize their blood pressure in response to treatment with small doses of agents that reduce ENaC function. We will also test for a synergistic effect of spironolactone with amiloride to lower blood pressure. In Specific Aim #2, we will test the hypothesis that the mechanism whereby the anti-ENaC drugs lower blood pressure is by reducing an intrinsically higher level of ENaC function, as evidenced by lower levels of renin and aldosterone at baseline and greater increments during treatment in responders. In Specific Aim #3, we will test the hypothesis that blood pressure responses to spironolactone are related to the presence of molecular variants in ENaC subunits, variants that have been shown previously to associate with level of blood pressure. In summary, we explore unique but simple approaches to treatment of lowrenin hypertension in blacks, a treatment modality that could prove useful to many patients currently with uncontrolled blood pressure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MACRONUTRIENTS AND CARDIOVASCULAR RISK Principal Investigator & Institution: Appel, Lawrence J. Associate Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2002; Project Start 25-MAY-2002; Project End 31-MAR-2007 Summary: While there is widespread consensus that the optimal diet to reduce cardiovascular risk should be low in saturated fat, the type of macronutrient that should replace saturated fat (carbohydrate, protein or unsaturated fat) is a major, unresolved research question with substantial public health implications. The proposed study will evaluate these 3 dietary approaches by studying their effects on established coronary risk factors and a selected group of emerging risk factors. The study design is a randomized, three period cross-over feeding study that will compare the effects on blood pressure and plasma lipids of a carbohydrate-rich diet (the DASH diet) to two other diets, one rich in protein and another rich in unsaturated (UNSAT) fat, predominantly monounsaturated fat. The DASH diet has been shown to reduce blood pressure and LDL-cholesterol substantially, and is currently recommended by policy makers. During a 1 week run- in, all participants will be fed samples of the 3 study diets (DASH, PROTEIN and UNSAT). Using a three period cross-over design, participants will then be randomly assigned to the DASH, PROTEIN OR UNSAT diet. Each feeding period will last 6 weeks; a washout period of at least 2 weeks will separate each feeding period. Throughout feeding (run-in and the 3 intervention periods), participants will be fed sufficient calories to maintain their weight. Trial participants (n=200, approximately 50 percent female, approximately 50 percent African-American) will be 20 years of age or older, with systolic blood pressure of 120-159 mmHg and diastolic blood pressure of 80-95 mmHg. Primary outcomes variables will be blood pressure and the established plasma lipid risk factors (LDL-C, HDL-C and triglycerides). Secondary outcomes will include apolipoproteins VLDL-apoB and VLDL-apoCIII, which should be superior to triglycerides as predictors of cardiovascular events, as well as total apolipoprotein B, non-HDL cholesterol, and lipoprotein(a). In this fashion, the trial should advance our fundamental knowledge of the effects of diet on both traditional and emerging risk factors, and in the process, inform policy makers and health care providers on the
46 Blood Pressure
relative benefits of carbohydrate, protein and unsaturated fat, predominantly monounsaturated fat, as means to reduce cardiovascular risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MAGNESIUM'S ANTIHYPERTENSIVE EFFECTS IN PREECLAMPSIA Principal Investigator & Institution: Standley, Cynthia A. Physiology; Midwestern University 555 31St St Downers Grove, IL 60515 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Preeclampsia consists of hypertension and proteinuria in pregnancy and is the most common cause of maternal mortality if left untreated. Hypertension in preeclampsia is implicated in the constellation of symptoms including seizures, glomerular damage and intrauterine growth retardation. Inhibition of nitric oxide synthase (NOS) in pregnant rats is an established model of preeclampsia, as it replicates these symptoms. Magnesium sulfate is the standard treatment for preeclampsia. However, magnesium's anti-hypertensive effects remain poorly understood. Magnesium acts as a vasodilator, an action customarily attributed to its ability to antagonize calcium entry into vascular smooth muscle cells (VSMC). Emerging evidence suggests that magnesium may also regulate vascular nitric oxide (NO). Therefore, magnesium may mediate vascular relaxation and reduction of blood pressure by activating the vascular NO/cGMP/protein kinase G (PKG) signaling pathway. We hypothesize that magnesium and NO act synergistically at the level of the vasculature to cause vasodilation and a reduction in blood pressure. Specifically, magnesium's ability to reduce blood pressure in the nitric oxide-inhibited animal model of preeclampsia is due to its ability to upregulate vascular NO/cGMP/PKG signaling, effectively reducing total vascular resistance and consequently blood pressure. To test this hypothesis, we will use the NOS inhibitor, NGnitro-L-arginine methyl ester (LNAME), to induce hypertension in pregnant rats. Then, graded doses of magnesium sulfate via chronic infusions in vivo, and acute treatment of vascular tissues ex vivo, will be used to address the following specific aims: 1) Determine if magnesium predictably reduces blood pressure and proteinuria and alters plasma/urinary NOS signaling metabolite levels, and whether these measures can be used therapeutically to predict and track hypertension; 2) Determine magnesium's effects on vascular inducible NOS (iNOS) and endothelial NOS (eNOS) expression; 3) Investigate magnesium's effects on vascular NOS signaling such as NOS activity, NO-mediated guanylate cyclase activity and PKG expression, and 4) Investigate magnesium's ability to regulate vascular reactivity in response to NO-generating stimuli. Data derived from these experiments will elucidate the anti-hypertensive effects of magnesium, its mode of action and the roles of NO and magnesium in preeclampsia and pregnancy-induced hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MARC PREDOCTORAL FELLOWSHIP Principal Investigator & Institution: Brisbon, Wendy; Anatomy and Physiology; Meharry Medical College 1005-D B Todd Blvd Nashville, TN 37208 Timing: Fiscal Year 2003; Project Start 29-AUG-2003; Project End 28-AUG-2006 Summary: (provided by applicant): My research focus is the role of estrogen in the neural control of blood pressure. Hypertension is a major health problem which greatly increases the risk of cardiovascular disease and stroke. In women, the incidence of cardiovascular disease and stroke increases dramatically following menopause. This is, most likely, due to estrogen depletion, which may trigger a slowly developing increase
Studies 47
in blood pressure. Also, hypertension and diabetes mellitus are often seen as coexisting conditions. My working hypothesis is that aging, estrogen loss, and diabetes mellitus cause decreases in anterior hypothalamic norepinephrine release and decreased activation of alpha-2-adrenoceptors. This leads to decreased sympathoinhibition, increased blood pressure, and increased stroke risk. The specific hypotheses to be tested are: [1] Estrogen maintains lower blood pressure through mechanisms that involve alpha-2-adrenoceptors in the anterior hypothalamic nucleus; and [2] Estrogen depletion and diabetes are associated with increased blood pressure and stroke risk. The increase in blood pressure associated with diabetes involves a decreased activation of alpha-2adrenoceptors in the anterior hypothalamic nucleus. My studies will use middle-aged hypertensive rats and transgenic mice. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MDRD LONG TERM FOLLOW UP STUDY Principal Investigator & Institution: Beck, Gerald J. Acting Chairman; Cleveland Clinic Foundation 9500 Euclid Ave Cleveland, OH 44195 Timing: Fiscal Year 1999; Project Start 30-SEP-1984; Project End 30-SEP-2004 Summary: The Modification of Diet in Renal Disease (MDRD) Study was a randomized clinical trial, funded by NIDDK, to determine the effect of dietary protein restriction and strict blood pressure control on the progression of chronic renal diseases of diverse causes in 840 patients. The planned duration of follow-up was 2-4 years, hence, the rate of decline in glomerular filtration rate (GFR), rather than the incidence of renal failure or death, was the primary outcome. The full-scale trial ended patient follow-up in January 1993. The purpose of this proposal is for the Data Coordinating Center (DCC) to obtain long-term followup data on the study Cohort and to continue data analysis. The fullscale trial showed a beneficial effect of the low blood pressure goal in patients with proteinuria and suggested a beneficial effect of reduced protein intake in patients with advanced renal disease (baseline GFR 13-24 mL/min/1.73 m2). However, the length of follow-up was insufficient to determine the efficacy of the low protein diet in patients with moderate renal disease (baseline GFR 25-55 ml/min/1.73m2, N = 585). During 10 months of additional follow-up after the end of the full-scale trial, the number of patients in the GFR 25-55 group to reach renal failure increased from 31 to 55, and a trend suggesting a benefit of the low protein diet on renal failure or death emerged (relative risk 0.63, 95% confidence interval: 0.30 - 1.02, p=.056). Based on observed rates of GFR decline, the projected number of patients in this group to reach renal failure increases to 163 by 9/96 and 263 by 9/2000, providing a unique opportunity for a much more accurate evaluation of this outcome. The primary goals of further follow-up are to assess the long-term effects of the diet and blood pressure interventions on 1) the incidence of renal failure or death and 2) nutritional status and cardiovascular outcomes prior to and following renal failure. Another fundamental goal is to document the longterm progression of renal disease by relating the extensive data from the full-scale study to long-term patient outcomes from the extended follow-up phase. Patient outcomes would be assessed from data provided by the patient and family, physicians' offices, hospital discharge summaries, and the USRDS. A pilot study demonstrating the feasibility of obtaining follow.up information has been completed. The MDRD Study Group has reported many results from the MDRD Study. This proposal will maintain this activity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
48 Blood Pressure
•
Project Title: MEDULLARY RESPIRATORY NEURONS AND SLEEP APNEA Principal Investigator & Institution: Vidruk, Edward H. Preventive Medicine; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 01-MAY-1999; Project End 30-APR-2003 Summary: Our ultimate goal is to determine the roles of the different types of medullary respiratory neurons in initiating, sustaining and terminating apneas. By extracellular recording of their activity in intact unanesthetized cats we will identify the influence of changes in state of arousal, carbon dioxide, oxygenation and blood pressure on the activity of these neurons. We will focus on three different areas. AIM 1 entails the study of the responses of medullary respiratory neurons to carbon dioxide in wakefulness and in NREM and REM sleep employing a preparation we've developed utilizing ventilatorinduced apnea. We will describe the activation thresholds of the various neurons to carbon dioxide as well as the pattern of discharge near the thresholds. AIM 2 focuses on hypoxia-induced periodic breathing. This is a pattern of waxing and waning (hypopneas) ventilatory periods induced in cats by mild hypoxia. It is a destabilized breathing rhythm which is often a precursor to apnea. We will record medullary respiratory neurons to determine their roles in producing this pattern. These studies also will be done in wakefulness, NREM and REM sleep. AIM 3 centers on interactions between blood pressure and breathing. Changes in blood pressure could be a significant factor in causing destabilized breathing since they often accompany hypopneas and apnea. We will determine whether increases and decreases in blood pressure, some produced pharmacologically and some occurring spontaneously, alter the activity of medullary respiratory neurons. In so doing we will identify neurons which could mediate the ventilatory effects of blood pressure changes. These studies will be done in wakefulness and NREM and REM sleep to detect stat effects. Overall, our studies will produce new information about the basic properties of medullary respiratory neurons and their potential roles in initiating, sustaining and terminating hypopneas and apneas in wakefulness and sleep. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MENSTRUAL CYCLE AND BLOOD EFFECTS ON ACUTE PAIN Principal Investigator & Institution: Sherman, Jeffrey J. Oral Medicine; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 01-MAR-2000; Project End 28-FEB-2003 Summary: (Adapted from applicant's abstract) Temporomandibular disorders (TMD's) are a group of pain conditions characterized by pain in the muscles of mastication and/or the temporomandibular joint. Population prevalence of TMD is about twice as high in women as in men and it is more frequently reported during the reproductive years. About 80% of clinic cases presenting for TMD pain are female. The reasons for the gender discrepancy may involve biologic, psychologic and social factors such as hormonal differences, differences in pain perception, or differences in pain expression or health care utilization. Some data suggest that TMD patients demonstrate greater sensitivity to ischemic pain delivered using the submaximal effort tourniquet test. Sensitivity to the stimulus may vary across the menstrual cycle and be positively correlated with blood pressure during the luteal and follicular phase of the menstrual cycle. Experimental pain sensitivity has been shown to be inversely related to blood pressure in normal males, but this relationship is considerably less clear in females and pain patients. The investigators propose to further assess the discriminative ability of the submaximal effort tourniquet test and to study systematically the interrelationships
Studies 49
between blood pressure, menstrual cycle phase, and ischemic pain sensitivity in TMD patients and pain free controls. They intend to augment an ongoing project funded by the NIDCR and ORWH by adding the submaximal effort tourniquet test as well as resting and reactivity blood pressure measurement during experimental pain stimuli. The study will assess blood pressure variability and variability in responses to ischemic pain at critical points (menses, ovulatory, mid-luteal and late luteal/premenstrual phases) across three consecutive ovulatory cycles in female TMD cases and appropriate controls, to ascertain the extent to which variability in blood pressures and pain may be attributable to female gender, hormonal status, and/or presence of clinical TMD pain. Thus, the proposed study will determine the discriminative ability of the tourniquet test for distinguishing female and male TMD patients from same-sex, pain free controls and evaluate the interrelationships between menstrual cycle, blood pressure and pain. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MENTORED DEVELOPMENT AW
PATIENT-ORIENTED
RESEARCH
CAREER
Principal Investigator & Institution: Mullaney, Scott; Medicine; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2001; Project Start 01-JUL-2000; Project End 30-JUN-2005 Summary: (Adapted from the applicant's abstract): Currently, over 280,000 patients in the U.S. undergo chronic HD for the treatment of end-stage renal disease (ESRD). Technical advances have improved the procedure, yet dialysis- related blood pressure alterations remains a common complication and may contribute to increased morbidity and mortality in HD. Intradialytic hypotension (IH) occurs in up to 48% of HD treatments, contributes to inadequate dialysis and reduces patient comfort and compliance. IH results from a complex interaction between the patient's volume status and the cardiovascular and hemodynamic responses to fluid and solute removal. Several mediators have been incriminated for their likely contribution to IH including inflammatory cytokines [interleukin 1(IL-1) and tumor necrosis factor alpha (TNFa)], complement, and recently NO. NO, a potent vasodilator formed by nitric oxide synthase (NOS), is released from the vascular endothelium. NO levels are elevated in ESRD, and recent studies have reported a strong association between NO and IH with increased NO being associated with more IH. Although NO may have a significant effect on the hemodynamic response to HD, the mechanisms contributing to elevated NO levels, including the effect of HD have yet to be clearly defined. The applicant proposes to test the hypothesis that NO is an important mediator of the hemodynamic response to HD, and that reducing NO would allow for prevention and treatment of dialysis-related events. The project will provide an evaluation of the prevalence of elevated NO in hemodialysis patients, as well as explore the relationship of these levels to hemodynamic profiles including an assessment of blood volume changes and distribution of fluid in various compartments during dialysis. Additionally, mechanisms that may elevate NO levels will be explored through systematic study of the effect of HD and dialysis-related factors on NO levels. Finally, the effect of reducing NO levels, via NO scavengers or NOS inhibitors, on blood pressure changes will be studied. The proposed work will add to the knowledge and understanding of the pathophysiology of blood pressure changes in the HD patient population, and permit development of better strategies to prevent and treat the occurrence of IH in the HD population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
50 Blood Pressure
•
Project Title: MISOPROSTOL EFFECTS ON BLOOD PRESSURE CHANGES IN ESSENTIAL HYPERTENSION Principal Investigator & Institution: Munger, Mark A.; University of Utah 200 S University St Salt Lake City, UT 84112 Timing: Fiscal Year 2001 Summary: This proposal tested the hypothesis that misoprostol attenuates the rise in blood pressure induced by diclofenac sodium (a non-steroidal anti-inflammatory drug) in elderly patients with salt-sensitive, stage I-II essential hypertension. Misoprostol is a prostaglandin E2 analog that had been shown to attenuate the effects of single-dose oral ibuprofen on glomerular filtration rate, renal blood flow, and on blood pressure. This study, conceived by the Principal Investigator, was supported by an unrestricted grantin-aid from the Searle pharmaceutical company. The proposal was considered an investigator-initiated, hypothesis-oriented study generated by the Principal Investigator and his associates, and was not considered to be a drug company-sponsored clinical trial. This study has been completed, and the hypothesis confirmed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MODEL OF THE RENAL MEDULLARY MICROCIRCULATORY FUNCTION Principal Investigator & Institution: Edwards, Aurelie; Chemical Engineering; Tufts University Medford Boston Ave Medford, MA 02155 Timing: Fiscal Year 2001; Project Start 15-JUL-1999; Project End 30-JUN-2004 Summary: The production of maximally concentrated urine is made possible by the renal countercurrent multiplication system, which generates and maintains a hypertonic inner medulla, comprised of cortico- medullary gradients of NaCl and urea. Many features of the multiplication system remain to be elucidated, in particular the role of the medullary microcirculation. By modulating blood flow, vasa recta (i.e., the blood vessels in the renal medulla) can have a major effect on sodium and water homeostasis as well as on the long-term control of arterial blood pressure; their role in hypertension and congestive heart failure is thus highly relevant. Changes in renal medullary hemodynamics are also directly involved in pressure natriuresis. The overall goal of this research is to develop a comprehensive mathematical model of the renal medullary microcirculatory function in order to predict the efficiency of countercurrent exchange of water, small solutes, and macromolecules by the vasa recta. The specific aims of this project are the following. 1. To investigate the specific role of water channels (AQP-1) and urea transporters in descending vasa recta, incorporating data obtained on wildtype mice, AQP-1 deficient mice and AQP-1 deficient mice in which the AQP-1 gene has been replaced by means of an adenovirus. 2. To determine the mechanisms that control interstitial albumin concentration. The effects of albumin concentration polarization at the vessel walls will be determined as a first step. 3. To model the transport of oxygen in the renal medulla and to examine the effects of changes in blood flow rate and tubular consumption on oxygen tension. Medullary hypoxia is a consequence of the need for countercurrent exchange; however, too little oxygen can cause medullary hypoxic injury. 4. To examine how secretion of the vasoactive hormone nitric oxide into the vascular exchanger affects medullary blood flow and interstitial osmolality, and to investigate the relationship between the reduced medullary hematocrit, medullary hypoxia and the effectiveness of NO in the medulla. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 51
•
Project Title: MODELING MECHANORECEPTORS
OF
NON
LINEAR
DYNAMICS
OF
Principal Investigator & Institution: French, Andrew S.; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, CA 90033 Timing: Fiscal Year 2001 Summary: Renal autoregulation of arterial blood pressure requires maintenance of plasma and extracellular fluid volumes. Two mechanisms are thought to be involved in renal autoregulation: the tubuloglomerular feedback (TGF) and a vascular myogenic mechanism. The objective of this project has been to characterize the nonlinear dynamics and the interactions of these autoregulation mechanisms by using induced broadband perturbations of arterial blood pressure and analyzing the resulting blood flow data with nonlinear modeling methodologies. Using the novel methodologies developed in Core Project #1, we were able to quantify the nonlinear dynamics and the interactions between the two regulatory mechanisms (myogenic and TGF). Comparisons of nonlinear models of renal blood pressure and flow data obtained for normotensive rats and spontaneously hypertensive rats show unambiguously that the relative effect of the TGF mechanism is diminished in hypertensive rats and for high-level of forcing. This finding advances our understanding of hypertension and may lead to more effective clinical treatments. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MODELS FOR STUDYING THE GENETICS OF HYPERTENSION Principal Investigator & Institution: Smithies, Oliver; Excellence Professor of Pathology; Pathology and Lab Medicine; University of North Carolina Chapel Hill Office of Sponsored Research Chapel Hill, NC 27599 Timing: Fiscal Year 2001; Project Start 30-SEP-1992; Project End 31-AUG-2002 Summary: The objective of this renewal application is to continue work begun during the prior funding period focused on the analysis of the role of various candidate genes in hypertension through the manipulation of their dosage in genetically engineered mice. This prior work involved using gene targeting to create mice with zero, one, two, three, and four copies of candidate genes targeted at their normal chromosomal locations and then assessing the impact of these defined alterations on hypertension in the mouse. The studies demonstrated that gene dosage determines the levels of expression of these genes which either directly impacted on blood pressure, or had blunted effects on blood pressure due to homeostatic adjustments mediated by other genetic elements. The hypothesis that was developed from these prior studies and which is to be tested in the proposed studies are that variations in the level of expression of a variety of genes will lead to blood pressure changes that may be a reflection of increased expression of the manipulated genes or may be blunted or completely missed depending on the homeostatic adjustments mediated by other elements. Dr. Smithies interprets these blunted changes as virtual blood pressure changes since homeostatic adjustments (i.e.) altered chronic expression by other non-manipulated genes sensing blood pressure changes) which can be demonstrated result in an absence of detectable blood pressure changes. This hypothesis and its implications for the genetics of hypertension will be tested by the applicant in five specific aims. The first four aims will investigate the effects on blood pressure of altered expression of f our candidate genes: 1) the renin 1C gene 2) the Agtr1A gene 3) the type A natriuretic peptide receptor gene 4) the natriuretic peptide "clearance" type receptor gene. The final specific aim involves the development of a path diagram displaying the interaction of these genetic
52 Blood Pressure
determinants from Aims 1-4. This includes predictions and the testing of these predictions using crosses between the mice generated for these studies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEURAL CONTROL OF CARDIORESPIRATORY FUNCTION Principal Investigator & Institution: Harper, Ronald M. Professor; Neurobiology; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 01-APR-1978; Project End 28-FEB-2005 Summary: (Applicant's abstract): Our hypotheses are that the substantial variation in breathing and blood pressure that occurs in rapid eye movement (REM) sleep results partially from state-induced activity changes on regions within the ventral medullary surface (VMS), and that recovery from extreme changes in blood pressure or sustained apnea within sleep depends on the cerebellar fastigial nucleus and one of its afferent structures, the inferior olive. In intact cats, we will 1) identify sites within cerebellar and other brain areas activated by chemoreceptor and blood pressure challenges, and the sequence of activation, using functional magnetic resonance imaging; 2) relate spontaneous respiratory and blood pressure changes during sleep-waking states to VMS regional activity, and activity in the cerebellar fastigial nuclei and inferior olive; 3) apply chemoreceptor and blood pressure challenges during sleep-waking states, and assess fastigial nucleus and inferior olive activity while charting respiratory and cardiovascular responses; 4) electrically stimulate the fastigial nucleus, and examine state-related influences on the VMS and on respiratory and cardiovascular activity; and 5) examine regional activity patterns over the entire VMS unilaterally with respect to ventilatory and blood pressure challenges during different states. Blood oxygen level dependent Echo-Planar functional magnetic resonance images will be obtained using a high-field animal scanner during blood pressure, chemoreceptor, and saline control challenges with anesthetized cats. Baseline and challenge images will be compared on a voxel-by-voxel basis, using t tests with multiple-comparisons correction. Microelectrode and optical probes will be placed in the fastigial nucleus and inferior olive, and a largearray optical probe will be placed over the entire VMS unilaterally. Single cell discharge, and images of scattered 660 and 560 nm light (to measure activity and perfusion, respectively) will be collected during baseline, ventilatory, and pressor challenges within each sleep-waking state. Correlations of regional VMS activity changes to respiratory and cardiovascular patterns will be assessed using cross-correlation, frequency-domain and event-related potential measures for optical signals, and pointprocess techniques for cell discharge. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEURAL CONTROL OF FLUID HOMEOSTASIS IN HYPERTENSION Principal Investigator & Institution: Fink, Gregory D. Associate Professor; Pharmacology and Toxicology; Michigan State University 301 Administration Bldg East Lansing, MI 48824 Timing: Fiscal Year 2001; Project Start 01-JUL-1987; Project End 31-JUL-2003 Summary: High blood pressure (hypertension) continues to have a major impact on mortality and morbidity in most human populations. This is particularly the case where dietary sodium chloride (salt) intake is high. Thus, the long-term goal of this project is to provide an understanding of the mechanisms by which abnormal regulation of body sodium and water balance promote hypertension development. It is very likely that
Studies 53
intrinsic kidney dysfunction plays a key role in this process. The central hypothesis motivating this work, however, is that humoral factors also involved in regulating body fluid volume and electrolyte concentration cause an increase in blood pressure by affecting neural cardiovascular control mechanisms (i.e. brain and autonomic nervous system). The proposed studies will focus on two such factors--angiotensin II and endothelin. Experiments utilizing chronic infusion of these peptides indicate that they influence blood pressure by at least two mechanisms: 1) "fast" pressor effects, primarily due to direct vasoconstriction; and 2) "slow" pressor effects, probably mediated via multiple indirect actions, including activation of neurogenic (sympathetic) pressor responses. High salt intake alone strongly enhances the slow pressor effects of angiotensin II and endothelin. Recent work, moreover, showed that both stenosis of a renal artery and experimental chronic renal failure (reduction in renal mass) also produced such enhancement (to the slow pressor effect of angiotensin II). The experiments proposed in this application will examine the mechanism and implications of these recent findings. All studies will be conducted in conscious Sprague-Dawley rats instrumented for direct, daily measurements of blood pressure and sodium/water balance; and for chronic administration of peptides. Several protocols will seek to establish if renal artery stenosis or reduced renal mass augment slow pressor mechanisms by: 1) affecting plasma peptide concentrations, 2) altering body fluid volume/electrolyte status, or 3) affecting neural input via renal sensory afferents. Others will address the question of how high salt intake is "sensed" by neurogenic pressor mechanisms responsive to angiotensin II and endothelin. The overall role of endothelin in the chronic maintenance of hypertension in rats with reduced renal mass will be assessed using newly developed pharmacological antagonists of endothelin receptors. Finally, a possible contribution of endothelin to angiotensin II induced hypertension will be explored. These investigations should provide new insights into the link between abnormalities in renal function and/or body fluid regulation and the pathogenesis of hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NITRIC OXIDE IN THE REGULATION OF RENIN RELEASE Principal Investigator & Institution: Beierwaltes, William H.; Case Western Reserve Univ-Henry Ford Hsc Research Administraion Cfp-046 Detroit, MI 48202 Timing: Fiscal Year 2001 Summary: The endothelium is a rich source of vasoactive factors which influence organ perfusion (blood flow), organ function, and blood pressure. We hypothesize that under normal conditions, endothelium-derived relaxing factor (EDRF) serves as a buffer against the effects of endogenous vasoconstrictors, especially angiotensin II (AII), or the endothelium- dependent constricting factor (EDCF), endoperoxide/thromboxane. We hypothesize further that under conditions resulting in increased AII, such as during sodium restriction or the development of hypertension, EDRF increases in response to elevated AII and/or increased blood pressure and counteracts vasoconstriction. Since the kidney is rich in AII, its perfusion is particularly influenced by EDRF. We will use a competitive substrate antagonist, NW-nitro-L-arginine (N-Arg), to inhibit EDRF. This will allow us to determine the influence of EDRF on the control of blood pressure and organ perfusion in normotensive rats as well as in various models of hypertension, particularly as it relates to endogenous AII. In specific aim #1 we hypothesize that the contribution of EDRF to vascular resistance is proportional to the basal blood pressure and/or the level of endogenous vasoconstrictors such as AII. We will examine the effect of blood pressure on the pressor response to N-Arg in normal rats. We will determine
54 Blood Pressure
the influence of basal blood pressure on the pressor response to EDRF inhibition with N-Arg, whether EDRF increases with blood pressure, and whether inhibition of EDRF increases the pressor response to exogenous vasoconstrictors. We will determine whether chronic L-arginine administration, the substrate for EDRF, alters pressor responses, and whether inhibiting endogenous vasoconstrictors alters the systemic and renal response to N-Arg. In specific aim #2, we hypothesize that the renal circulation is particularly responsive to EDRF inhibition. To show this, we will compare the response of the renal and mesenteric vasculatures to EDRF inhibition and determine the relative changes in resistance, particularly those influenced by AII. In specific aim #3 we hypothesize that EDRF is increased in hypertension, particularly in AII-dependent models. We will determine whether EDRF is antihypertensive and buffers against increases in blood pressure, especially in renin-angiotensin dependent models of hypertension. We will determine whether systemic pressor and renal responses to EDRF inhibition are greater in hypertension, and whether this is a function of the dependence of different models of hypertension on AII. We will also examine whether chronic EDRF inhibition accelerates the onset of hypertension, and whether supplemental L-arginine administration retards its onset. In specific aim #4 we will study whether agents which transiently decrease renal function, such as diagnostic contrast materials, act by poisoning endothelial cells and consequently inhibiting EDRF production. We will examine whether contrast agents added directly to isolated vessels, or given to rats decreases endothelium- dependent vasodilation or renal function. The results of these studies will help us understand how the endothelium regulates blood pressure and modulates renal perfusion and function, particularly in opposition to constrictor influences such as AII and EDCF. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL APPROACHES IN LINKAGE ANALYSIS FOR COMPLEX TRAITS Principal Investigator & Institution: De Andrade, Mariza; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Hypertension affects 50 million Americans and is the single greatest risk factor contributing to diseases of the brain, heart, and kidneys. There is a strong evidence that hypertension has a genetic basis. In this application, we propose to develop novel approaches to better understand the genetic mechanisms contributing to measures of blood pressure (BP) level, diagnostic category (hypertension versus normotension) and correlated traits. To achieve this goal, in the aim 1 we propose to localize genes influencing measures of blood pressure levels, diagnostic category and their correlates. To do so we will apply genome-wide multivariate linkage analyses based on the variance components approach and utilizing clusters of traits correlated with measures of blood pressure and/or diagnostics category. In the aim 2, we propose to develop exploratory diagnostic tools for linkage analysis of complex traits to further enhance our ability to localize genes influencing measures of blood pressure, diagnostic category and their correlates. To do so, we will extend the diagnostic tools used in regression analysis to the variance components approach used for linkage analysis of quantitative traits. In our case, for example, it can be used to identify outlier families since previous studies have shown that families with outlier values yield false-positive results. We will also extend tree-structure models to pedigree data. Tree-based modeling is an exploratory technique for uncovering structure in the data. The use of tree-structure models is advantageous because no
Studies 55
assumptions are necessary to explore the data structure or to derive parsimonious model. These models are accurate classifiers (binary outcome) and predictors (quantitative outcomes). Thus, they will help us to better understand the underlying structure of the familial data. All these tools will be incorporated in the S-Plus software as a function. S-Plus was selected due to its capability and flexibility for analyzing large data sets. We will analyze family data from the Rochester Family Heart Study, collected in previously NIH funded grants (R01 HL30428 "Sodium Transport: Genetics and Hypertension", and R01 HL51021 "Molecular Epidemiology of Essential Hypertension"). No new data will be collected for this grant proposal. The application clearly fits the goal of this NHLBI grant program since it will explore new approaches using an existing data set collected through NHLBI support. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL PEG-HEMOGLOBIN MODIFICATION FOR BLOOD REPLACEMENT Principal Investigator & Institution: Vandegriff, Kim D. Vice President; Sangart, Inc. 11189 Sorrento Valley Rd, Ste 104 San Diego, CA 921211341 Timing: Fiscal Year 2001; Project Start 05-MAY-1999; Project End 31-AUG-2002 Summary: The goal of this Phase II proposal is to produce and test a new pegylated hemoglobin solution formulated under Phase I(HL 62818-01) with the long-term goal to commercialize this solution for blood replacement therapies based on oxygen transport and blood expansion properties. Critical physicochemical properties of hemoglobin solutions have been defined that work effectively at blood replacement. This is due to the absence of a vasoconstrictive response, a side-effect that is the rule rather than the exception for commercial hemoglobin-based oxygen carriers now in clinical trials. Key properties for an effective solution are: l) high viscosity, 2) high colloid osmotic pressure, and 3) high oxygen affinity. Phase I research formulated a specific hemoglobin solution using new, maleimide pegylation chemistry. This Phase II application proposes to produce pilot-scale batches of this protein (Specific Aim 1), and to test for in vitro diffusive oxygen transport using an artificial capillary system (Specific Aim 2), evaluation of blood pressure responses, cardiac output, and prevention of tissue hypoxia in a rat model (Specific Aim 3), and evaluation of effects on the microcirculation, including functional capillary density, vessel diameters, direct measurements of intravascular and tissue oxygenation, and NO levels in a hamster model (Specific Aim 4). PROPOSED COMMERCIAL APPLICATIONS: The method to modify hemoglobin with polyethylene glycol has significant potential to be developed into a commercial product for use as a blood replacement fluid. Such a product can be used in emergencies, wartime, or anytime blood is not available. Moreover, this product has the potential to be inexpensive and universally compatible with recipients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOVEL THERAPY FOR FEMALE SEXUAL DYSFUNCTION Principal Investigator & Institution: Southan, Garry J.; Inotek Pharmaceuticals Corporation 100 Cummings Ctr, Ste 419E Beverly, MA 01915 Timing: Fiscal Year 2001; Project Start 14-SEP-2001; Project End 30-SEP-2002 Summary: (provided by applicant): Female sexual dysfunction is increasingly recognized as a significant and widespread abnormality, contributing to coital pain, decreased libido, and a loss of sexual pleasure. In contrast to the enormous scientific investment in discovering methods to correct male sexual dysfunction, there has been
56 Blood Pressure
virtually no attention directed at elucidating the fundamental mechanisms accounting for clitoral engorgement, vaginal lubrication, and alterations in vaginal and vulval mucosal blood flows accompanying sexual arousal. Increasing anatomic evidence points to a role for nitric oxide as a mediator of female genital hyperemia, similar to the situation in the male. Topical application of traditional nitric oxide donors to the female genitalia, however, produces profound systemic side effects, including headache and hypotension. What is needed is a potent, but regionally restricted nitric oxide donor, that acts on the local vaginal circulation exclusively. Towards this end, we have developed a nitric oxide pro-drug (DS1) that is restricted from transepithelial flux by virtue of its large hydrodynamic radius. Nitric oxide is released from DS1 and is able to traverse mucosal surfaces and vasodilate underlying arteriolar beds, whereas the prodrug cannot traverse the epithelium and is confined to the apical mucosa. Nitric oxide that reaches the systemic circulation is immediately inactivated by hemoglobin and therefore does not circulate as a systemic vasodilator. Thus, DS1 represents a true "regional" vasodilator. We have obtained preliminary data in rats that topical DS1 applied to the vaginal mucosa produces profound and immediate increases in vaginal blood flow, with no effect on systemic blood pressure. Utilizing an anesthetized rat model, we now propose to obtain a pharmacodynamic profile of DS1. We will simultaneously compare the regional blood flow and the mean peripheral arterial pressure in order to verify regional selectivity. Justification of further development towards commercialization will require 1) no decrease in systemic blood pressure, 2) >100 percent increase in vaginal blood flow, and 3) duration of regional hyperemia >30 minutes. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OHIO STATE UNIVERSITY APPLICATION TO AASK Principal Investigator & Institution: Hebert, Lee A. Director, Division of Nephrology; Internal Medicine; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, OH 43210 Timing: Fiscal Year 2001; Project Start 15-AUG-1994; Project End 30-JUN-2003 Summary: The African-American Study of Kidney Disease and Hypertension (AASK) is a multicenter, prospective, double-masked, randomized study which will determine the extent to which control of blood pressure, using 3 different antihypertensive regimens, can control the progression of hypertensive nephrosclerosis in African-Americans. The study is currently in Phase II. The Ohio State University seeks to be one of the 14 centers to be involved in the full-scale study (Phase III). We suggest that the Ohio State University program is well qualified to participate in Phase III of the AASK by virtue of: 1. Our experience in the conduct of controlled clinical trials involving blood pressure control and/or renal disease. These include: NIH Modification of Diet in Renal Disease (MDRD) Study; NIH/Bristol-Squibb Study of Captopril Therapy in Type I Diabetes and Nephropathy; NIH Trial of Plasmapheresis in Severe Lupus Nephritis; NIH Study of the Adult Nephrotic Syndrome; NIH/Hoechst Study of Ramipril therapy in Type I Diabetes and Nephropathy (active); NKF of Canada/Sandoz North American Nephrotic Syndrome Study (active); Sandoz MIST Study of Salt Sensitivity and Calcium Channel Blocker Therapy in Essential Hypertension (active); ADA Study of Insulin Sensitivity and Blood Pressure in Black Patents (active). 2. Our documented ability to recruit African-Americans and women into these clinical trials in proportion to their numbers in Central Ohio and the disease entity. 3. The favorable demographics of Columbus, Ohio, "urbanized area', including a population of approximately 1.4 million, 12% of whom are African-American (165,000). 4. The well-developed Nephrology clinical
Studies 57
research space including an experienced GFR laboratory which performs approximately 500 GFRs/year for both clinical and research purposes. 5. Our ongoing studies specifically addressing the problem of hypertension and renal disease in AfricanAmericans. 6. The presence of ongoing programs that will directly aid in recruitment and retention of patients for the AASK. Those programs include: our affiliation with the State of Ohio "Ohio Risk Reduction Program (ORRP)", which is in the process of screening 1,200 adult urban African-Americans for health risk factors such as hypertension. Blood studies will identify those with increased serum creatinine levels for evaluation for the AASK; our Continuing Medical Education (CME) programs on hypertension and the kidney for Central Ohio physicians; support of the AASK by prominent members of the Central Ohio African-American community. 7. Our preparedness to begin recruitment to the AASK. We have already identified 17 patients from our programs who are candidates for the AASK. Thus, we are prepared to begin recruitment immediately. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXYGEN TRANSPORT CYS CELL FREE HEMOGLOBIN Principal Investigator & Institution: Winslow, Robert M. Adjunct Professor; Sangart, Inc. 11189 Sorrento Valley Rd, Ste 104 San Diego, CA 921211341 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2003 Summary: A hemoglobin-based oxygen carrier for clinical use remains elusive, primarily because cell-free hemoglobin induces vasoconstriction and reduced tissue oxygenation. We propose that vasoconstriction produced by cell-free hemoglobin is the result of normal autoregulatory mechanisms which are engaged in response to increased diffusive O2 transport when hemoglobin is free in the plasma space. We have discovered that the critical properties of cell-free hemoglobin responsible for this diffusive phenomenon, (ligand affinity, viscosity and colloid osmotic pressure) markedly influence the ability of cell-free hemoglobin to deliver O2 to tissue. Different types of chemical modification of hemoglobin elicit a range of physiological effects from vasoactivity and acid-base status to changes in blood volume in animals. These findings have led us to question the long-standing assumption that for cell-free hemoglobins to effectively transport O2, they must mimic the properties of RBCs. We will evaluate key physical and biochemical characteristics of modified hemoglobin solutions to identify pertinent properties that determine physiologic differences in O2 transport. Specific focus will be on ligand binding (O2 and NO), solution properties (viscosity and oncotic pressure), and molecular size. The proposal contains 4 Specific Aims. 1) To select and characterize model cell-free hemoglobins for study on the basis of ligand binding properties believed to be critical determinants of O2 transfer to tissue. These include O2 binding and NO reactivity at the hemes and as nitrosothiol. 2) To select and characterize model cell-free hemoglobins for study on the basis of solution properties believed to be critical determinants of O2 transfer to tissue. These include viscosity, colloid oncotic pressure, molecular weight and molar volume, and the influence of the type of modification (intramolecular versus surface). 3) To use these model cell-free oxygen carriers in an artificial capillary system to determine the alteration to 02 diffusion resulting from the physicochemical properties of the carriers. This system is independent of biological regulatory mechanisms. 4) To measure in vivo hemodynamic cardiac output, acid-base balance, lactate production, and blood volume responses to isovolemic exchange transfusion with the model carriers and subsequent hemorrhage in rats. The effect of the selected carriers on mean arterial blood pressure and cardiac output will provide indications of vasoactive response to hemodilution with these cell-
58 Blood Pressure
free oxygen carriers in intact animals. Blood volume will be monitored to provide an indication of the fluid shifts that occur in response to isovolemic exchange transfusion. Arterial lactic acid and acid-base status provides additional indicators of the balance between O2 supply and demand. Taken together, these aims will not only lead to rationally-designed oxygen carriers for clinical use, but also important insight into mechanisms of vasoactivity and control of tissue oxygenation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: OXYGENASE METABOLITES AND RENAL MICROVASCULAR REACTIVITY Principal Investigator & Institution: Imig, John D. Associate Professor; Phys Med and Rehabilitation; Medical College of Georgia 1120 15Th St Augusta, GA 30912 Timing: Fiscal Year 2002; Project Start 01-JAN-1998; Project End 30-JUN-2006 Summary: (provided by the applicant): Hypertension that develops following the longterm administration of initially subpressor doses of angiotensin II in rats has many of the same renal and vascular changes that are associated with human essential hypertension. In the past five years, we have provided compelling evidence that CYP45O-derived epoxyeicosatrienoic acids (EETs) have anti-hypertensive properties and play a part in the maintenance of renal microvascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for the conversion of the biologically active EETs to dihydroxyeicosatrienoic acids (DHETs) that are void of effects on the preglomerular vasculature. Recently, a role for soluble epoxide hydrolase (sEH) in the long-term control of arterial blood pressure and the pathogenesis of experimental hypertension has been proposed. Preliminary studies in our laboratory demonstrate increased kidney sEH protein expression during angiotensin II hypertension. In addition, we have observed a decrease in arterial blood pressure in angiotensin II hypertension following administration of a highly selective sEH inhibitor. Based on these observations, we hypothesis that during the development of hypertension increased kidney sEH will decrease kidney EET levels which contributes to increased renal microvascular reactivity, blood pressure and renal vascular injury. We will directly determine the involvement of epoxide hydrolases to the excessive preglomerular vasoconstriction during the development of angiotensin II hypertension using the juxtamedullary nephron preparation. We will also determine renal microvascular EET and DHET levels and the regulation of kidney epoxide hydrolase enzymes during hypertension. The proposed studies will employ newly developed highly selective epoxide hydrolase inhibitors to determine their ability to lower arterial blood pressure and improve renal microvascular function in angiotensin II hypertension. Collectively, these studies will provide a comprehensive understanding of epoxide hydrolases in the long-term regulation of blood pressure and renal hemodynamic function during angiotensin II hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PAIN REGULATORY SYSTEM DYSFUNCTION IN CHRONIC PAIN Principal Investigator & Institution: Bruehl, Stephen; Anesthesiology; Vanderbilt University 3319 West End Ave. Nashville, TN 372036917 Timing: Fiscal Year 2001; Project Start 15-JAN-1999; Project End 31-DEC-2002 Summary: Elevated resting blood pressure (BP) is consistently related to diminished acute pain sensitivity. Ibis cardIovascular-related antinociception (mediated in part by endogenous opioids) is an important component of adaptation to pain in healthy
Studies 59
individuals. it is unknown whether these antinociceptive mechanisms operate normally in chronic pain patients. Previous research indicates deficits in endogenous opioid levels in chronic pain patients, although little is known about the functional impact (e.g., diminished analgesia) of these deficits. Given the mediating role of endogenous opioids in cardiovascular-related antinociception and likely opioid deficits in chronic pain conditions, it is hypothesized that chronic pain patients will display alterations in these normally adaptive cardiovascular-pain regulatory relationships. The long-term objective of these studies is to explore the nature of dysfunction in the endogenous pain regulatory systems of chronic pain patients. improved understanding of the mechanisms contributing to chronic pain has the potential to lead to improved treatment for chronic pain patients. The specific aims of these studies are threefold: 1) examine the relationship between resting blood pressure and acute pain sensitivity in both neuropathic and nociceptive chronic pain patients as contrasted to normals, 2) examine possible differences in degree of endogenous opioid mediation of the relationship between resting blood pressure and acute pain sensitivity across the pain patient and normal control subgroups, and 3) examine whether endogenous opioid dysfunction in chronic pain is progressive and therefore related to pain duration. Sixty chronic pain patients (study l=neuropathic back pain, study 2=nociceptive back pain) and 60 healthy controls will undergo a laboratory ischemic pain stimulus once under placebo and once under opioid blockade with naloxone (randomized, counterbalanced order). in both sessions, resting BP will be determined at baseline. Pain patients will also rate their clinical pain before and after drug administration. it is expected that controls will display significant negative correlations between resting BP and acute pain sensitivity, which is at least partially eliminated by naloxone. Pain patients are expected to demonstrate no correlation or a positive correlation between resting BP and acute pain responsiveness, and will be unresponsive to opioid blockade. Greater pain duration is expected to be associated with smaller changes in the BP/pain relationship in response to opioid blockade. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PAIN, OPIOID ANALGESIA AND BLOOD PRESSURE CONTROL Principal Investigator & Institution: Taylor, Bradley K. Division of Pharmacology; University of Missouri Kansas City Kansas City, MO 64110 Timing: Fiscal Year 2001; Project Start 15-FEB-1998; Project End 31-JAN-2003 Summary: (Applicant's Abstract) Previous studies found that hypertensive SHR rats showed smaller pain responses in acute pain models and suggested that blood pressure control systems can attenuate the processing of brief nociceptive signals. By contrast, preliminary studies found that SHR rats show exaggerated nociceptive responses in a model of inflammatory pain (the formalin test). To test the hypothesis that hypertension decreases nociception in tests of acute pain, and increases nociception in tests of persistent pain, AIM 1A will evaluate nociceptive responses in awake, unrestrained rats in two acute models of nociception and in the formalin test (a short-duration model of persistent inflammatory pain) after: 1) Reduction of blood pressure in SHR rats; and 2) Increases of blood pressure in normotensive rats. Whereas inflammatory pain in the formalin test lasts one hour, inflammatory pain in an arthritic model and neuropathic pain in a spinal nerve ligation model is manifested by hyperalgesia that lasts days to weeks. AIM 1B will evaluate nociception in these models using SHR rats and other experimental models of hypertension. Naloxone eliminates the difference in acute pain sensitivity between normotensive and SHR rats, indicating that tonic endogenous opioid activity is greater in the SHR rat. To test the hypothesis that opioids regulate
60 Blood Pressure
inflammatory hyperalgesia in the hypertensive rat, AIM 2 will evaluate the effects of selective opioid receptor agonists and antagonists on persistent pain in the SHR rat and other experimental models of hypertension. Sympathetic activity is a crucial determinant of blood pressure, and may also exacerbate the inflammatory hyperalgesia associated with tissue injury. Based on preliminary results obtained with a short-acting opioid agonist, it was concluded that peripheral mechanisms during acute nociception modulate the temporal profile of persistent nociception. To test the hypothesis that hypertension contributes to the magnitude and temporal profile of inflammation, AIM 3A will evaluate the effects of opioids on plasma extravasation and prostaglandin content in multiple models of hypertension. Nociception and cardiovascular systems are also controlled by supraspinal sites, notably the noradrenergic locus coeruleus (LC). Since activity of the LC is depressed in the SHR rat and since activation of the LC is antinociceptive, the exaggerated nociceptive responses in the SHR may reflect abnormal functioning of the LC. To test this hypothesis, AIM 3B will use a novel neurotoxin to selectively lesion the noradrenergic neurons of the LC, followed by evaluation of arterial pressure and nociception. The results of these studies will facilitate our understanding of the mechanisms that contribute to chronic pain in the hypertensive patient. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PATIENT-ORIENTED RESEARCH IN EARLY LIFE ORIGINS OF CVD Principal Investigator & Institution: Gillman, Matthew W. Associate Professor; Harvard Pilgrim Health Care, Inc. 93 Worcester St Wellesley, MA 02481 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2006 Summary: The lifecourse approach to chronic disease proposes that factors operating not only in adult life, but also from conception, have impact on lifelong health. Among the more publicized findings in this area are associations between lower birth weight and adult cardiovascular disease mortality, incidence, and risk factors such as blood pressure. These newer investigations have led to a series of exciting research questions and opportunities concerning underlying mechanisms, relations of pre- and post-natal determinants, and implications for clinical medicine and public health. This proposed K24 award will allow Dr. Gillman and his mentees to focus intensively on this area of research for the next five years, a critical period not only for the field itself, but also for expanding his potential for significant contributions and for nurturing the next generation of patient-oriented researchers in this field. The specific aims of this proposal are 1. Research project to examine associations among maternal gestational protein intake, placental hormone activity, and blood pressure in the offspring. This project will take advantage of the infrastructure provided by an ongoing NIH-funded prospective cohort study of pregnant women and their offspring (Project Viva). 2. To provide a nourishing professional environment for the training and advancement of beginning clinical researchers, who will conduct and analyze data from Project Viva and other ongoing patient-oriented research studies in the area of the lifecourse approach to chronic disease. Major foci will be in the areas of pregnancy and infancy determinants of a. childhood cardiovascular risk factors, chiefly blood pressure, b. asthma in early childhood, and c. development of obesity in childhood and adolescence. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PERINATAL ASSESSMENT OF AT RISK POPULATIONS Principal Investigator & Institution: Fifer, William P. Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, NY 10032
Studies 61
Timing: Fiscal Year 2001; Project Start 30-SEP-1994; Project End 30-APR-2004 Summary: (adapted from investigator's abstract) The long-term objectives of this proposal are to elucidate physiologic mechanisms that underlie the Sudden Infant Death Syndrome, and to develop age-appropriate, non-invasive tests that will identify infants who are at the greatest risk for SIDS. These tests focus on assessments of peripheral and central mechanisms involved in the integrated control of cardiac, blood pressure, and respiratory function. Subjects are the fetuses and infants of mothers from a lowsocioeconomic status population in New York City and from a rural Native American population on the Pine Ridge Reservation in South Dakota, which is at unusually high risk for SIDS. The proposed studies begin with measurements made during late gestation. Assessments then continue through infancy to document the physiologic changes that coincide with the period of maximal risk for SIDS. These postnatal studies incorporate measurements made during sleep under basal conditions as well as during head-up and head-down tilting. The principal dependent variables are heart rate and several indices of heart rate variability, respiratory rate and variability, body temperature, and electrocortical activity and beat-to-beat blood pressure. Five experiments will address the following aims; Patterns of developmental change in cardiorespiratory activity measured from the late fetal period through infancy will distinguish groups of infants at increased risk for SIDS How postnatal development of heart rate, blood pressure and respiratory responses to the challenge of head-up and head-down tilting will be altered in groups of infants at increased risk for SIDS Physiologic responses to tilt are dependent upon sleep state and this dependency may change with age Blood pressure decreases to head-up tilt are larger in the prone sleeping position Head-up tilting will induce cortical activation which will be diminished during the period of greatest vulnerability to SIDS Respiratory and heart rate responses to tilt will be diminished in the morning hours and Responses to tilt will vary with time after feeding. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHYSICAL ACTIVITY ON BLOOD PRESSURE OF FEMALE AFRICAN-AMERICANS Principal Investigator & Institution: Muntner, Paul; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2002; Project Start 20-SEP-2002; Project End 31-AUG-2007 Summary: We propose to conduct an efficacy trial and an effectiveness trial of a physical activity intervention among African-American women with hypertension (systolic/diastolic blood pressure [BP] > 140/90 mmHg or currently taking antihypertensive medications). The first open, randomized, controlled trial with two parallel arms will include a supervised physical activity intervention program. Eligible participants (African-American women with established hypertension) will be randomly assigned to participate in a 12-week monitored aerobic exercise program (n65) or usual care (n=65). Study participants will be recruited from the general internal medicine (GIM) clinics at the Medical Center of Louisiana in New Orleans (MCLNO). The primary aim of the efficacy trial is to determine the BP lowering effect of 12 weeks of aerobic exercise. The second trial being proposed is a two center randomized controlled trial to determine the effectiveness of physician counseling on physical activity levels and blood pressure. African-American women with hypertension will be recruited from the general internal medicine (GIM) clinics at the Medical Center of Louisiana in New Orleans (MCLNO) and Tulane University. The proposed study is an open, randomized, controlled trial with two parallel arms. A total of 180 sedentary
62 Blood Pressure
African-American women (90 in each arm) with hypertension will be recruited for this study. Eligible and enrolled participants will meet with one of 20 primary care providers who will be randomized to provide usual care (n=10) or a tailored 10-minute educational program (n=10) aimed at increasing the participant's physical activity levels in addition to usual care. Reinforcement and further tailored counseling will be provided by the physician at a 3-month follow-up visit and through bi-weekly telephone calls by a trained health educator. Change in fitness, assessed by VO2 max testing, between the group receiving physical activity counseling and the group receiving usual care at the 6-month follow-up visit will be the primary endpoint. Change in physical activity levels and blood pressure will also be examined as secondary endpoints. In sum, these studies should help to address the challenge of health disparities in African-Americans. Because of the current high prevalence of inactivity in the United States, increasing physical activity could have a tremendous impact on the disproportionate burden of CVD, stroke, diabetes mellitus and ESRD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHYSIOLOGIC IMMIGRANTS
STRESS/BLOOD
PRESSURE
IN
FILIPINO
Principal Investigator & Institution: Brown, Daniel E. Professor; University of Hawaii at Hilo Box 1357 Hilo, HI 96720 Timing: Fiscal Year 2001 Summary: The effect of social and biological factors on physiological measures of stress will be examined in non-managerial hotel workers in a rural and a urban region of Hawaii. A large number of hotel-workers are immigrants from the Philippines and they will be the major focus of the study. Filipino-Americans have high prevalence rates of hypertension and high mortality rates from strokes compared with means for the state of Hawaii. Preliminary studies suggest that Filipino immigrants have elevated age- and body mass-adjusted blood pressure during sleep compared with Caucasians, and that Filipinos have differential stress perceptions of some daily activities than do Caucasians and that Filipinos have differential stress perceptions on some daily activities than do Caucasians. This study proposes to add to under understanding of how cultural, social and psychological orientation influence the biological stress response and cardiovascular health of Filipino immigrant hotel workers, and to compare these relationships with those of their Filipino-American (non- migrant) and non-Filipino coworkers The study will investigate the influence of sex, reported mood, job strain, lifestyle incongruity, differing degrees of orientation toward Western versus traditional Filipino (Ilocano) lifestyles, rural-urban contrasts, and other behavioral variability on ambulatory blood pressure and urinary catecholamines measured at work, home and while asleep. The relationship of these factors to cortisol excretion during work and to fasting blood lipid profiles will also be examined. An ecological design is used, with monitoring of physiological measures during a typical work day, and information about the subjects' body size and composition, attitudes toward work and home life, and health histories will be obtained. The research is designed to provide insights into how stress may contribute toward the high hypertension prevalence among Filipinos in Hawaii. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PLANT-BASED DIETRY INTERVENTION IN TYPE 2 DIABETES Principal Investigator & Institution: Barnard, Neal D.; Physicians Committee for Responsible Med Responsible Medicine Washington, DC 20016
Studies 63
Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Diabetes often leads to serious complications, including coronary heart disease, kidney disease, and blindness, among others. Previous studies have suggested that low-fat, plant-based diets can have a strongly favorable effect on the management of type 2 diabetes mellitus, as well as on the elevations of body weight and serum cholesterol that often accompany it, reducing the risk of complications, and raising the possibility of reducing or even eliminating medication use for many individuals. Evidence suggests that the dietary recommendations that are most effective in diabetes management may be similar to the low-fat, vegetarian diets that have demonstrated utility in reversing coronary artery blockages. However, no study to date has examined the effect of a low-fat, vegetarian diet as an intervention for diabetes in a substantial number of participants, and most studies using plant-based (near-vegetarian) diets have also included exercise as a major intervention component, making it impossible to separate the effects of physical activity from those of diet or to reach any definitive conclusion as to which type of dietary intervention is best. This study, which follows an encouraging preliminary trial reported in Preventive Medicine in 1999, will test the hypothesis that a low-fat, vegetarian diet yields significant improvements in key indices of diabetic control, including glycosylated hemoglobin, fasting serum glucose and insulin concentrations, microalbuminuria, and medication requirements, as well as in cardiovascular risk factors, such as body weight, serum lipids, and blood pressure, in a 22-week intervention controlled throughout for exercise, with a 1-year follow-up. Sixty-eight volunteers with type 2 diabetes will be randomly assigned to a low-fat, vegan (intervention) diet or a control diet deriving 15-20percent of energy from protein and < 7percent of energy from saturated fats, with carbohydrate and monounsaturated fats together providing 60-70percent of energy intake, based on current American Diabetes Association guidelines. Participants in both groups will be asked to attend weekly meetings for nutrition and cooking instruction and group support, and will be asked not to alter their exercise patterns. Physical activity will be monitored by use of the Bouchard 3-Day Physical Activity Record. (Bouchard 1983) Diets will be assessed at baseline and 11, 22, and 74 weeks, using a 3-day dietary record. Fasting serum glucose will be monitored for the study duration and will be used to adjust medications according to a set protocol. Glycosylated hemoglobin, insulin concentrations, 24-hour urinary albumin, body weight, blood pressure, serum lipids, and related cardiovascular risk factors will be measured at baseline, 22 weeks, and 74 weeks. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PORTAL VENOUS FATTY ACIDS AS A DETERMINANT OF BLOOD PRESSURE Principal Investigator & Institution: Grekin, Roger J.; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, MI 481091274 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2002 Summary: Obesity markedly increases the risk of developing hypertension, but the mechanisms which lead to obesity-related hypertension are poorly understood. The long-term objectives of this proposal are to evaluate the role of non-esterified fatty acids (NEFA) in the genesis of obesity-related hypertension. In particular, the relationship between splanchnic production of NEFA and blood pressure regulation will be explored. Four specific aims are proposed. The relationship between splanchnic and systemic NEFA production, sympathetic nerve activity and blood pressure in lean individuals and subjects with visceral and lower body obesity will be determined. The
64 Blood Pressure
suppressibility of NEFA production in these individuals will also be compared to measurements of sympathetic activity. The effects of dietary induced weight reduction and pharmacologic therapy on splanchnic and systemic NEFA production, sympathetic nerve activity and blood pressure will be assessed. Ninety women will be studied. Thirty lean control subjects, thirty individuals with lower body obesity and thirty individuals with upper obesity will be studied. Body fat distribution will be characterized using DEXA and CT scanning and blood pressure will be assessed using ambulatory monitoring. Splanchnic and systemic NEFA production will be determined using infusions of 3H-palmitate following hepatic venous catheterization. Renal norepinephrine (NE) spillover will be measured and NE production will be estimated using kinetic analysis of norepinephrine (NE) spillover will be measured and NE production will be estimated using kinetic analysis of the decay of infused 3H-NE. Suppressibility of NEFA production will be determined during a hyperinsulinemic, euglycemic clamp study. Measurements of both NEFA production and NE kinetics will be repeated during the clamp study. Thirty women will undergo a sixteen week supervised weight loss program entailing weekly meetings with a dietitian and dietary supervision. Body composition, blood pressure, NEFA production and suppressibility and NE spillover and kinetics will be measured after completion of the weight loss program to determine the relationship between the hypotensive effects of weight loss and changes in NEFA metabolism. A second intervention study will be performed in third women to test the effects of pharmacologic lowering of NEFA production on blood pressure and NE kinetics. Individuals will be treated with nicotine acid and troglitazone to reduce fasting NEFA levels by 50%. Studies will be repeated at the conclusion of the pharmacologic intervention. Taken together, these studies should provide information regarding the role of splanchnic NEFA in the genesis of obesityrelated hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREDICTING SYSTOLIC BP CONTROL IN THE ELDERLY Principal Investigator & Institution: Bailey, Kent R. Professor; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2004 Summary: NHANES III data show that fewer than 30% of patients who are hypertensive have been treated to the goal blood pressure of less than 140/90 mm Hg. Older patients are more likely to have uncontrolled blood pressure than are younger patients. The SHIELD Study revealed that 41% of people over the age of 65 years and 65% of African Americans over that age have poorly controlled hypertension. Poor blood pressure control also disproportionately causes cardiovascular disease in patient over 60. Systolic blood pressure is the primary predictor in this age group for the development of stroke, congestive heat failure (most common reason for hospitalization in the elderly), renal failure and coronary heart disease. There is even exciting new data showing that control of systolic blood pressure in the elderly reduces the risk for the development of Alzheimer?s dementia. Failure to achieve blood pressure control is determined by three factors: physician practice (behavior), antihypertensive medication efficacy, and adherence to the prescribed medications (patient factors). Our study proposes to develop models that describe each of these factors independently and then develop a model that encompasses all three factors. Specific Aim 1 will identify and quantify differences in physician response to elevated systolic blood pressure in hypertensive patients greater than 60 years of age compared to their younger counterparts. Specific Aim 2 will analyze the differences in responsiveness of systolic blood pressure to
Studies 65
treatment regimens using one or more antihypertensive medications. Specific Aim 3 examines adherence and postulates that adherence is the same between younger and older hypertensives. This study is to be conducted using a unique clinical database. Over 7,000 patients with more than 25,000 observations are present in the Mayo Clinic Rochester Hypertension Continuity Clinic Database. This Sybase database is well constructed to answer the important questions posed in Aims 1-3 regarding the management of hypertension. This study will provide significant and generalizable answers to the question of why control rates for systolic hypertension remain low and will provide direction for altering clinical practice to reduce cardiovascular morbidity and mortality among older hypertensives. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRENATAL SET POINT FOR ADULT BLOOD PRESSURE Principal Investigator & Institution: Faber, Job J. Professor; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2002; Project Start 01-JUN-2002; Project End 31-MAY-2007 Summary: Late gestation fetal sheep will be treated to create systemic and pulmonary arterial hypertensions. One group will have high circulating angiotensin-II levels. There will be two normotensive control groups, one with normal and one with low angiotensin-II. The animals will be studied as fetuses, as newborns and as young adults. Circulatory measurements will include arterial pressures, right and left atrial pressures and cardiac outputs. We will also make plasma renin activity/renal ar6terial pressure response curves and measurements of glomerular filtration rates. Analytical measurements will include plasma renin activities, circulating angiotensin-II levels, catecholamines, plasma protein and blood hemoglobin concentrations, blood gases, osmolalities and electrolytes. Coronary pressure-flow relations will be determined under anesthesia with and without chemical dilation by means of adenosine infusions to determine coronary reserve. The animals will be killed for structural studies of heart and kidney. It is anticipated that prenatal hypertensions will produce lasting circulatory abnormalities later in life. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PRESSURE AND FLOW INDUCED REMODELING OF CORONARY ARTERY Principal Investigator & Institution: Kassab, Ghassan S. Biomedical Engineering; University of California Irvine Campus Dr Irvine, CA 92697 Timing: Fiscal Year 2003; Project Start 15-DEC-1997; Project End 30-JUN-2007 Summary: (provided by applicant): The study of adaptation mechanisms in structure and function of blood vessels in response to physical stress is important in human health and disease. The objective of this proposal is to gain a better understanding of the adaptation mechanisms in the structure, mechanical properties and function of the coronary arteries to altered mechanical forces, including principal and shear stresses, in experimental models of hypertension and flow-overload, respectively. The effects of increased pressure and flow will be examined separately by studying the right coronary artery in aortic and pulmonary banding, respectively. The specific aims are: 1) To measure and state the physical loading acting on the blood vessels precisely and analytically with the nonstationary, nonlinear, and stochastic features taken into account; 2) To study the morphometric remodeling of coronary arterial blood vessels in vivo during the progression of hypertension and/or fiow-overload; 3) To determine the
66 Blood Pressure
stress-strain relationship and the stress-tissue remodeling relationship in response to hypertension and/or flow-overload; 4) To study the remodeling of the threedimensional structure of elastin and collagen under the various mechanical loadings prescribed in Aim 3 in unfixed, unstained tissue; and 5) To study the dynamics, linearity, superposability and non-linearity of the changes of morphometry and mechanical properties of Aims 2 and 3 in response to the dynamic changes of the magnitude and direction of the loading in Aim 1. The recorded in vivo blood pressure and flow data will be characterized with the intrinsic mode function method. The time course of change of blood vessel diameter, length and volume will be measured using digital subtraction angiography and video densitometery. The remodeling of the mechanical properties of coronary arteries will be measured in circumferential distension, longitudinal extension and torsion using a tri-axial machine. The changes in collagen and elastin fibers will be visualized with multi-photon microscopy. This research will clarify the role played by increased flow and pressure on coronary blood vessel remodeling by expressing the results mathematically in terms of indicial response functions and by using these functions to clarify the structural and mechanical remodeling that signifies hypertension and hypertrophy as important risk factors for coronary artery disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRIMATE MODEL OF HYPERTENSIVE CEREBROVASCULAR DISEASE Principal Investigator & Institution: Killiany, Ronald J. Anatomy and Neurobiology; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2003 Summary: Within the next twenty years, 50% of all individuals in this country will be 50 years old or older, an aging time point that has been characterized in cross sectional data by the onset of cognitive decline. This shifting of the population to a proportionately greater number of older individuals has fueled concerns about the effects of aging and age-related diseases and their relationship to cognitive decline. One of the most common conditions affecting individuals as they age is hypertension, the incidence of which is 25% among all adults in the US., and greater than 50% among all adults over the age of 65. At present, this condition affects over 60 million people in the U S alone, of whom it is estimated 50% may be untreated. Moreover, evidence has accumulated to show convincingly that hypertension, in addition to aging, produces impairment in multiple domains of cognitive function, even at mildly elevated levels of blood pressure. In addition, hypertension is a major risk factor for cerebrovascular dementia which alone accounts for approximately 20% of all dementia and likely contributes to another 15% to 20% of the dementia cases. However, the mechanism by which hypertension induces neuropathological changes is poorly understood, in part because only limited animal models exist for studying these processes. The purpose of this project is to test a novel device for inducing hypertension in the non-human primate. The device is surgically implanted into the chest of the monkey surrounding the thoratic arota. The device can be adjusted externally to narrow the diameter of the arota (but not fully constricting it) resulting in increased blood flow and hypertension to the upper limbs and head. By adjusting the device gradually over a period of time, the blood pressure can be raised gradually until hypertension is induced. We will test this device in non-survival and short-term survival situations in five monkeys. They will be continuously monitored for blood pressure, body temperature, EKG and activity using radiotelemetry devices and values compare from pre-implant to post-implant levels.
Studies 67
Finally, as part of a preliminary effort to understand the mechanism by which neuropatholoigical processes are induced in the brain, we will survey the brain and aorta for signs of pathology. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PSYCHOLOGICAL PREDICTORS OF BLOOD PRESSURE IN AFRICAN AMERICANS Principal Investigator & Institution: Harrell, Jules P.; Howard University 2400 6Th St Nw Washington, DC 20059 Timing: Fiscal Year 2002; Project Start 01-JUN-1977; Project End 31-JUL-2006 Summary: The sequelae of hypertension rank among the chief causes of death in the African American community. Interrupting the chain of events that contribute to hypertension would improve substantially the health status of this group. Borderline hypertensives are more likely to develop established hypertension over time. However, predictive models are in need of improvement. Behavioral approaches seek to identify modifiable elements of the environment or of persons that predispose one to cardiovascular disease. The present study tests the utility of three psychological and two psychophysiological predictors of arterial monitored for a period of four years. Resting blood pressure, depressive affect, and psychological stress levels will be assessed twice each year. Participants will complete indices of hostility and cultural orientation during the first and third years of the study. Regression models will determine if hostility, stress, depression, and cultural orientation predict existing blood pressure levels or increases in pressure over time. Cardiovascular reactivity to handgrip and psychomotor tasks will be expressed in terms of systemic overperfusion (additional cardiac output) and the ratio of shared versus simple contributions of cardiac and vascular determinants of blood pressure. These indices will be employed as predictors of both causal blood pressure levels and changes in blood pressure across the four-year measurement period. The study is designed to identify a set of predictors of blood pressure status that are subject to modification prior to the onset of the target organ damage associated with hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PSYCHOSOCIAL FACTORS AND CARDIOVASCULAR DISEASE Principal Investigator & Institution: Pickering, Thomas G. Professor of Medicine; Medicine; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2003; Project Start 01-SEP-1994; Project End 31-AUG-2008 Summary: (provided by applicant): This program Project proposal represents a continuation of our existing Program Project (PO1HL47540), which is now entering its 10th year. Supported by NHLBI since 1985, it comprises a body of work that focuses on the role of psychosocial factors in the development of hypertension and cardiovascular disease, led by a well-established, multidisciplinary group of investigators at Mount Sinai School of Medicine and focus on a set of inter-related themes concerning the causes and consequences of sustained blood pressure elevation. Project 1 (International Follow-Up of Ambulatory BP and CV Events) extends our focus on the utility of ambulatory blood pressure monitoring in a clinical and research applications. The goal is to complete the data collection for a comprehensive database of ambulatory blood pressures and follow-up cardiovascular events in patients seen in our clinic over the past 23 years. These data will be pooled with the dose-response relationship between ambulatory blood pressure and cardiovascular events and investigate
68 Blood Pressure
similarities/differences across cultures. Project 2 (Masked Hypertension-Risk Factors and Consequences) focuses on the difference between ambulatory and clinic blood pressures and those persons who exhibit normal clinic blood pressure but hypertensive blood pressure during ambulatory monitoring in the natural environment. These persons (estimated at 10%-20% of the population) represent an important model for the study of human hypertension, as these persons may be at elevated risk for end organ damage due to their elevated ambulatory blood pressure and are unlikely to be treated. This study will investigate the reproducibility of the ABP/clinic BP difference, the psychosocial factors that are associated with this difference, and whether this difference is associated with left ventricular structure and function. Project 3 (Effects of Angry Perseverative Cognition on Ambulatory BP) is an extension of our research examining the cognitive and psychological underpinnings of prolonged blood pressure elevation. This study will utilize a field manipulation of angry cognition, and examine the effects on blood pressure recovery in the laboratory and in the field. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PULSATILE ARTERIAL LOAD IN PREECLAMPSIA Principal Investigator & Institution: Shroff, Sanjeev G. Mcginnis Professor of Bioengineering& Me; Magee-Women's Health Corporation 204 Craft Ave Pittsburgh, PA 15213 Timing: Fiscal Year 2002; Project Start 14-JUN-2002; Project End 31-JAN-2007 Summary: Changes in pulsatile arterial load (PAL) early in gestation (e.g., increased global arterial compliance, AC) play an important adaptive role in normal pregnancy (e.g., minimize arterial pressure and flow pulsatiles) and preliminary data suggest that aberrant PAL responses may be involved in the pathophysiology of preeclampsia. Working model: AC does not increase early in gestation in subjects destined to develop preeclampsia resulting in increased arterial pressure and flow pulsatiles, and consequently, increased pulsatile (oscillatory) shear stress at vascular endothelium, which is known to cause a sustained activation of endothelial pro-oxidant processes. Over time, this sustained endothelial dysfunction and/or inadequate compensation by anti-oxidant defenses can lead to the hemodynamic milieu commonly seen with the onset of the clinical syndrome of preeclampsia (high blood pressure; high systemic vascular resistance, SVR; and normal-to-low cardiac output). Thus, the focus of the present proposal is to comprehensively examine systemic arterial and left ventricular (LV) properties in primiparous control and prior preeclamptic women, both in the nonpregnant state and throughout the second gestation. Hypotheses: 1) In subjects with a history of preeclampsia, differences in vascular mechanical properties (PAL in particular) and/or endothelial function exist in the non-pregnant state and chronic antioxidant therapy(vitamin C supplementation) can help reduce these differences. 2) In subjects destined to develop preeclampsia, the increase in AC during early gestation, which is seen in normal pregnancy, is significantly attenuated. Two groups of primiparous women will be studied at 6-12 months post- partum (Aim 1a): i) prior preeclamptic subjects (n=70, Group 1) and ii) control subjects (n=70, Group 2). Group 1 subjects will be restudied following an 8-week supplementation with either vitamin C (N=35) or placebo (n=35) (Aim 1b). Finally, a longitudinal study will be conducted in two groups of primiparous women (pre-conception-during second gestation-postpartum) (Aim 2): i) prior preeclamptic subjects (n=70) and ii) control subjects (n=15). Non-invasive measurements will be performed to quantify arterial properties (global: aortic input impedance spectrum, SVR, AC, wave reflection indices; regional: pulse wave velocity, pressure-diameter relationships, indices of vessel wall stiffness), LV
Studies 69
properties (size, shape, and mass, indices of myocardial contractility), and endothelial function (forearm blood flow response to mental stress). Blood and urine samples will be analyzed to derive indices of endothelial activation, oxidative stress, and dyslipidemia. Results of these studies are expected to provide insights into the role of pulsatile arterial load in the pathogenesis of preeclampsia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PULSATILE HEMODYNAMICS AND CAROTID STENTING Principal Investigator & Institution: Quick, Christopher M. Veterinary Physiology & Pharmacology; Texas A&M University System College Station, TX 778433578 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2007 Summary: (provided by applicant): Angioplasty and stenting of the large conductance vessels that supply the brain is a relatively new treatment that may be a viable alternative to carotid endarterectomy. Based on the extensive history of coronary artery stenting, it can be surmised that restenosis will be a key factor limiting the long-term success of carotid arterial stenting. The hemodynamic factors that influence restenosis, especially pulsatile pressure and flow, have received little scrutiny. We hypothesize that the degree of in-stent restenosis is related to pulsatility of pressure and flow. The following four specific aims will address this hypothesis: 1) To measure the degree of restenosis after carotid artery stenting and associated changes in pulsatile blood pressure and flow; 2) To predict with a patient-specific computational model the short and long-term changes in pulsatile pressure and flow after stenting; 3) To compare restenosis in rabbit iliac arteries that are subjected to high and low levels of pulsatile pressure and flow; 4) To compare remodeling factors in chronically stented vessels subjected to high and low levels of pulsatility. Dr. Quick is an engineer who has an extensive background in computational modeling of pulsatile hemodynamics in vascular beds. Funding is sought for a five-year training periodfor Dr. Quick to transition to a career in quantitative vascular biology. This project, addressing the interaction of hemodynamics and vascular biology, is a fundamentally new direction forDr. Quick, yet complements his expertise. Having studied the effect of vascular mechanical properties on oscillatory blood pressure and flow, he can now focus on the effect of oscillatory pressure and flow on vascular mechanical properties. This project represents a natural progression from theoretical tools to study the phenomena of vascular remodeling to the experimental tools to study the mechanisms of remodeling. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: RACISM, COPING AND AMBULATORY BLOOD PRESSURE Principal Investigator & Institution: Brondolo, Elizabeth N. Psychology; St. John's University Jamaica, NY 11439 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 31-MAY-2007 Summary: (provided by applicant): Racial disparities in health status, and in particular the excess rates of hypertension (HT) among Blacks, are widely recognized. Investigators have hypothesized that social stressors, including exposure to racism or ethnic discrimination, may contribute to increased risk for HT and cardiovascular disease (CVD). The specific aim of the proposed study is to test a model of the relationships among ethnic discrimination, coping, and ambulatory blood pressure (ABP). The model proposes that perceived exposure to ethnic discrimination will be positively associated with the average level of ABP and with the magnitude and duration of acute blood pressure and heart rate responses to current negative
70 Blood Pressure
interpersonal interactions. Coping styles and strategies used to manage ethnic discrimination are expected to mediate the relationship of ethnic discrimination to ABP. Socioeconomic status (SES) is expected to moderate the relationship of racism to coping and the relationships of ethnic discrimination and coping to ABP. To test the generalizability of this model, the hypotheses will be tested in a multi-site sample of 720 American-born Black and Latino men and women drawn from urban primary care medical practices. These practices are located in culturally diverse communities, serving patients from a range of socioeconomic backgrounds. Participants will wear an ambulatory blood pressure monitor for 24 hours. Questionnaires will be used to assess past exposure to ethnic/racial discrimination. Diaries completed at the time of each ambulatory blood pressure reading will be used to identify day-of-testing negative and potentially discriminatory interactions. Both characteristic styles of coping and episodespecific strategies for coping with ethnic discrimination are examined. Demographic and personality variables likely to affect perceptions of ethnic discrimination will be examined and controlled. Structural equation modeling will be employed to evaluate the relationships among perceived ethnic discrimination to coping and ABP. Additional analyses will examine the association of gender, SES, and race/ethnicity to the use of different styles and strategies for coping with ethnic discrimination, and the effects of these characteristics on the relationship of coping to ABP. The study has implications for theories concerning the relationship of psychosocial stress to risk for HT and for the development of interventions to reduce racial disparities in health status. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RACISM, SOCIAL SUPPORT, AND ALCOHOL USE AND BLOOD PRESSURE IN AFRICAN AMERICANS Principal Investigator & Institution: Robinson, Elwood L. Professor; North Carolina Central University 160 Alexander-Dunn Bidg. Durham, NC 27707 Timing: Fiscal Year 2001 Summary: Two of the leading threats to american health are high blood pressure and alcohol-abuse. It is well documented that high blood pressure is linearly related to higher rates of certain forms of coronary heart disease (CHD) and stroke, and the relationship between hypertension and mortality is especially strong for African Americans. Moreover, African Americans alcoholics may run a greater risk than white alcoholics for blood pressure elevations as their drinking careers lengthen. Stressors, or the problems and pressures of life, have long been suspected as culprits linked to both hypertension and alcohol abuse. Racism has been reported to prevail as a primary stressor facing African Americans today. Several studies have described the potentially damaging social, economic, and political consequences of racism and its negative effects on individual well-being (Jaynes & Williams, 1989; Katz & Taylor, 1988; Schuman, Steeth, & Bobo, 1985). Recent studies from epidemiological literature have suggested that exposure to chronic stress of racism, prejudice, and discrimination may contribute to the disproportionately high rates of hypertension among African Americans. Social support has been purported to exert a buffering effect in ameliorating or attenuating the deleterious effects of stress on physical and mental health. Many epidemiological studies suggest that social support is related to reduced morbidity and mortality, particularly for cardiovascular disease. However, most of these studies have focused on white populations in the United States, Western Europe, and Scandinavia. This study proposes to investigate racism/discrimination, social support, alcohol use, and blood pressure in subjects that were drawn from a random sample survey of household residents in Erie county, New York. Overall, three waves of data are available for both
Studies 71
cross-sectional and longitudinal data analysis. The specific aims are: (l) To examine the influence of racism on alcohol use and BP in African Americans; (2) To determine if social support buffers these relations and investigate the relation between social network measures and social support; and (3) To assess the effects of age, gender, and socioeconomic status on the above relations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RECIPES, MENUS, AND FOOD GUIDELINES FOR TREATMENT & PREVENTION OF HYPERTENSION Principal Investigator & Institution: Mcmurry, Martha; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2001 Summary: The purpose of this study is to develop recipes which are tasty and which sound like foods which American families might like to prepare and eat. These foods will be based on the DASH (Dietary Approaches to Stop Hypertension) national blood pressure study. The DASH diet has been found to lower blood pressure. We will examine the results of using this diet in persons with high blood pressure or are at risk for high blood pressure (also called "hypertension"). We will provide meals which include foods to sample that are based on the DASH eating plan. These foods and recipes will be evaluated according to taste preferences and eating habits, with feedback requested on how we can improve them. 15 mealtime sessions will occur at the CRC over a 6 month period. Participants will be members of the "DASH Foods Tasting Panel." Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REDOX CONTROL OF MEDULLARY FUNCTION AND BLOOD PRESSURE Principal Investigator & Institution: Cowley, Allen W. Professor and Chair; Medical College of Wisconsin Po Box26509 Milwaukee, WI 532264801 Timing: Fiscal Year 2003; Project Start 01-MAR-2003; Project End 28-FEB-2008 Summary: The overall goal of this project is to advance our understanding of the role that reactive oxygen species (ROS) and reactive nitrogen species (RNS) play in determining renal function, especially that of the renal medulla, a region that is vulnerable to excess O2- production. We have previously established that changes in renal medullary blood flow play an important role in sodium homeostasis and the longterm regulation of arterial pressure and shown that nitric oxide (NO) production plays a key role in the regulation of blood flow to this region. We hypothesize that excess production of ROS in the renal medulla reduces NO bioavailability, lowers medullary blood flow, increases tubular sodium reabsorption and results in a salt-sensitive form of hypertension. This project, as all others in this PPG, utilizes Dahl salt-sensitive rats that are genetically defined (SS/Mcw) and a newly developed consomic control strain derived from the inbred SS/Mcw strain in which chromosome 13 from the saltinsensitive BN/Mcw strain has been introgressed into the genomic background of the SS/Mcw rat (SS.BN13 consomic strain). This consomic SS.BN13 strain is 98% identical to the SS/Mcw strain but is relatively salt-insensitive. Aim 1 will determine if the renal medulla of Dahl salt-sensitive rats (SS/Mcw) produces excess ROS (O2, H2O2, ONOO) that feeds back to uncouple nitric oxide syntheses enzymes (NOS) and reduce the redo ratio of tetrahydrobiopterin (BH4)/dihydrobiopterin (BH2) (i.e., a vicious cycle of O2. production). Newly developed fluorescent microdialysis and HPLC analytical
72 Blood Pressure
techniques will enable comparison of ROS and NO pathways in salt-sensitive (SS/Mcw) and in salt-insensitive consomic SS.BN13 rats. Our preliminary data indicate that this control strain exhibits significantly lower levels of medullary ROS. Studies will also determine whether lowering of ROS in the medulla of SS/Mcw rats by chronic medullary infusion of antioxidants increases medullary blood flow and reduces saltinduced hypertension. Aim 2 will determine the effects of induced medullary elevations of ROS in salt-insensitive SS.BN13 consomic rats. Medullary blood flow, renal interstitial hydrostatic pressure (RIHP), arterial pressure (AP) and the pressure-natriuresis relationships will be determined in response to chronic elevations of O2-, H2O2, and ONOO-. The concept of NOS uncoupling will be examined by measurement of medullary tissue BH4/BH2 ratios determined by HPLC, and NO, O2 and H2O2 values obtained by microdialysis techniques. Aim 3 will determine the dynamic interrelationships of O2 and NO within and between vascular and tubular segments of the renal medulla using thin, superfused medullary tissue stripes. NO responses to agents that stimulate and inhibit ROS will be compared in control SS.BN13 and salt-sensitive SS/Mcw rats. Novel fluorescent dyes, coupled with high speed capture of microscopic images will enable the measurement of intracellular NO independent from NO in the interstitial space thereby determining whether NO released from tubules could act as a paracrine substance to control medullary blood flow. Taken together, these studies will provide novel and clinically relevant data defining the role that ROS play in the regulation of renal medullary function and the development of salt-sensitive hypertension, information that would be expected to lead to new therapeutic modalities in the treatment of human hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF INTRAOCULAR PRESSURE AND OCULAR BLOOD FLOW Principal Investigator & Institution: Liu, John H. Professor; Ophthalmology; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, CA 92093 Timing: Fiscal Year 2003; Project Start 01-NOV-1991; Project End 30-NOV-2007 Summary: (provided by applicant): Glaucoma is a leading cause of blindness. An elevated intraocular pressure (IOP) is a major risk factor. We have been studying the 24hour pattern of IOP under strictly controlled laboratory conditions. Data have been collected from healthy young and elderly volunteers, from untreated glaucoma patients/suspects, and from glaucoma patients treated with timolol or latanoprost. In order to know whether or not surgical treatment sufficiently reduces IOP in glaucoma patients at night, we will study the 24-hour pattern of IOP in glaucoma patients receiving laser trabeculoplasty (Aim 1). An elevated IOP alters the ocular perfusion pressure and consequently may affect ocular blood flow. How the 24-hour variation of IOP affects ocular blood flow is unknown. Ocular blood flow may very well vary independently from IOP over the 24 hours. Therefore, we will study the 24-hour pattern of ocular blood flow in healthy individuals (Aim 2). Blood flow in the retrobulbar blood vessels will be characterized using the color Doppler imaging technique in the laboratory. Young and elderly volunteers will be selected based upon their home recordings of ambulatory blood pressure, sleep conditions, and IOP. Since an abnormal ocular blood flow may be another risk factor for glaucoma, we will study the 24-hour pattern of ocular blood flow in glaucoma patients (Aim 3). Similar home recordings will be performed to select representative glaucoma patients with excessive dipping of nocturnal blood pressure and with sleep apnea. Laboratory data will be collected from untreated glaucoma patients/suspects and from glaucoma patients receiving medical
Studies 73
treatment with timolol or latanoprost and those surgically treated with laser trabeculoplasty. The long-term goal of the proposed studies is to define the endogenous mechanisms in the regulation of human IOP and ocular blood flow. Experimental results should provide fundamental information about how ocular blood flow is regulated during the day and at night in healthy individuals. New knowledge of ocular blood flow and IOP in patients would have implications for the better diagnosis and treatment of glaucoma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF RENAL OXYGENATION AND BLOOD PRESSURE Principal Investigator & Institution: Zou, Ai-Ping; Associate Professor; Physiology; Medical College of Wisconsin Po Box26509 Milwaukee, WI 532264801 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): It has been demonstrated that the activities of many paracrine or autocrine systems such as nitric oxide synthases, cyclooxyganses, heme oxygenases and others are much higher in the renal medulla than in the renal cortex. These local humoral systems have been indicated to importantly control the constancy of renal blood flow and oxygenation, sodium excretion and arterial blood pressure. However, the mechanism activating these renal medullary protective systems is still poorly understood. Our preliminary experiments have shown that a low PO2 milieu and corresponding activation of gene transcription in the renal medulla may contribute to the great activity of these paracrine and autocrine systems. An oxygen-sensitive transcription factor, hypoxia inducible factor-la (HIF-1alpha) was found highly expressed in the renal medulla and upregulated in response to decrease in tissue oxygenation or cell hypoxia. Inhibition of HIF-1alpha in this kidney region resulted in increase in arterial blood pressure and enhancement of the salt sensitivity of arterial blood pressure. Based on these data, we hypothesize that HIF-lalpha-activated transcription in the renal medulla may increase the expression of oxygen-sensitive genes, which contributes to the oxygen homeostasis and prevention of hypoxic injury in this kidney region and thereby participates in the control of renal function and arterial blood pressure. In this grant proposal, we will determine whether this HIF-1alphamediated gene transcription in the renal medulla is importantly involved in the renal adaptive response to high salt intake and whether blockade of HIF-1alpha increases the salt sensitivity of arterial blood pressure in rats. We will also determine whether alterations of HIF-1a levels influence the reactivity of renal medullary vessels to different vasoconstrictors and whether increased HIF-1alpha levels protect the renal medulla from vasoconstrictive or hypoxic injury. Furthermore, we will determine the functional significance of those HIF1alpha-activated genes in the control of renal function and arterial blood pressure by analyzing the expression of a prototype gene, heme oxygenase-1. Finally, we will determine whether an abnormality of HIF-1alphamediated gene transcription contributes to the increased salt sensitivity of arterial blood pressure in Dahl salt-sensitive hypertensive rats. These studies will clarify the underlying mechanism regulating renal medullary function and the salt sensitivity of arterial blood pressure and ultimately may suggest new therapies for the treatment of renal ischemia and hypertension at gene transcriptional level. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REGULATION OF RENAL VASCULAR CELLS IN HYPERTENSION Principal Investigator & Institution: Gelband, Craig H. Associate Professor; Physiology and Functional Genomics; University of Florida Gainesville, FL 32611
74 Blood Pressure
Timing: Fiscal Year 2001; Project Start 01-JUL-1996; Project End 19-APR-2002 Summary: (Verbatim from Applicant's abstract): The relationship between renal blood flow and glomerular filtration rate is well established. A decrease in renal blood flow lowers glomerular filtration rate, triggering water retention and increases in extracellular fluid volume, cardiac output and arterial pressure. If both renal blood flow and glomerular filtration rate remain suppressed, the initial steps in the development of hypertension have taken place. Since changes in renal blood flow have been implicated in certain vascular disorders, including hypertension and renal vasospasm, this research will help fill the existing gap of knowledge regarding the relationship between ion channel regulation and vascular reactivity in the renal vasculature. It has been clearly shown that Kv, KCa and L-type Ca2+ channel activity in small resistance arterioles of the kidney are altered in the spontaneously hypertensive rat (SHR) and deoxycorticosterone acetate (DOCA) hypertensive rat when compared to their proper control. Yet the mechanism(s) by which these alterations take place has yet to be elucidate. The general hypothesis of this application is that regulation of K+ and Ca2+ channel activity, either by signaling molecules or by a change in number, depolarize membrane potential in renal resistance arteriolar vascular smooth muscle cells from hypertensive rats thereby increasing vascular smooth muscle tone. Using a multifaceted approach of vascular reactivity, patch clamp electrophysiology, molecular techniques (Western blot and RNase protection) and confocal microscopy, this research project will advance our understanding of the involvement of membrane conductances in the regulation of renal vascular excitation-contraction coupling and blood pressure in health and disease. The aims of the proposed research are fourfold: (1) To biophysically and pharmacologically characterize the mechanism(s) by which there is a decrease in Kv channel current density in renal resistance arteriolar vascular smooth muscle cells of hypertensive rat models. (2) To biophysically and pharmacologically characterize the mechanism(s) by which there is an increase in L-type Ca2+ channel current density in renal resistance arteriolar vascular smooth muscle cells from hypertensive rat models. (3) To characterize the relationship between Ca2+ release from the sarcoplasmic reticulum, PKC and the depressed activity of KCa channels in renal resistance arterioles and renal vascular smooth muscle cells from hypertensive rat models. (4) To examine if lowering blood pressure with antisense gene therapy targeting the rennin-angiotensin system can prevent/reverse the mechanism(s) that lead to alterations in Kv, KCa, and Ltype Ca2+ channel activity. The results from these studies should significantly increase our knowledge of the mechanism(s) of hormonal modulation of vascular tone in a clinically relevant tissue, the renal vascular bed and its role in the development of hypertension. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RENAL BLOOD FLOW,SODIUM HANDLING AND THE DASH DIET Principal Investigator & Institution: Conlin, Paul R. Assistant Professor of Medicine; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 31-JAN-2008 Summary: (provided by applicant):This application for a K24 award is to provide support for Paul R. Conlin, MD to allow him protected time to devote to patientoriented research and to act as a mentor for beginning clinical investigators. His longterm goal is to make significant contributions to the understanding of lifestyle modifications as they impact on renal and cardiovascular disease risk factors through clinical trials. Dr. Conlin has investigated the impact of dietary patterns and sodium on renal/adrenal function and cardiovascular disease risk factors. He was recently a
Studies 75
collaborating investigator in the DASH (Dietary Approaches to Stop Hypertension) and DASH-Sodium studies, which showed that a low-fat diet enriched in fruits, vegetables and low-fat dairy products (DASH diet) either alone or with sodium restriction significantly lowered blood pressure. He is now studying the effect of three dietary patterns on renal and cardiovascular disease risk factors (blood pressure and lipid profile). This application proposes new specific aims in which he will study the effects of the DASH diet on the kidney- in particular, renal blood flow, renal vascular resistance and sodium excretion. These studies will test the hypotheses that the DASH diet vasodilates the renal vasculature and enhances sodium excretion in a manner that mimics ACE inhibition. These studies will be performed in individuals with high normal and Stage 1 hypertension, and subgroup analyses will be performed in African Americans. The results of these studies will reveal the added-value of the DASH diet on risk factors and protective effects on renal function in patients at risk for renal/cardiovascular disease. Dr. Conlin is fully committed to recruiting and mentoring junior clinical investigators destined for careers in patient-oriented research, particularly those interested in renal cardiovascular physiology, interventional nutrition or academic endocrinology, He has recently mentored 6 fellows and junior faculty, many of whom have achieved independent grant support. In addition, he will teach junior patientoriented research investigators in the K30 funded "Scholars in Clinical Science" Program at Harvard Medical School. Thus, with the support of this award he will have significant impact on future patient-oriented research at multiple levels. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: RENAL SODIUM TRANSPORT IN THE OBESE ZUCKER RAT Principal Investigator & Institution: Ecelbarger, Carolyn A. Professor; Medicine; Georgetown University Washington, DC 20057 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2008 Summary: (provided by applicant): Obesity and insulin resistance are associated with hypertension. Inappropriate retention of sodium by the kidney is likely to play a major role. We previously showed that the obese Zucker rat (a model for these disorders) have increased renal protein abundance for three major sodium transport proteins: the alpha1 subunit of Na-K-ATPase, the thiazide-sensitive NaCI cotransporter (NCC or TSC) and the beta-subunit of the epithelial sodium channel (ENaC). In contrast, as, they aged, obese rats developed renal hypertrophy along with diabetes and had a relative decrease in many important salt and water transport proteins, as compared to age-matched controls. We suggest that dysregulation of several important hormone systems in sodium balance may play a role in both alterations in sodium transport protein expression, as well as, the rapid develop of nephropathy. Candidate systems include the renin-angiotensin-aldosterone system (RAAS) and insulin (and or insulin resistance). We hypothesize that dysregulation of major sodium transport proteins of the kidney in the obese Zucker rat with age, is due at least in part to increased RAAS activity, and hyperinsulinemia, which in combination, result in inappropriate sodium retention and elevated blood pressure. Our specific aims include: 1) to determine if angiotensin II At1a receptor expression, binding, and activity is upregulated in the obese Zucker rat and whether this upregulation plays a role in changes in renal sodium transporter regulation, blood pressure, and renal hypertrophy; 2) to determine if enhanced mineralocorticoid receptor (MR) activity plays a role in increased whole kidney protein abundance of the thiazide-sensitive NaCI cotransporter (NCC), blood pressure, and renal hypertrophy, in the obese Zucker rat; 3) to determine the cellular location and sensitivity of the renal insulin receptor in obese Zucker rats relative to lean age-mates; 4)
76 Blood Pressure
to determine whether treatment of insulin resistance with a PPAR-gamma agonist will decrease relative renal protein abundance of NCC, beta-ENaC, and Na-K-ATPase, as well as reduce blood pressure and renal hypertrophy in the obese Zucker rat, and whether these effects are reversed with short-term insulin infusion. These studies will allow us to determine the importance of each of these potential regulatory hormone systems in dyregulation of sodium transporter expression, sodium balance, and blood pressure in these obese rats. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REPERFUSION EFFECTS ON CEREBRAL ARTERY FUNCTION Principal Investigator & Institution: Cipolla, Marilyn J. Neurology; University of Vermont & St Agric College 340 Waterman Building Burlington, VT 05405 Timing: Fiscal Year 2001; Project Start 15-JUL-1999; Project End 31-MAR-2004 Summary: (from the Abstract) Ischemic brain injury is one of the most common pathophysiological processes affecting more than 400,000 people per year in the US in the form of stroke. Restoration of blood flow following short periods of ischemia has been shown to benefit the brain, however, experimental and clinical evidence indicates that reperfusion following longer periods of ischemia may worsen brain injury. While the effects of ischemia and reperfusion have been extensively studied in neuronal injury, little information regarding these effects on cerebral arteries, and how this dysfunction affects stroke outcome, is available. This study investigates the ischemic and reperfusion effects on cerebral artery function, focusing on myogenic tone and reactivity to pressure, both important components of vascular resistance and autoregulation of cerebral blood flow. The intraluminal suture model of focal cerebral ischemia in rats will be used to induce controlled ischemia and reperfusion in middle cerebral arteries. The arteries will then be dissected from the occluded side of the brain and studied in vitro in a system that allows control of intravascular pressure and continuous measurement of lumen diameter. Arteries will be studied under variable periods of ischemia and reperfusion to determine the threshold duration of ischemia and reperfusion that arteries can still maintain viable myogenic responses (Aim 1). Since preliminary experiments determined that 2 hours of ischemia followed by 24 hours of reperfusion results in significantly diminished reactivity to pressure and abnormal basal tone of middle cerebral arteries, we will investigate alterations in cerebral artery structure (e.g., actin cytoskeleton) and function (e.g., myogenic behavior) that may contribute to the loss of function. In addition, inhibitors of compounds known to be detrimental during ischemia and reperfusion (e.g., nitric oxide, superoxide radical) will be used to determine if cerebral artery function can be preserved during reperfusion (Aim 2). Lastly, one promising therapeutic approach involves thrombolysis to restore blood flow to ischemic regions of the brain; however, the use of thrombolytic agents carries the risk of edema formation and hemorrhage. One mechanism that may contribute to these processes during thrombolysis is an effect of the agents themselves on cerebral artery myogenic behavior. Normal cerebrovascular resistance is important during reperfusion and during treatment with thrombolytic agents if vascular integrity is to be maintained and tissue damage minimized. Therefore, Aim 3 will investigate the effects of two types of thrombolytic agents (tissue-type and urokinase) on cerebral artery function, including myogenic processes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 77
•
Project Title: PREGNANCY
ROLE
OF
ANG-(1-7)
IN
NORMAL
AND
HYPERTENSIVE
Principal Investigator & Institution: Brosnihan, K. Bridget. Professor; Surgery; Wake Forest University Health Sciences Winston-Salem, NC 27157 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2004 Summary: (provided by applicant): PIH is estimated to affect 7% to 10% of all pregnancies in the United States. Despite being one of the leading causes of maternal death and a major contributor of maternal and perinatal morbidity, the mechanisms responsible for the pathogenesis of PIH are unclear. It is well known that the RAAS is stimulated in normal pregnancy. The physiological consequences of the stimulated RAAS in normal pregnancy are incompletely understood. Initial findings from our group demonstrate that the novel heptapeptide of the RAAS, Ang-(1-7) is increased in pregnancy and reduced in PIH and preeclampsia. Since Ang-(1- 7) has been shown to act as a vasodilator and thus may counter regulate the actions of Ang II, our findings provide a basis for a possibly important physiological role of Aug-( 1- 7) in the course of pregnancy. It is our hypothesis that an appropriate balance of the vasoconstrictor and vasodilator components of the RAAS exerted by Ang II and Ang-(1- 7), respectively, constitute a crucial feature of cardiovascular regulation during an uncomplicated pregnancy. In particular, normal pregnancy may be characterized by vasodilatory actions of Aug-(1-7) that balance the vasoconstrictor effects of Ang II. In contrast, PIH and preeclampsia may result from an unbridled pressor action of Ang II as a consequence of marked reduction of vasodepressor effects of Ang-(1- 7). The hypothesis will be tested by the following Specific Aims. Specific Aim 1 will determine the time course of changes in the circulating and urinary levels of Ang II and Ang-(1- 7) as the principal vasoconstrictor and vasodilator components, respectively, of the RAAS throughout the course pregnancy of pregnancy in rats. Findings obtained in normal pregnant rats will be compared to a rat model of PIH produced by chronic reduction in utero placental perfusion pressure (RUPP). We will also monitor levels of active renin concentration, Ang I, angiotensin converting enzyme (ACE), Angiotensinogen (Aogen), and aldosterone in normal pregnant rats and in rats subjected to RUPP. Specific Aim 2 will demonstrate that long-term blockade of Ang-(1- 7) by chronic infusion of the Ang(1- 7) specific antagonist, ([D-Ala7]-Ang-(1-7) in otherwise normal pregnant rats tips the balance of blood pressure regulation toward hypertension. Also we will determine whether chronic administration of Ang-(1-7) reverses the hypertension of RUPP animals. We also propose to assess the response of mesenteric and uterine resistance arterioles to Ang peptides in normal pregnancy and hypertension caused by RUPP. The major goal of these studies is to understand the contribution of the vasodilator component of the RAAS to blood pressure regulation in normal pregnancy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ROLE OF CEREBROVASCULAR K+ CHANNELS IN HYPERTENSION Principal Investigator & Institution: Rusch, Nancy J. Professor; Physiology; Medical College of Wisconsin Po Box26509 Milwaukee, WI 532264801 Timing: Fiscal Year 2002; Project Start 01-MAR-1998; Project End 30-NOV-2005 Summary: The goal of this project is to provide a profile of the disease-specific expression of the Shaker (Kv1) gene family of voltage-gated K+ channels in the cerebral microcirculation of hypertensive rats. Our early results suggest that Shaker Kv1 channels upregulate in the cerebral circulation of normal Wistar Kyoto (WKY) rats during the maturation of the animal to emerge as predominant contributors to cerebral
78 Blood Pressure
arterial membrane potential and diameter. However, this progression is highly suppressed in spontaneously hypertensive rats (SHR), in which maturation results in the exposure of the cerebral microcirculation to progressively higher blood pressure levels in vivo. Indeed, patch-clamped cerebrovascular smooth muscle cells from adult SHR show reduced Shaker Kv1 current compared to cells from normal Wistar Kyoto (WKY) rats, and this alteration is associated with smooth muscle cell depolarization and constriction. Notably, this vasoconstriction is regarded as a fundamental adaptive response of small cerebral arteries to the development of high blood pressure in vivo, which minimizes the damaging transmission of the high systemic pressure to the blood brain barrier. Based on these findings, and our evidence that the remodeling of K+ channels in the cerebral circulation critically protects this vascular bed from the lethal effects of high blood pressure, we will: (a) combine RT-PCR gene expression studies, Western blotting, and patch-clamp techniques to examine the expression and function of Shaker Kv1 channels in rat cerebrovascular smooth muscle cells during the development of genetic and renal forms of hypertension, and after correction of hypertension by vasodilator drugs (b) assess the physiological impact of these changes in Shaker Kv1 channel expression on the membrane potential and diameter of isolated cerebral arteries in vitro and arterioles in vivo, and (c) test the hypothesis that pressure-induced membrane depolarization is a triggering stimulus for the remodeling of Shaker Kv1 channels in the vascular smooth muscle membranes of the cerebral circulation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SAFETY, TOLERABILITY & ANTIHYPERTENSIVE EFFICACY OF MULTIPLE DOSE L-753 Principal Investigator & Institution: Elijovich, Fernando; University of Texas Medical Br Galveston 301 University Blvd Galveston, TX 77555 Timing: Fiscal Year 2001 Summary: The proposed research is a multicenter Phase II clinical trial of a new endothelin receptor antagonist (L-753,037), with a large ETz/ETb selectivity ratio). Its antihypertensive efficacy, as well as safety and tolerability, will be explored in Afreican American patients with essential hypertension. This project targets patients of African American background because the prevalence of salt-sensitivity of blood pressure is highest in this racial group (about 75%) and because there is evidence (in experimental animals and humans) that endothellin may be important in the regulation of vasoconstriction and blood pressure in salt-sensitive hypertension. The trial will be double blind, with two comparators, placebo, and the antigypertensive dihydropyridine amlodipine. Patients will be selected according to strict inclusion/exclusion criteria, including a narrow blood pressure window to be determined during an outpatient washout period (discontinuation of previous medications). The actual study will be carried out during an 8-day (9-night) admission to the GCRC. After two days on placebo, to establish a baseline and to exclude those patients that may fall below the blood pressure window as a response to hospitalization, the drugs will be administered as oral solutions for five days. The pharmacist will be the only member of the research team that will not be blind to the medication administered. Blood pressures will be recorded several times per day. Routine laboratory measurements will be carried out to assess safety of the compound. Measurements of vasoactive compounds and hormones will be also carried out, to unravel the mechanisms of blood pressure reduction, if any, by endothelin receptor blockade. Pulmonary function tests and blood gases will be measured because high doses of the compound have been found to have untoward effects on repiratory function of experimental animals. Once the period of
Studies 79
administration of the drug is completed, the patients will be observed for an additional day at the GCRC, and later, on a follow-up outpatient visit. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SCOR: MOLECULAR GENETICS OF HYPERTENSION Principal Investigator & Institution: Lifton, Richard P. Chairman, Department of Genetics; Genetics; Yale University 47 College Street, Suite 203 New Haven, CT 065208047 Timing: Fiscal Year 2001; Project Start 01-FEB-1996; Project End 31-JAN-2006 Summary: The Yale Specialized Center of Research in Hypertension focuses on identification of the inherited abnormalities that contribute to high blood pressure and its consequences. To date, we have identified mutations in 4 genes that raise blood pressure, 8 genes that lower blood pressure, linkage for two more Mendelian hypertensive disease, and linkage for blood pressure in the general population. These findings have demonstrated the key role of renal salt homeostasis in determination of blood pressure variation in humans, and have begun to identify molecular mechanisms underlying relationships between blood pressure and bone density. In the current proposal, we propose a series of investigations that will extend these studies. Taking genes in which we have shown mutations alter blood pressure, we examine the impact of variants in these genes on blood pressure and related phenotypes in the Framingham Heart Study. We also search for a gene accounting for a substantial fraction of blood pressure variance in this population, and search for genes contributing to a common complication of hypertension, end stage renal disease. We continue our identification of Mendelian traits that affect blood pressure, and pursue the clinical consequences of these mutations. Finally, since virtually all known causes of hypertension act via a common pathway of increased activity of the amiloride-sensitive epithelial sodium channel, we investigate the signaling pathway that regulates the activity of this channel. These studies will continue to provide key information regarding the causes and consequences of hypertension in humans that have clinical and therapeutic implications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SECONDARY PREVENTION IN SMALL SUBCORTICAL STROKES (SPS3) Principal Investigator & Institution: Benavente, Oscar R. Associate Professor; Medicine; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, TX 78229 Timing: Fiscal Year 2001; Project Start 05-SEP-1999; Project End 30-NOV-2002 Summary: Small subcortical strokes (S3), also known as lacunar infarcts, comprise nearly 25 percent of brain infarcts, are harbingers of vascular dementia, and are particularly frequent in Mexican- Americans. Combination antiplatelet therapy using clopidogrel plus aspirin and intensive lowering of blood pressure could substantially reduce major vascular events and cognitive decline in S3 patients. However, a large randomized clinical trial is required to define the efficacy and safety of these interventions specifically in patients with S3 due to presumed small vessel disease. This proposal is for a pilot study to: 1. Determine the lowest tolerable, achievable target blood pressures among survivors of S3. 2. To assess whether the difference between the lowest tolerable blood pressures are sufficiently different from that achieved by standard targets to substantially impact the occurrence of subsequent stroke and cognitive decline. 3. To quantitatively assess white matter abnormalities in S3 patient by serial MRI, correlating these with patient features, cognitive status, blood pressure
80 Blood Pressure
control and antiplatelet treatment. 4. To assess the relationship of Mexican-American ethnicity to blood pressure interventions, tolerance of antiplatelet therapy, extent and progression of white matter abnormalities, and cognitive status, as well as to modify and assess existing screening tests of cognitive status for those who primarily speak Spanish. Participants with S3 attributed to small vessel disease will be randomized to treatment with aspirin (650mg/d) or aspirin plus clopidogrel (75mg/d) (double-blind), while those with a history of hypertension will additionally be randomized to three different target levels of blood pressure lowering (not blinded). The tolerance and achieved blood pressures in each target level will be the primary outcome, with tolerance and side-effects of antiplatelet therapy also assessed. Quantitative MRI will be done at entry and after a mean of one year, correlated with cognitive status, interventions and ethnicity. No clinical trials have assessed secondary prevention in S3, the most common type of stroke in Mexican Americans and accounting for about 150,000 strokes yearly in the US. While this pilot study is a necessary first-step for a larger, definitive clinical trial, valuable and unique information about blood pressure control after stroke and about issues relevant to stroke prevention in MexicanAmericans will emerge. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SECRETION AND RENAL EFFECTS OF CARDIAC PEPTIDES Principal Investigator & Institution: Dietz, John R. Physiology and Biophysics; University of South Florida 4202 E Fowler Ave Tampa, FL 33620 Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 31-MAR-2003 Summary: (Adapted from the Investigator's Abstract) Hypertensive cardiovascular disease affects approximately 40-60 million Americans and is thought to be a primary contributor to coronary artery disease and stroke which collectively account for most of the cardiovascular deaths in this country. Over a period of many years it has become apparent that the regulation of arterial blood pressure is intimately linked to body salt and water balance. Recent evidence suggests that several peptides derived from the Nterminal portion of the atrial natriuretic factor (ANF) prohormone also play an important role in regulating kidney function and arterial blood pressure. The long term goals of the present application are to obtain a better understanding of the role of ANF and ANF prohormone peptides in the regulation of kidney function, blood volume and blood pressure. The applicant will carry out studies to investigate the role of nitric oxide, endothelin and adenosine on the paracrine regulation of ANF and proANF release. The applicant has shown previously that proANF 1-30 produces natriuresis and hypotension through, as yet, undefined mechanisms. He proposes to investigate four likely potential mechanisms that may contribute to the natriuretic properties of this peptide. These include prostaglandin synthesis, alterations in hemodyn